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From acute to chronic illness 
In the traditional care delivery model, a doctors’ main job was to respond rapidly and efficiently to 
situations requiring immediate medical care. The focus was on the definition of the problem and the 
initiation of treatment. Since the full clinical course usually took only a short amount of time, there 
was little need for the patient to develop any disease-related skills and the patient’s role was largely 
passive [1]. Nowadays, however, the majority of patients suffer from chronic disease(s), requiring a 
completely different relationship between patient and healthcare professional. The patient needs to 
be the manager of his own healthcare and the healthcare professional fulfils a coaching role [2]. The 
following metaphor nicely illustrates the position of chronically ill patients and their healthcare 
professionals:  
‘Living with chronic illness is like flying a plane. If the plane is flown well, one gets where one wants to 
go. If it is flown badly, one either crashes or lands shakily in the wrong airport, reluctant to ever leave 
the ground again. The patient must be the pilot, because the other possible pilot, the health care 
professional, is only in the plane a few hours every year, and this plane rarely touches ground [1].’ 
Patients have to become more independent and perform certain care tasks themselves. However, this 
does not mean that patients should be left to fend for themselves. A new task for healthcare 
professionals is to assure that their patients are ‘skilled pilots’, by giving them the confidence and skills 
to manage their condition[1]. Patients managing their own condition is often referred to as self-
management.  
 
Self-management and self-monitoring 
There are several definitions of self-management, but the one most often cited comes from Barlow 
and colleagues: Self-management refers to the individual’s ability to manage symptoms, treatment, 
physical and psychological consequences and life style changes inherent in living with a chronic 
condition. Efficacious self-management encompasses the ability to monitor one’s condition and to 
effect the cognitive, behavioural and emotional responses necessary to maintain a satisfactory quality 
of life[3]. In this definition, monitoring one’s condition is considered an essential element of self-
management. Self-monitoring in the context of chronic illness has been defined as a patient 
undertaking one or more of the following activities (i) self-measurement of vital signs, symptoms, 
behaviour or psychological well-being, (ii) self-interpretation of self-measured data; or (iii) self-
adjustment of medication, treatment, lifestyle or help-seeking behaviour as a result of self-awareness 
or self-interpretation[4, 5]. Patients can self-monitor by using highly advanced measurement devices 
that can sometimes even replace laboratory analysis, but one can also self-monitor by keeping a diary 
 
 
(either digitally or with paper and pencil) to track symptoms. It is important that patients closely 
monitor their condition themselves, as chances are very small that the onset or worsening of 
symptoms happens just prior to the few moments that ‘the other pilot is on board’. If patients keep 
track of their own condition, exacerbations, complications and potentially even death can be 
prevented[6].  
 
The (potential) merits of self-monitoring in chronic conditions  
The concept of self-monitoring has been mainly studied and applied in conditions that need frequent 
monitoring to achieve optimal medication management. For example, diabetic type 1 patients need 
to monitor their glucose level several times a day to adjust their insulin doses. It would be extremely 
burdensome for both patients and healthcare capacity if these measurements could solely be 
performed by healthcare staff. It is therefore not surprising that the idea of diabetics self-testing goes 
back to the mid-1970s[7]. The first study in which self-monitoring blood glucose (SMBG) was 
successfully applied was performed in 1978[8]. Since then, many studies have followed showing that 
self-monitoring can lead to reductions in HbA1c[9-12] in patients with diabetes. This has resulted in 
the universal recognition of SMBG to be an essential element of optimal type 1 diabetes 
management[13]. Much experience with self-monitoring has further been gained on the usability of 
self-monitoring International Normalized Ration(INR) [14-19]. INR is an assay to determine the clotting 
tendency of blood, which is important information for patients with thrombosis who receive oral 
anticoagulant therapy. Due to the narrow target ranges, INR needs to be frequently monitored in 
order for anticoagulant medication to be appropriately dosed[16]. Studies have shown that with self-
monitoring INR, the number of thromboembolic events in this population can be reduced [15, 16]. In 
other disease populations, self-monitoring has also been shown to be beneficial: patient self-
monitoring blood pressure has a positive impact on the management of hypertension [20-24] and self-
monitoring asthma symptoms can lead to improved asthma control [25]. Further, several studies in 
different disease populations have shown that patients who self-monitor experience higher levels of 
quality of life[26-29] and more empowerment[14, 18, 29-31] than patients who do not. In addition, 
patients seem to prefer self-monitoring above regular care in a variety of chronic conditions[14, 18, 
23, 26, 27, 29].  
Besides being beneficial for the individual patient, self-monitoring has also been shown to offer a way 
to control volume and costs of chronic care[32-34]). There are great concerns that the increasing 
numbers of chronically ill will outgrow the capacity of the working-age population to both finance the 
public health spending and fulfil the healthcare capacity needs. In the last decennium, 10% of the 
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care costs have been increasing more than the GDP[35] and are expected to increase further posing a 
risk for the sustainability of health care financing [36]. With more than 70% of the total healthcare 
expenditure being spent on chronic diseases[37], it is not surprising that efforts to decrease healthcare 
costs are mainly targeted at the management of chronically ill patients. Due to the positive effect of 
self-monitoring on healthcare spending [32-34], improving the self-monitoring skills of people with 
chronic conditions has become an important objective in chronic care management[5]. With the 
widespread availability of the Internet, self-monitored data can be easily shared and discussed with 
healthcare providers enabling the provision of care while patient and doctor are remote in place and 
even in time. This has made self-monitoring an attractive addition or alternative to regular care for 
many chronic conditions. Using the Internet to provide care at a distance is often referred to as 
eHealth. EHealth can bring efficiency to healthcare delivery, for example by reducing routine 
healthcare visits[38], and is therefore seen as a key solution to the challenge of rapidly increasing 
numbers of patients requiring chronic care.  
 
The potential of self-monitoring and eHealth in (kidney) transplant follow-up 
Recipients of solid organ transplantations have to pay frequent and usually routinely scheduled visits 
to the hospital to monitor graft function. As the onset of complications like acute rejection usually 
does not run synchronously with the monitoring appointment interval, it would be highly beneficial 
and efficient if patients could monitor graft function themselves. Studies regarding the potential of 
transplant patients self-monitoring health parameters at home have been mainly performed in a 
population of lung-transplant recipients. As these patients have an even higher risk for acute rejection 
and infection than recipients of other solid organs[39, 40], they need to frequently self-monitor vital 
signs to enable early detection of changes in their condition. Self-monitoring with electronic devices 
and the support of technology systems has been shown to be a valid and reliable way to detect 
complications after lung-transplantation early[41, 42] and to lead to better survival[43] and a higher 
quality of life for lung-transplant patients[44].  
Self-monitoring may also be a promising approach for kidney transplant follow-up, with the frequent 
and usually routinely scheduled appointments to monitor kidney function being highly burdensome 
to the recovering patient and to healthcare resources. Although significant improvements in kidney 
transplant outcome have been achieved in the last decade [45], patients continue to be at risk for 
acute rejection of their kidney graft, mainly in the first year after transplantation. As early detection 
of a rejection episode is mandatory to minimize permanent damage to the kidney graft[46-51], kidney 
transplant patients in the Netherlands visit the outpatient clinic about 20 times during the first year 
post-transplantation. Despite the high frequency of outpatient visits, the potential of self-monitoring 
 
 
after kidney transplantation has not yet received a great deal of attention. Studies that did cover this 
subject focused on the viability of self-monitoring blood pressure after kidney transplantation, 
showing that self-monitoring blood pressure is an effective way to detect poor control of 
hypertension[52-54]. Although blood pressure is an important parameter to be monitored after 
transplantation, healthcare professionals and patients are especially interested in serum level of 
creatinine. Creatinine is a waste product of the muscles that is filtered from the blood by the kidneys. 
In case of a deteriorating kidney function, for example due to rejection, the level of creatinine and 
other waste products in the blood will increase. Besides the accumulation of waste products in the 
body, which eventually becomes toxic, a decreased kidney function leads to increased blood pressure 
via two routes. First, as kidneys filter and excrete excess fluid, suboptimal kidney function leads to the 
accumulation of fluid in the body resulting in an increased pressure that is put on the blood vessels. 
Second, the kidneys play an important role in keeping blood pressure in a healthy range by the 
excretion of blood pressure regulating hormones. Decreased renal function will therefore result in 
suboptimal blood pressure regulation. The relationship between kidney function and blood pressure 
is bi-directional: through the increased pressure that is put on the vessels, the dense network of blood 
vessels present in the kidneys can become damaged, reducing the ability to remove waste and excess 
fluid from the body. This will again lead to increased pressure that is put on the blood vessels, resulting 
in a downwards spiral. The narrow relationship between kidney function and blood pressure makes 
the frequent monitoring of both parameters necessary.  
 
Aim and outline of this thesis 
Based on the experiences in other conditions requiring chronic care, self-monitoring kidney function 
after transplantation has the potential to increase patient independency and satisfaction and 
accelerate the detection of complications while reducing healthcare consumption at the same time. 
The general objective of this thesis was to investigate whether self-monitoring kidney function after 
transplantation supported by an online self-management support system is well accepted by patients, 
and can replace part of regular care safely and without loss of quality of care. The different studies 
that have been performed to answer this question are outlined below.  
 
Chapter 2. Enabling patients to monitor kidney function at home could decrease the high frequency 
of outpatients visits and improve speed of rejection detection. For this to be possible, however, 
patients have to be willing to self-monitor. In this chapter, the results of a prospective pilot study 
investigating patients’ experiences and satisfaction with self-monitoring kidney function after 
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Chapter 3. For the design and implementation of self-management support systems (SMSS), it is 
important to understand the factors that influence patients’ acceptance of a SMSS. In the 
questionnaire study described in this chapter, we identified key factors influencing renal transplant 
patients’ acceptance of the SMSS. The questionnaire items were developed based on literature 
describing factors that influence patients’ acceptance of a new system.  
 
Chapter 4. The StatSensor® Xpress-i ™, a point-of-care system for blood creatinine measurement, 
offers patients the possibility to self-monitor kidney function. As this device has never been used in a 
kidney transplant population before, we investigated whether the StatSensor® can be applied safely 
for kidney transplant follow-up by examining its’ analytical performance for both detecting current 
renal function and monitoring renal (dys)function over time. 
 
Chapter 5. This chapter describes the results of a randomized controlled trial (RCT) in which the safety 
and usability of self-monitoring creatinine and blood pressure with the support of an online SMSS 
during the first year post-transplantation was investigated. Self-monitoring kidney function after 
transplantation was compared to usual care with regard to healthcare consumption, kidney function 
(eGFR), blood pressure, quality of life, satisfaction and self-efficacy regarding self-management 
behaviour. 
 
Chapter 6. For self-monitoring to be a safe alternative to regular face-to-face follow-up, patients have 
to adhere to a monitoring schedule, report test results accurately and act upon test results if these 
suggest graft failure may occur. We used data that was collected in the RCT to investigate level of 
adherence to both the self-measurement regimen and to the automatic advice patients received upon 
registering their creatinine measurements in the online SMSS (e.g. repeat measurement, contact the 
hospital) and to assess the reliability of the measurements that were registered in the SMSS.  
 
Chapter 7. The results presented in the previous chapters and their implications are discussed in a 
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After a kidney transplantation, patients have to visit the hospital very often to monitor early signs of graft 
rejection. Self-monitoring of creatinine in addition to blood pressure at home could alleviate the burden 
of frequent outpatient visits, but only if patients are willing to self-monitor and if they adhere to the self-
monitoring measurement regimen. A prospective pilot study was conducted to assess patients’ 
experiences and satisfaction.  
During three months after transplantation 30 patients registered self-measured creatinine and blood 
pressure values in an online record to which their physician had access too. Patients completed a 
questionnaire at baseline and follow-up to assess satisfaction, attitude, self-efficacy regarding self-
monitoring, worries, and physician support. Adherence was studied by comparing number of registered 
with number of requested measurements.  
Patients were highly motivated to self-monitor kidney function and reported high levels of general 
satisfaction. Level of satisfaction was positively related to perceived support from physicians (p<.01), level 
of self-efficacy (p<.01) and amount of trust in the accuracy of the creatinine meter (p<.01). The use of 
both the creatinine and blood pressure meter was considered pleasant and useful, despite level of trust 
in the accuracy of the creatinine device being relatively low. Trust in the accuracy of the creatinine device 
appeared to be related to level of variation in subsequent measurement results, with more variation 
being related to lower levels of trust. Protocol adherence was generally very high, although the range of 
adherence levels was large and increased over time. 
Patients’ high levels of satisfaction suggest that at home monitoring of creatinine and blood pressure 
after transplantation offers a promising strategy. Important prerequisites for a safe implementation in 
transplant care seem to be support from physicians and patients’ confidence in both their own self-






Kidney transplantation is the treatment of choice for end stage renal disease (ESRD) patients. It is 
associated with a reduced risk of mortality and cardiovascular events as well as better quality of life 
than treatment with chronic dialysis.1 However, patients are at risk for acute rejection, predominantly 
in the first 6 months after transplantation.2 Most patients who develop acute rejection are 
asymptomatic and present only with an increased serum creatinine. Consequently, frequent 
laboratory monitoring is essential in order to detect a creatinine increase as early as possible. Further, 
as hypertension is both a potential indicator of decreased kidney function and an important risk factor 
for kidney transplant failure3-6, blood pressure needs to be closely monitored too. Besides being 
burdensome to healthcare capacity, the high frequent monitoring visits are a burden to patients. First, 
because many patients need to travel a considerable distance to get to the hospital. Second, because 
fear of rejection, the most common stressor among kidney transplant patients7-10, is more intense 
prior to clinical visits.10 The latter is conceivable, as the visits focus on discussing laboratory results 
that indicate how patients’ graft is functioning.  
Being able to monitor creatinine and blood pressure at home could alleviate the burden of frequent 
outpatient visits and high levels of stress prior to consultations. With the development of a handheld 
point of care creatinine device, patients are now enabled to self-monitor creatinine. In contrast to 
self-monitoring creatinine, patients self-monitoring blood pressure is more common practice yet and 
the clinical benefits of home-based blood pressure measurements in kidney transplant patients have 
already been shown.11;12 However, experiences and satisfaction with self-monitoring of transplanted 
patients have never been taken into account. Research in other chronic disease populations shows 
that self-monitoring is generally highly valued by patients.13-17 However, this does not pertain to every 
patient. A factor that seems to influence patients motivation for and satisfaction with self-monitoring 
is level of trust. Patients have to trust the accuracy and reliability of the monitoring device(s)18;19 and 
their own self-monitoring skills20;21, and they have to experience support and trust from their clinician 
as well.22;23 Further, previous studies showed that self-monitoring increased patients’ feelings of 
security, reassurance and control over their own medical condition13;14;16;24;25, suggesting that 
worrisome patients have more to gain from self-monitoring than those worrying less. On the contrary, 
self-monitoring bodily symptoms can also rouse intrusive feelings of fear and doubt, especially when 
frequent self-monitoring picks up even small fluctuations.13;26 
To the best of our knowledge, there is a lack of data about the attitude of kidney transplant patients 
towards self-monitoring. This poses a problem, as the feasibility of self-monitoring is highly dependent 
on the willingness and ability of patients to monitor at home.19;27 The aim of the current study was as 
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follows. Firstly, to study kidney transplant patients’ willingness to self-monitor after kidney 
transplantation and their experiences with self-monitoring. Secondly, to assess how worries and trust 
regarding devices, personal skills and the doctor-patient interaction are related to experienced level 
of satisfaction. Thirdly, to study patients’ adherence to the measurement protocol, as a good 
adherence to the protocol is a prerequisite for safety from a clinical point of view.  
 
 
MATERIALS AND METHODS 
 
Subject and methods 
This prospective pilot study was performed at the Leiden University Medical Centre in advance of a 
randomized control trial on the applicability of self-monitoring after kidney transplantation. The study 
protocol was reviewed and approved by the Medical Ethics Committee. Patients were recruited from 
June 2010 to January 2011, at 2-4 weeks prior to a living donor transplantation. Inclusion criteria were 
being ≥ 18 years of age, mastering the Dutch language and having access to the Internet. All 
participants provided written informed consent.  
All patients received transplant care as usual. Immunosuppressive regimens comprised of basiliximab 
for induction (except for one patient receiving Alemtuzumab) and glucocorticoids, tacrolimus and 
mycophenolate mofetil for maintenance therapy. To optimize levels of the immunosuppressive agents 
regular monitoring of through levels was combined with monitoring systemic exposure (as measured 
by areas under the curve) at 6 weeks and 6 months post-transplantation and yearly afterwards.  
In addition to regular outpatient care, participants monitored level of whole blood creatinine and 
blood pressure at home during the first 12 weeks after kidney transplantation. They received a 
planning starting from the day after discharge. Measurement frequency was decreased stepwise, 
ranging from daily in the first weeks to once a week in weeks 9-12. Patients registered their 
measurement results in an online disease management system (DMS) to which their physician had 
access too.  
Patients completed a questionnaire at discharge from hospital after kidney transplantation (i.e. 
baseline) and at the end of the study period after twelve weeks (i.e. follow up). Baseline 
questionnaires and return envelopes were supplied one day in advance of discharge from the hospital. 
Follow-up questionnaires were sent out after completing the study period, that is after 12 weeks.  
The first 10 patients who finished participation were interviewed about their experiences. A semi-
structured protocol was applied with open-ended questions that reflected topics from the 
questionnaire (see Supplemental table 1). Interviews were recorded and transcribed in full. As 
 
 
interview data were only used to facilitate interpretation of quantitative results, no further formal 
coding and analysis was conducted.  
 
Self-monitoring procedure 
Prior or immediately following transplantation, patients received instructions about how to perform, 
interpret and record the creatinine and blood pressure measures. 
For self-monitoring creatinine, each participant received a StatSensor® Xpress-i™ Creatinine Hospital 
Meter (Nova Biomedical, Waltham, USA; certified according to ISO 13485:2003, IVDD, meets IEC 
61010, UL and FDA labelled for in-vitro diagnostic use), and measurement accessories (i.e. test strips, 
control solution to test the quality of the strips, and safety lancets for capillary blood sampling). 
Although the devices’ accuracy for detecting current kidney function with a single creatinine 
measurement is debated 28-31, it seems suitable for monitoring creatinine trends with serial creatinine 
measurements in kidney transplant patients.31 It is important to distinguish between these 
applications, as this determines the analytical performance requirements of the device.32 In case of 
trend monitoring, the accuracy of a single creatinine test result is less critical as test results are used 
to detect changes between sequential measurements. Patients received specific instructions about 
how to interpret sequential results, rather than single measurements. Further, values registered in 
the online DMS were depicted in a graph to support trend-wise interpretation of test results.  
For self-monitoring blood pressure, each participant received a Microlife WatchBP® Home (Microlife, 
Heerbrugg, Switzerland), an oscillometric device for blood pressure self-measurement on the upper 
arm. The Microlife WatchBP® Home fulfils the validation requirements of the ESH International 
Protocol for self-monitoring blood pressure at home.33  
 
Questionnaires 
Both validated and questionnaires that were specifically developed for the study were used. We 
measured level of general and more specific satisfaction, experience with self-monitoring, amount of 
transplant related worries (Worry scale, Transplant Effects Questionnaire34, trust in own monitoring 
skills (self-efficacy) and patients’ perception of the level of autonomy support from their physician 
(Health Care Climate Questionnaire35). Item examples, answering scales and time of application are 
listed in table 1.  
Demographics that could not easily be extracted from the hospital system (marital status, nationality, 
educational level and Internet use) were self-reported at baseline. Education level was based on the 
highest level of education accomplished, and categorized in three categories according to the 
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Creatinine and blood pressure values that were recorded by the patients were exported from the DMS 
database. Number of registered measurements was counted per 3-week study period (week 1-3, week 
4-6, etc.). Laboratory creatinine and eGFR (according to the Modification of Diet in Renal Disease 
(MDRD) Study equation) were exported from the hospital system. Average eGFR was calculated per 
3-week study period for each individual patient.  
 
Statistical analyses 
Descriptive statistics were calculated for patients’ creatinine, kidney function, blood pressure (Mean 
Arterial Pressure, MAP) and anti-hypertensive treatment, as well as for level of general satisfaction, 
experience with using the devices, self-monitoring skills and experienced autonomy support. When 
applicable, scores on the five-point Likert scales were grouped into three categories to describe 
patients’ views: don’t agree (score ≤2), agree (score ≥4) or neutral (score 3). T-tests were used to 
assess whether patients’ self-monitoring experiences differed between the creatinine and blood 
pressure device. Paired samples t-tests were used to compare baseline and follow-up scores regarding 
satisfaction and self-monitoring skills. To investigate whether specific patient characteristics were 
related to experiences and attitudes, Pearson’s correlations were computed with a pre-set subset of 
patient characteristics that was derived from the literature, being age, gender, level of trust in 
accuracy of the devices (creatinine and blood pressure), support from the physician to be 
autonomous, self-efficacy regarding self-monitoring and transplant related worries.  
Adherence to measurement frequency according to protocol was calculated by dividing the number 
of online registered measurements per week by the number of requested measurements per week. 
This procedure has been used before to calculate adherence to self-monitoring blood glucose.37  
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During period of inclusion, 42 patients received a kidney from a living donor. Of the 34 eligible patients, 
32 gave informed consent. Two patients dropped out because of serious medical complications 
following surgery. Thirty patients received the self-monitoring equipment and started performing self-
measurements after a mean of 8 (SD=3) days after transplantation. One patient was lost to follow-up 
(see supplementary data figure 1 for the study flow chart). Characteristics of the study population are 
shown in table 2. The majority of patients were female, married or living together and of Dutch origin. 
Just over half was transplanted prior to initiation of dialysis (preemptive).  
The baseline questionnaire was completed by 30 (100%) and the follow-up measure by 25 (83%) 
patients. Although the number of patients who did not complete the follow-up questionnaire was too 
low to conduct formal analyses, non-responders to the follow-up questionnaire seemed to perceive 
more disadvantages of performing and interpreting self-measurements at baseline than responders. 
The ten patients that were interviewed seemed representative of the total study population (i.e., no 
differences were observed regarding sociodemographics, internet experience, satisfaction and 
opinions about self-monitoring (data not shown). Patient quotes that reflect questionnaire results are 
given in table 3.  
 
Clinical data 
Mean level of creatinine and mean eGFR measured at baseline was 132 (SD 35) and 51 (SD 19), 
respectively. Mean level of creatinine and mean eGFR at follow-up was 134 (SD 37) and 49 (SD 11), 
respectively. Mean arterial pressure (MAP) was 101 (SD 7) at baseline and improved over time (see 
table 2). Twenty-one out of 30 patients (70%) were prescribed antihypertensive treatment at 
discharge after transplantation. For one patient, baseline antihypertensive treatment could not be 
traced. The remaining patients (n=8) did not use any antihypertensive medication at baseline. Mean 
number of antihypertensive prescriptions was 1.28 per patient (ranging from 0 to 3).  
During period of inclusion, three patients experienced an episode of acute rejection (at 26, 84 and 90 
days post-transplantation, respectively). For two of these patients, a steep increase in blood level 
creatinine was visible in the self-measured creatinine values preceding hospital admittance for 
rejection treatment. The third patient did not self-monitor creatinine in the week preceding diagnosis 
of acute rejection. It therefore remains unclear whether this specific rejection could have been 
detected at home. 
 
 



























¹ Laboratory based assessment; ² Baseline = measured at first outpatient consult (mean 13 days since transplantation); 
follow-up = measured at first outpatient consult after finishing study participation (mean 101 days since transplantation); 3 
Home-based assessment; 4 Baseline = first value measured at home (mean 8 days since transplantation); follow-up = last 
value measured at home (mean 88 days since transplantation). 
 
  
Characteristics Study population (N=30) 
Sociodemographic  
Age (years)  
Mean ± SD 49.5 ± 13.01 
Min - max 25 - 70 
Male, no. (%) 10 (33.3) 
Marital status, no. (%)  
Single  4 (13.3) 
Married or living together 26 (86.7) 
Nationality, no. (%)  
Dutch 27 (90) 
Other  3 (10) 
Educational level, no (%)  
Low  9 (30) 
Middle  9 (30) 
High 12 (40) 
Clinical  
Renal status prior to transplantation,  
no (%) 
 
Pre-emptive 17 (57) 
Dialysis dependent 13 (43) 
Hemodialysis  8 (27) 
Peritoneal dialysis  5 (16) 
Creatinine (µmol/l) mean ± SD  
Baseline² 132 (35) 
Follow-up²  134 (37) 
  eGFR¹ mean ± SD  
Baseline² 51 (19) 
Follow-up²  49 (11) 
  MAP3 (mmHg) mean ± SD mean   
Baseline4 101 (7) 
Follow-up4  97 (13) 
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Patients’ experiences with using the measurement devices  
The majority of patients considered using the creatinine and blood pressure devices to be pleasant 
(95% and 100%, respectively), useful (91% and 100%, respectively) and reassuring (63% and 76%, 
respectively). Trust in accuracy of the creatinine meter was significantly lower than trust in accuracy 
of the blood pressure meter (p <.001) (see figure 1). Based on the remarks patients made during the 
interviews (table 3, quote 1), we hypothesized that levels of unexplained variation in successive 
creatinine measurements might have resulted in lower levels of trust in the accuracy of the creatinine 
meter. To verify this, we calculated variation in creatinine measurements designated as the mean 
percentage change from successive measurements (i.e. difference between two measurements 
divided by their average). In line with the hypothesis a higher level of mean variation was related to a 
lower level of trust in the creatinine meter (p=.03). However, no associations were found between the 
amount of mean variation in creatinine results and whether using the creatinine meter was considered 
pleasant, reassuring or useful (p=.78, .71 and .57, respectively). The same analyses were conducted 
with regard to variations in successive measurements of Mean Arterial Pressure (MAP). Mean 
variation in MAP was neither related to trust in accuracy of the blood pressure meter (p=.86), nor to 
whether use of the blood pressure meter was considered pleasant, reassuring or useful (p=.88, .43 
and .99, respectively). 
 
Psychological measures: self-efficacy, perceived autonomy support and worries 
Patients reported a high amount of trust in their own monitoring skills at baseline (M= 4.37, SD=.49) 
already and this did not change over time (p=.69; follow-up M=4.31, SD =.78). In line with this, 
interview data suggest that self-monitoring was perceived as very easy, with half of the patients (n=5) 
spontaneously mentioning the simplicity of the required actions, while none reported any difficulties 
(table 3, quote 2).  
Although patients were generally satisfied with the level of autonomy support they received, (M=3.87, 
SD=.70) half of the interviewed patients (n=5) stated that their physicians had only limited interest in 
patients’ self-measured creatinine data. Despite the seemingly limited attention some physicians paid 
to the creatinine values measured at home, patients considered self-monitoring creatinine to be 
beneficial anyway (table 3, quote 3).  
Physicians did, however, pay attention to patients’ self-measured blood pressure results (table 3 
quote 4). In line with this, analysis of hospital records revealed that for 80% of our patients home-
based blood pressure measurements were registered in the hospital system. On average, patients 
seemed to be somewhat worried about their transplantation, but these worries declined over time 
(baseline (M=2.98, SD=.88, follow-up M=2.38, SD=.82, p.=01). 
 
 
Figure 1. Patients’ experiences with using the creatinine and blood pressure device at follow-up.  
¹ Having access to a creatinine device is pleasant / reassuring / useful; ² I have trust in the accuracy of the creatinine / blood 
pressure meter; ³ On a scale of 1 to 5.  
 
Table 3. Patient quotes from the interviews (N=10).  
Quote 1 “The accuracy [of the creatinine device] is not optimal. That’s why you start to 
take everything with a pinch of salt after a while.” Male, age 38. 
Quote 2 “When you’ve seen it once, you can start doing it yourself right away.” Male, 
age 38. 
Quote 3 “That you’re on top of it yourself is the most important to me.” Male, age 51. 
Quote 4 When I took the list with all my measures with me, the doctor only looked at my 
blood pressure.” Male, age 65. 
Quote 5 “It gives a sense of security that if something happens, you notice it right away.” 
Male, age 65.  
Quote 6 “I sometimes get the idea that the outpatient appointments are only there to 
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Patients reported high levels of satisfaction with the self-monitoring facilities of the DMS (baseline 
M=7.25, SD=1.23) which significantly increased over time (follow-up M=7.78, SD=1.19, p=.01) A high 
level of satisfaction at follow-up was related to higher levels of trust in the accuracy of the creatinine 
meter (p<.01), perceived autonomy supportiveness of physicians (p<.01) and self-efficacy concerning 
self-monitoring skills (p<.01).  
The most important perceived advantage of self-monitoring at follow-up was the receipt of an 
automatic warning in case creatinine level was increased (table 4 and table 3, quote 5). In general, 
patients tended to agree with the list of suggested advantages, whereas they tended to disagree with 
the list of suggested disadvantages (table 4). Slight changes were observed in the ratings of advantages 
and disadvantages over time (table 4). For example, the advantage that physicians had access to the 
values measured at home was rated as less advantageous at follow-up than at baseline (p=.01).  
 
Patients’ adherence to measurement protocol 
Level of adherence to measurement protocol is depicted in figure 2. As number of registered 
creatinine and blood pressure values was similar within patients, adherence rates pertain to both 
creatinine and blood pressure measurements. Mean adherence was consistently close to or greater 
than 100% (i.e. more measurements than requested were registered). However, there were large 
differences between patients that increased over time. Adherence ranged from 0 to 367% during the 
follow-up period in week 10-12, with 4 patients recording less than 80% and 14 patients recording 
more than 120% of the required measurements. None of the patient characteristics was related to 
measurement adherence. We hypothesized that either patients’ kidney function (i.e. eGFR according 
to the MDRD formula using laboratory serum creatinine) or the amount of variation in successive 
measurements might be related to how frequent patients measured their creatinine and blood 
pressure. Additional analyses showed that kidney function was not related to measurement frequency 
(p .33). However, between measurement frequency and mean variation in successive measurements 
a trend was observed (p .08), suggesting a higher amount of variation to be related to lower 







Figure 2. Percentage adherence to measurement frequency per protocol. 




Patient self-monitoring after kidney transplantation could possibly alleviate the burden of frequent 
outpatient visits and high levels of stress prior to consultations. The feasibility of self-monitoring, 
however, is highly dependent on the willingness and ability of kidney transplant patients to monitor 
at home. The current results showed that patients were highly motivated to self-monitor kidney 
function and reported high levels of general satisfaction. The use of both the creatinine and blood 
pressure meter was considered pleasant and useful, despite level of trust in the accuracy of the 
creatinine device being relatively low. Trust in the accuracy of the creatinine device appeared to be 
related to level of variation in subsequent measurement results, with more variation accompanying 
lower levels of trust. Average adherence to the monitoring protocol was good, but large individual 
differences between patients were found that increased over time. 
Our results indicate that self-monitoring may be highly attractive to transplanted patients. Especially 
in the first six months after transplantation, when a relative high risk of rejection2 necessitates high 
frequent monitoring, self-monitoring may provide both additional reassurance to patients about how 
their graft is functioning and a potential measure to diminish number of outpatient appointments. 
The experience of an extra sense of security, reassurance and control has been reported in other self-
monitoring studies.14-17 Our high response rate (32 out of 34 willing to participate) further suggests 
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their graft is functioning and a potential measure to diminish number of outpatient appointments. 
The experience of an extra sense of security, reassurance and control has been reported in other self-




Table 4. Experience of advantages and disadvantages of self-monitoring at baseline and follow-up.  
 Baseline Follow-up Dependent  
t-test 
It is an advantage that… Mean* SD Mean* SD   p 
- I can control creatinine regularly 4.20 .91 3.84 1.38 .15 
- I can control blood pressure regularly 4.20 .91 4.08 1.15 .60 
- Physicians have direct access to results 4.72 .46 3.96 1.31 .01 
- Changes in my condition are noticed  
 quickly 
4.76 .52 4.08 1.19 .02 
- I have to take up a more active role in my 
 own care 
4.68 .56 4.04 1.06 .01 
- I receive a warning in case of raised 
 creatinine levels 
4.76 .44 4.20 1.04 .01 
It is a disadvantage that…      
- I have to perform measurements myself 1.60 1.00 1.36 .91 .16 
- Performing the measurements takes  
 time 
2.00 1.32 1.48 .92 .05 
- I have to interpret results myself 1.72 1.17 1.16 .47 .03 
- I can keep track of values digitally 1.88 1.13 1.12 .44 .00 
- I have to take up a more active role in my 
 own care 
1.68 1.18 1.36 .91 .12 
* On a scale of 1-5.  
that self-monitoring is not just an attractive option for a small selection of patients, which has been 
observed in other chronic disease populations27;38-40, but may be appealing to the majority of 
recipients of a living donor kidney. 
However, for a successful implementation of self-monitoring into post-transplantational care some 
barriers should be considered. Several factors were related to patients’ satisfaction with self-
monitoring. Firstly, although patients’ relatively low levels of trust in the accuracy of the creatinine 
meter did not seem to discourage them from measuring, patients were more satisfied if they 
perceived the self-monitoring devices as being reliable. This corresponds with existing literature, 
showing that patients’ confidence in the accuracy and perceived reliability of devices is an important 
prerequisite to the acceptance of these devices.18;19 Although patients received instructions for trend 
monitoring, their unfamiliarity with interpreting successive rather than single measurement values 
may have hampered their trust in the creatinine device. Indeed, trend monitoring may be more 
 
 
demanding than interpreting a single measurement value, as trend monitoring requires a careful 
consideration of the combination of several measurements.  
Secondly, satisfaction about self-monitoring was related to patients’ perceived support from their 
physicians to be autonomous. This is in line with self-determination theory41, which emphasizes the 
need of autonomy supportive social contexts. It also emphasizes that patients do consider self-
monitoring as a care system in which their physicians keep playing an important role. Indeed, several 
studies show that patients consider self-monitoring as a less attractive option if this automatically 
implies a loss of human interaction with the clinical staff.19;42  
Although patients were satisfied with the general amount of autonomy support from their physicians, 
interview data revealed that several physicians paid little attention to the self-measured creatinine 
data. Previous studies have also shown that physicians may be somewhat hesitant towards patient 
self-monitoring.43;44 It has been suggested that physicians consider it difficult to determine whether 
patients are capable of self-monitoring and interpreting the measurements45;46, are afraid that self-
monitoring will lead to a loss of control over therapy, and think that allowing patients to self-monitor 
will be more time-consuming.45;47;48 However, in the current study physicians did pay attention to self-
measured blood pressures. The difference in attention for creatinine and blood pressure 
measurements might be due to a relatively low level of trust in the accuracy of the creatinine device. 
Although they were also informed on the suitability of the device for monitoring creatinine trends, 
physicians expressed doubts about the accuracy of the meter due to a variation in successive 
measurements. The greater familiarity with home-based blood pressure monitoring might have also 
played a role. The positive effects of self-monitoring blood pressure on therapy outcomes have been 
clearly demonstrated27;49, whereas for self-monitoring creatinine this has yet to be established.  
Thirdly, patients were more satisfied if they had a high self-efficacy regarding their own monitoring 
skills. The importance of self-efficacy for experienced satisfaction has been shown before20;21, 
suggesting that thoroughly instructing and supporting patients are important prerequisites for 
successful and satisfactory self-monitoring.  
Our data did not support the suggestion that self-monitoring bodily symptoms could cause 
(unnecessary) worry and doubts13;26, or would be more or less beneficial for worried patients.  
Finally, to enhance a safe implementation of self-monitoring in which self-measured values are an 
important source of information, patients should adhere to the self-monitoring protocol. Non-
adherence to the protocol may leave serious complications unnoticed, which could ultimately lead to 
permanent loss of kidney function. Protocol adherence in the current study was generally good with 
the majority of patients measuring more often than requested. Considering that fear of rejection is 
common in patients after a (recent) transplantation7-10, it is tempting to assume that conducting extra 
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measurements indicates a high need for reassurance. In the current study, however, no relation was 
found between measurement frequency and level of transplant related worries. Besides patients 
performing more measurements than required, some patients did not adhere to the protocol and 
their number increased over time. The current dataset did not offer a clear-cut explanation for this 
finding, although a trend for a negative relation between measurement frequency and amount of 
variation in subsequent creatinine test results was observed. This suggests the existence of a relation 
between higher amount of variation and lower measurement frequency and vice versa. In addition to 
the suggested role of level of variation, two features of this study could have contributed to a lower 
level of adherence over time. First, the limited attention some physicians paid to measurement results 
might have reduced the perceived need to perform the measurements. Second, as self-monitoring 
creatinine and blood pressure was an add-on service to regular outpatient care, patients were not 
dependent upon their own measurements for information on their kidney function. This could have 
diminished patients’ perceived need to self-monitor. Adherence might therefore improve when 
monitoring at home has a more prominent role in post-transplantational care instead of being just an 
add-on service. Nevertheless, protocol non-adherence remains a serious issue to consider in future 




To the best of our knowledge, this is the first study to investigate the possibility of self-monitoring 
kidney function after kidney transplantation and the first study on kidney transplant patients’ attitude 
towards self-monitoring. The results show that self-monitoring creatinine and blood pressure after 
kidney transplantation is well received by kidney transplant patients. However, the relatively small 
number of participants and the selection of recipients of living donor kidneys prevents us from 
drawing strong conclusions that can be generalized to the entire kidney transplant population. 
Further, as non-responders to the follow-up questionnaire seemed to be somewhat less positive about 
self-monitoring at baseline, the absence of their follow-up experiences could have introduced a small 
bias towards a positive evaluation.  
Overall, our results suggest that a self-monitoring care system has the potential to improve post-
transplantational care in several ways. Firstly, by increasing patient satisfaction.14;17;24;27;37;38;50-52 
Secondly, by decreasing the high number of outpatient visits, as important parameters can be 
monitored at home. Finally, by advancing the detection of acute rejection and hypertension due to 
higher frequent monitoring, which may improve kidney graft survival.5;53-59 Future studies should 
 
 
determine whether it is feasible and safe to implement patient monitoring kidney function and blood 
pressure into transplantational care.  
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Self-management support systems (SMSS) have been proposed for renal transplant patients to increase 
their autonomy and reduce the number of hospital visits. For the design and implementation of such 
systems, it is important to understand factors influencing patients’ acceptance of a SMSS. This paper aims 
to identify these key factors.  
From literature, possible factors and related questionnaire items were identified. Afterwards, focus groups 
with experts and patients were conducted to adapt the items to the application domain. To investigate 
acceptance of a SMSS and the influencing factors, fifty renal transplant patients answered the questionnaire 
before and after using the SMSS for four months.  
All the questionnaire constructs had a satisfactory or higher level of reliability. After using the SMSS for four 
months, trust and performance expectancy could explain part of the variation in behavioural intention of 
using the SMSS, but not beyond the explanation given by patients’ affect towards the system, which 
accounted for 26% of the variance. 
We anticipate that in future caregivers implementing a SMSS will benefit from taking steps to improve 






Chronic kidney disease (CKD) is regarded as a major public health problem [1]. In the last stage of this 
disease, referred to as end-stage renal disease (ESRD), the preferred treatment is renal transplantation. 
Mortality rates for these patients are less than half compared to patients receiving dialysis treatment [2]. In 
addition, patients gain more freedom and energy from a successful kidney transplantation than from dialysis 
[3]. After kidney transplantation, however, patients need to adhere to a strict medication regimen and are 
followed-up frequently to monitor for signs of graft dysfunction or comorbidities. Kidney transplant patients 
are therefore still considered to have a chronic disease.  
Self-management, the process of managing symptoms, treatment, physical and psychosocial consequences 
by patients themselves in daily life, has been proposed to be useful when dealing with chronic illness [4]. 
Self-management support systems (SMSSs) can help to increase the level of self-management [5]. These 
systems aim at empowering patients by giving them more control of their care process and daily activities 
and thereby increasing their autonomy [5].  
SMSSs have already been successfully used in the health domain to support healthy behaviours, and reports 
indicate that people are capable of using them. Examples include an internet-based diabetes self-
management and support system [6], and systems to manage physical activities [7-9], fruit and vegetables 
consumption [8], and medication intake [9].  
 
Need For a Specific Model 
Besides users’ capability, their willingness, i.e. acceptance of using a SMSS, is also important. Several 
theories and models have been proposed to explain users’ acceptance of information technology (IT) or 
information systems. These theories explore the underlying factors of users’ acceptance, so that designers 
and organisations can anticipate on them to improve system acceptance. Both generic and specific models 
have been developed. The theory of reasoned action (TRA) [10], the theory of planned behaviour (TPB) [11], 
and the technology acceptance model (TAM) [12] are generic models formulated to apply across domains. 
Specific models, which are often derived from generic models, have been formulated for specific domains, 
such as models for Internet commerce [13, 14], online gaming [15], and mobile commerce [16].  
In the area of health informatics and chronic diseases, understanding the acceptance of a SMSS could benefit 
from a specific model with its own unique set of factors and values, as the use of the technology may 
influence patients’ health and lives: people may be more concerned and reserved to use an SMSS. For 
example, interviews with diabetic patients about a SMSS for their insulin therapy showed that emotional 
aspects were important, such as being embarrassed to inject insulin in public or fear of hypoglycaemia when 
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increasing insulin dose [17]. For patients with depression or with an increased risk of cardiovascular 
problems, the level of interest in using a telehealth application was found to be related to confidence and 
perceived advantages and disadvantages of the application [18]. Furthermore, studies of internet-based 
testing for sexually transmitted diseases [19] and the use of personal electronic health records and secure 
messaging [20] put forward internet and technology usage, health care access, provider satisfaction, 
interactions between environmental factors, and interactions between patient activation and tool 
empowerment potential as key factors determining people’s use of SMSSs. Arning and Karsh have also 
noticed that the current IT acceptance models were insufficient to understand patients [21, 22], and various 
researchers have worked on determining relevant factors that explain patients’ behavioural intention to use 
eHealth technology [22-25]. 
Renal transplant patients, however, might be at more risk than the previous examples of chronic patients, 
as rejection can occur acutely with the risk of losing the transplanted kidney. Although other domains such 
as office applications or e-commerce, even the eHealth domain in general, have received substantial 
research attention, less is known about patient acceptance of a SMSS in general and more specifically, the 
acceptance of a SMSS by renal transplant patients. 
 
Objective 
To better understand the renal transplant patients and their acceptance of using a SMSS, this paper studies 
their intention of using a SMSS and the underlying factors that explain this use intention. This understanding 
would allow system designers and health program managers to direct their attention and effort effectively 
and efficiently.  
Literature Review  
The most well-known models or theories that have been used to explain peoples’ acceptance of technology 
are the theory of reasoned action (TRA) [10], the theory of planned behaviour (TPB) [11], the technology 
acceptance model (TAM) [12], and their extensions, such as TAM2 [26], the unified theory of acceptance 
and use of technology (UTAUT) [27], and TAM3 [28]. These models are used widely, and their coefficient of 
determination (R2) ranged from 17% to 70%. In other words, the factors in these models can explain this 
amount of variation between people’s intentions to use information technology [27]. R2 is calculated by the 
squaring the correlation between the predicted behavioural intention by the model and the actual 
behavioural intention reported by the individuals. Further meta-analysis and review showed that TAM and 
its extensions are valid and robust, but more variables should be integrated to enhance the explained 
  
 
variance regarding the acceptance and use of technology [29, 30]. These models are generic as they were 
aimed to apply across domains, and did not consider the different context of specific domains, such as 
eHealth or eCommerce. These generic theories and models have been used to formulate a renal transplant 
patient technology acceptance (RTPTA) model for a SMSS (Figure 1). In the remainder of this section, each 
determinant in the model is defined and provided with the theoretical justification. 
Performance Expectancy 
Performance expectancy (PE) is adapted from UTAUT [27] and is defined here as the degree to which renal 
patients believe that using the system will help them attain gains or make losses with the performance of 
their health management. It investigates if participants expect that the system can help them with 
monitoring their health. PE is strongly related to the perceived usefulness construct in TAM [31]. In many 
studies, PE has been shown to be one of the strongest predictors of behavioural intention [23, 24, 27] and 
it has been used in the health informatics domain before, for example by Ahadzadeh [23] and Beenkens 
[24]. This leads to the first hypothesis:  
H1: Performance expectancy positively correlates with patients’ intention to use the SMSS. 
Effort Expectancy 
Effort expectancy (EE) is defined as the degree of ease associated with the use of the system [27], e.g., 
whether patients experience any difficulties using the system. Perceived ease of use (PEOU) in TAM is a 
theoretically similar construct and is mainly found an effective predictor for peoples’ use intention when 
they are new to a technology [27]. EE has been shown to have a significant effect on patients’ intention of 
using an e-health service [24]. This leads to the second hypothesis:  
H2: Effort expectancy positively correlates with patients’ intention to use the SMSS. 
Social Influence 
Social influence (SI) is also adapted from UTAUT [27] and is defined here as the degree to which renal 
patients perceive that important others believe they should use the system. It refers to what people in the 
patients’ environment think of using the system. TRA, TPB, TAM2, and TAM3 refer to this construct as 
subjective norm [11, 26, 28, 32]. Venkatesh et al. were unable to find SI as an effective predictor for 
voluntary technology use [27]. However, they did find it to be an effective predictor in a compulsory use 
context, for example when the working environment requires using that specific software application; but 
only at a stage where people had limited use experience. In the context of health-management, patients’ 
usage of a technology is often voluntary, the decision on whether or not using a system might be influenced 
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by health-providers, family members, or fellow patients. Kim and Park have reported subjective norm to 
have a strong indirect association with patients’ behavioural intention of using health information 
technology via perceived usefulness [25]. This leads to the third hypothesis:  
H3: Social influence positively correlates with patients’ intention to use the SMSS. 
Facilitating Conditions 
The factor referred to as facilitating conditions (FC) is often put forward as an effective predictor [27, 33]. In 
the current model, FC is defined as the degree to which renal patients believe that there are objective factors 
available in their environment to support their use of the system [27]. Examples of these objective factors 
include a computer that is appropriate for use of the system, and the availability of supporting others who 
can help to use the system if needed. Studies have reported mixed outcomes concerning the relevance of 
facilitating conditions for behavioural intention[27, 34, 35]. In the eHealth domain, however, facilitating 
conditions are considered an important predictor of patients’ acceptance [22]. This leads to the fourth 
hypothesis:  
H4: Facilitating conditions positively correlate with patients’ intention to use the SMSS. 
Affect 
Affect (AF) is defined as the renal patients’ overall affective reaction towards using the system. It addresses 
whether individuals find it pleasant to use the system. TRA, TBP, TAM nor UTAUT include the emotional 
reaction in performing the intended behaviour directly in their model. Instead, emotional outcomes are only 
indirectly included in the models as attitude towards the intended behaviour [12, 32, 36, 37]. Others have 
argued for the inclusion of affect as a separate construct because one’s liking of a technology could influence 
his or her actual usage of this technology [38]. For example, computer games are used in healthcare domain 
because they have the advantage of entertaining people in otherwise painful or boring health promoting 
processes [39]. Anxiety, as the opposite of liking, is expected to negatively influence system use [38]. In fact, 
affect has been found to be a predicting factor for general IT usage [38]. This leads to the fifth hypothesis:  
H5: Affect positively correlates with patients’ intention to use the SMSS. 
Self-efficacy 
Self-efficacy (SE) is a key factor in predicting people’s behaviour as it determines if they will initiate certain 
behaviour, how much effort they will spend on it, and how they will cope with potential obstacles [40]. In 
the current model, SE is defined as the degree to which renal patients judge themselves capable of using 
the system to manage their health, which is in line with Compeau and Higgins[38]. The concerning items 
  
 
address if patients think they can handle the system. So far, results concerning the role of self-efficacy in 
technology acceptance have been mixed. Venkatesh et al., for example, left out self-efficacy in the UTAUT 
model because they failed to find a stable association over time between self-efficacy and behavioural 
intention [27]. Others, however, do report self-efficacy beliefs as a significant precursor to information 
technology use [41, 42]. In the health informatics domain, however, self-efficacy was found to be indirectly 
linked with behavioural intention by influencing perceived usefulness and perceived ease of use [25]. This 
leads to the sixth hypothesis:  
H6: Self-efficacy positively correlates with patients’ intention to use the SMSS. 
Trust 
Trust (TR) is defined as the degree to which patients believe that using the system will occur in a safe and 
reliable manner, consistent with their expectations of the health management task [13]. The latter is 
important because using any system does not mean that the patients themselves will always be safe, but 
that the system will run in a safe and reliable way. Participants are therefore asked how trustworthy they 
find the system. Although trust is not included in the generic models, it has been included in extensions of 
these models, for example as an extension of TAM regarding Internet shopping [43, 44]. In this case, people 
are concerned about losing their money, which might stop them from making online purchases. Similarly in 
the health informatics domain, various trust aspects have been identified, including personal technical 
insecurity, perceived threat, and perceived health risk [23-25]. Renal patients’ trust in a SMSS is therefore 
suggested to influence their willingness to use such a system. This leads to the seventh hypothesis:  
H7: Trust positively correlates with patients’ intention to use the SMSS. 
Behavioural Intention 
Behavioural intention (BI) is defined as the degree to which an individual intends to perform a certain 
behaviour [12]. People’s behavioural intention determines their performance of the behaviour and it is 
widely used to evaluate user acceptance of technology [12, 15, 23, 24, 27]. In the case of a SMSS for renal 
patients, the intended behaviour is the patients’ use of this system for managing their health. In this paper 
it is hypothesised and tested that all the factors introduced earlier on, i.e. PE, EE, SI, FC, AF, SE, and TR, 
positively correlate with patients’ intention to use and therefore acceptance of the SMSS (figure 1).  
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address if patients think they can handle the system. So far, results concerning the role of self-efficacy in 
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The data used in this study were collected in the context of a randomized controlled trial, which included an 
intervention group that used a SMSS during the first year post-transplantation and a control group that 
received usual care, which did not include self-management. The general aim of the randomised controlled 
trial was to investigate whether part of the post-transplantation care can be transferred to a home setting 
using a SMSS without compromising on the quality of care.  
The study presented in this paper focuses on a survey completed by the intervention group only. The survey 




Patients used a blood pressure meter and a creatinine device at home to measure their blood pressure and 
kidney function according to a fixed schedule. They were instructed to enter the measured values into a 
specially designed website called MijnNierInzicht (MNI), which was designed by the LUMC with help from 
the Dutch Organization for Applied Scientific Research (TNO) and maintained by company Bonstato. After 
entering their measured values, the website provided patients with an overview of their measurement 
history, an evaluation of their current renal function, and instructions for further actions, which could be: to 
continue their regular schedule, to conduct an additional measurement, or to contact the hospital. Besides 
the advice and monitoring function, the system included online learning modules (eLearning) providing 
relevant information, such as bodily functions, renal transplantation, and self-management. The system 
further allowed patients to record their weight, body temperature, and scheduled face-to-face and phone 
appointments with their doctors. The measuring devices, MNI website, and eLearning formed together the 
SMSS and in the survey it was referred to as the ADMIRE (Assessment of a Disease management system 
with Medical devices In REnal disease) system.  
 
Measures 
A tailored renal transplant patient technology acceptance questionnaire was developed for this study. This 
questionnaire included several items to measure each construct included in the renal transplant patient 
technology acceptance model. Initial questionnaire items were based on the questionnaires reported in the 
literature [12, 13, 31-33, 36-38, 45-48]. These initial items were discussed in workshops with a doctor, 
experienced patients, and researchers in the self-management domain. This resulted in an adjusted set of 
items that was adapted to 1) the content of the SMSS and 2) patients’ language and knowledge. The items 
were all statements that had to be rated on a 7-point Likert scale with 1 for totally disagree to 7 for totally 
agree with the statement and a ‘not applicable’ option. Participants were asked to complete the 
questionnaire at the start of the study (T0) and after four months of using the SMSS (T1). In most cases, at 
T0, the questionnaire items formulation prompted for future use, while at T1 the items formulation 
prompted for current use. For example, the performance expectancy item PE1 at T0 was formulated as “with 
the ADMIRE system, I will be able to monitor my health very well myself”, while at T1 it was formulated as 
“with the ADMIRE system, I can monitor my health very well myself”. Still, both in T0 and T1 items related 
to the behavioural intention always prompted for future usage. The items were in Dutch. An English 
translation of the T1 questionnaire items can be found in Additional file 1. At T0, patients’ demographic data 
was collected, including the knowledge dimension items of the Partners in Health (PIH) scale that assesses 
patients’ perceived chronic condition self-management knowledge [49]. The PIH items were rated on a 9-
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point Likert scale from 1, for very poor, to 9 for very good. In addition, health-related information was 
obtained from the hospital record.  
Besides collecting data related to the RTPTA model, additional data was collected related to the specific 
implementation of this SMSS. The additional questions focussed on satisfaction with the training given in 
using the system (training), patients’ options on conducting self-management through the system (self-
management), contact with doctors (doctor), the time needed to use the system (time), the use of the 
creatinine device measuring kidney function (creatinine), the use of the blood pressure meter (blood 
pressure), and their feeling of conducting self-management at home (feeling, only asked at T1 as patients 
had to have experience with using the SMSS before being able to respond to these items, see Additional file 




Intake and training procedure differed between patients receiving a kidney from a living donor and those 
receiving a kidney from a deceased donor. For recipients of a living donor kidney, the transplantation 
procedure could be well prepared, so they received an explanation about the experiment, signed the 
consent form, and got access to MNI website and eLearning before the transplantation. They were explained 
how to use the system and were encouraged to try it themselves before transplantation. For patients who 
received a kidney from a deceased donor, the whole procedure was postponed to after transplantation, but 
was preferably arranged before discharge from the hospital. Around the day of discharge (T0), all patients 
were asked to complete the T0 questionnaire. At home, patients were asked to use the system regularly, 
according to a predefined schema for one year: measure and log the data daily during the first four weeks, 
every other day for week 5-9, twice a week for week 10-15, and weekly from week 16 onwards. After four 
months of using the system (T1), patients were again asked to complete the questionnaire. Both the baseline 
and the follow-up questionnaires were distributed in paper form.  
 
Participants 
The intervention group consisted of renal transplantation patients who had their most recent 
transplantation in the LUMC. Sixty-five patients were enrolled into the trial, fifty of them responded to the 
questionnaire at least once, and 47 completed the one-year trial. Eighteen patients dropped out: one 
patient’s transplantation was cancelled, four patients cancelled participation before start, one patient was 
excluded due to high level of creatinine after transplantation, two patients died before start, one patient 
died after start, four patients never used the system, and five patients quitted after using the system for a 
  
 
while. These five patients indicated a variety of reasons for this: variety in self-measured creatinine values 
(n = 3), stress caused by self-monitoring (n = 1), and too little benefit (n = 1). The profile of the participants 
who responded to T0 and T1 questionnaire is shown in Table 1. In both cases, 46 patients completed the 
questionnaires. Although these populations were not made up of the exact same responding patients, no 
significant differences in profile were found between the populations who responded at T0 and T1. 
 
Data preparation  
Not Applicable and Missing Data 
A distinction was made between situations where participant specifically indicated that a question was not 
applicable (NA) for them, or when they had left the question unanswered, i.e. missing values. The relative 
NA percentage, i.e., the number of NA/(the number of participants - the number of missing values) × 100% 
for each item was calculated. The majority of questionnaire items (77.03%) had less than 5% of the 
participants rated the question as NA. However, items with a relative NA percentage above 1.5 × 
interquartile range (4.88%) + 3rd quartile (4.88%) = 12.20% were regarded as outliers [50] as apparently an 
unusual number of patients considered them as not applicable to their situation and were therefore not 
appropriate items to capture the underlying constructs across the patient sample. Twelve items (18%) 
turned out to be outliers and were therefore removed from the analysis, leading to the removal of the social 
influence construct all together and facilitating condition item 3 and 4 (all at T0 and T1, Additional file 1). 
For the remaining items, ‘not applicable’ was treated as missing.  
There were 394 (12.71%) values missing in total. Fifteen out of fifty (30%) participants answered all the 
questionnaire items, and none of the items was answered by all participants. To avoid exclusion of 
participants and thereby biasing the analysis [51], Maximum Likelihood methods using the expectation–
maximization (EM) algorithm was applied to substitute missing data of the RTPTA questionnaire items. This 
method produces unbiased parameter estimates with missing (completely) at random data [52]. Patients’ 
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Table 1. Participant profile 
Participants T0 T1 
Number 46 46 
Male (%) 30 (65.22%) 29 (63.04%) 
Living donor recipients (%) 40 (86.96%) 39 (84.78%) 
Dialysis before transplant (%) 24 (53.17%) 23 (50.00%) 
Age at transplant (sd) 51.43 (14.09) 51.87 (14.33) 
Educational level   
Median (number, %) Middle (24, 53.17%) Middle (22, 47.82%) 
Mode (number, %) Middle (24, 53.17%) Middle (22, 47.82%) 
Number of kidney transplants   
1 43 (93.48%) 42 (91.30%) 
2 3 (6.52%) 4 (8.70%) 
PIH - knowledge score (sd) 7.88 (1.31) 7.96 (1.33) 
 
Behavioural Intention at T0 
The behavioural intention at T0 and T1 was computed by taking the mean score of the five questionnaire 
items, as their Cronbach’s s were 0.66 and 0.79, respectively. Figure 2 shows the histogram for the score 
at both T0 and T1. At T0 almost half (45.7%) of the patients had given the maximum score, and data showed 
limited variation. Variation at T1 was larger, therefore further analyses predominantly focus on data 
collected at T1. 
 
Data Analysis 
The data were analysed using SPSS version 22. The analyses included: Pearson correlation analyses to 
examine the constructs’ correlation coefficients, controlled correlation analyses to examine factors’ 
association with behavioural intention, t-tests to analyse the factors’ change between T0 and T1, and 
  
 
hierarchical multiple linear regression to understand how much each factor explains the observed variation 
between patients’ behavioural intention. To understand the possible underlying factors, correlations 
between patients’ characteristics, factors from RTPTA model, and behavioural intention were analysed, for 
which Pearson correlation, Kendall rank correlation, or point-biserial correlation were used depending on 
the data level. Bootstrapping procedure with 1000-sample was applied to the above analyses. This 
procedure is less biased by deviation from normality assumptions and by extreme values in a small sample 
[53, 54]. Furthermore, the analysis included Cronbach’s  and principal component analysis to examine the 
constructs’ reliability. As there are currently limited reports available that directly support the proposed 
model, the principal component analysis helped to explore how well questionnaire items of the same 
construct correlated with each other, and how they related with items from other constructs. Note that at 
a later stage when the model is more mature, the application of statistical techniques such as confirmative 
factor analysis would be desirable [55].To examine the position of the rating on a 1-7 Likert scale, scores 




Reliability and Principal Component Analysis 
Table 2 shows the results of the reliability analysis for each construct at T1. The table also shows Cronbach’s 
 after items deletion for those constructs with initially low reliability level. The construct performance 
expectancy was split into three dimensions: 1) insight, meaning gaining insight into one’s renal condition; 2) 
health improvement, meaning gaining a better health status; and 3) time, meaning spending less time on 
outpatient appointments. As the dimension health improvement had a low reliability level, these items were 
excluded in further analyses.  
A principal component analysis (PCA) was conducted on the remaining 20 independent items with 
orthogonal rotation (varimax). The Kaiser–Meyer–Olkin (KMO) measure verified the sampling adequacy for 
the analysis, KMO = 0.64, respectably above the 0.5 criterion. Two individual items had a KMO value clearly 
below the acceptable limit of 0.5 [56], indicating that these items share limited variance with other items. 
Bartlett’s test of sphericity Χ² (153) = 662.24, p < .001, indicated that correlations between items were 
sufficiently large for PCA. The analysis resulted in five components with an eigenvalue over Kaiser’s criterion 
of 1. Combined they explained 73.26% of the variance. The factor loading after rotation, sampling adequacy, 
eigenvalue, the percentage of variance, and communality scores can be found in Additional file 2. 
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Figure 2. Histogram of behavioural intention measured around the discharge day (T0) and four months 
after (T1). 
 
Although some components were mainly associated with the items from a single construct, such as 
performance expectancy - time dimension and effort expectancy, other components were associated with 
multiple constructs. The items for the constructs trust, affect, and the insight dimension of performance 
expectancy loaded almost together on a single component, and the same was observed for the constructs 
self-efficacy and facilitating conditions. This, therefore, suggested dependency between some of the 
constructs.  
T0 versus T1 Measurement 
 presents mean and standard deviation for variables of the renal transplant patient technology acceptance 
(RTPTA) model. Overall patients seemed positive towards using this SMSS. Paired t-tests comparison 
between T0 and T1 showed that ratings on effort expectancy, doctor, and time increased over time, while 
behavioural intention decreased over time. The behavioural intention had an exceptionally high score at T0, 





Table 2. Construct reliability 
Constructs Cronbach’s  Items to delete Cronbach’s  if 
items deleted 
Performance expectancy .56   
Insight (PE1, PE2, PE3)  .73   
Health improvement (PE4, PE5, PE6) .15 PE6 .54 
Time (PE7, PE8) .93 - - 
Effort expectancy .67 EE3 .73 
Facilitating conditions .99   
Affect .75   
Self-efficacy .21 SE3, SE4 .85 
Trust .77   
Behavioural intention .79   
 
Correlations 
 shows correlations between the factors of RTPTA model at T1. Performance expectancy (both insight and 
time dimension), affect, and trust correlated significantly with behavioural intention. These factors also 
correlated with each other.  shows the results of controlled correlations between behavioural intention and 
the four (sub-)factors when controlled for the other (sub-)factors that correlated with behavioural intention. 
Only affect had a significant correlation with behavioural intention when controlled for other (sub-)factors.  
 
Regression Analysis 
Hierarchical multiple linear regression was conducted on behavioural intention. Bootstrapping with 1000 
samples was again applied. First, affect, the factor that partially correlated with behavioural intention, was 
entered as a predictor (model 1). After this, all remaining factors that correlated with behavioural intention 
were entered into the model (model 2). Model 1 resulted in a significant (F(1, 44) = 15.80, p < .001 ) model 
with R2 of 0.26, meaning that affect could account for 26% of the variance between patients’ usage 
intention, and the p-value suggests it was a significant predictor (table 6). Although Model 2 has its R2 
improved (0.38), it was not found significantly better in explaining behavioural intention (R2 change = 0.12, 
59
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sig. F change = 0.06) than Model 1. In other words neither performance expectancy nor trust could explain 
patients’ behavioural intention beyond affect, which was again the only significant predictor.  
The model was examined for possible biases caused by outliers or influential cases. First, the model fit did 
improve (F(1, 42) = 23.55, p < .001, R2 = 0.36) after removing two outliers with standardized residuals larger 
than 2.58, which is more than 1% of the sample cases [56]. Secondly, influential cases were examined by 
calculating Cook’s distance, leverage, and DFBeta. No cases were found having Cook’s distance or 
standardised DFBeta larger than the recommended upper value of 1 [56]. Still two patients had their 
leverage value larger than the recommend upper value of 0.13, i.e. 3×(the number of predictors+1)/n [55]. 
Excluding these two patients resulted in a model with F(1, 42) = 16.13, p < .001, R2 = 0.28. The original model 
therefore seems stable and not influenced by possible outliers or influential cases. 
Correlation with Exogenous Variables 
The constructs affect and behavioural intention were future explore by examining correlations with patient 
characteristics, i.e. age, gender, donor type, educational level, the number of kidney transplants, being 
dialyses before transplant, and PIH - knowledge dimension. The analyses were done on paired complete 
cases. The analyses revealed that deceased, compared to living donor recipients, were associated with a 
higher Affect level, rpb = .29, 95% CI[.16, .47], n = 42. Furthermore compared to patients that did not receive 
dialyses before transplant, patients that did were associated with a higher Affect level, rpb = .34, 95% CI[.07, 
.55], n = 42. The analysis also revealed that female, compared to male patients, were associated with a 





Table 3. Descriptive statistics 
 
Constructs 
T0 T1 Correlation 
T0 and T1 
Difference T0 
and T1, t(41)  Mean SD Mean SD 
   
   











Performance expectancy - insight 6.22** 0.80 6.04** 0.98 0.29 -1.47 
Performance expectancy - time 6.32** 0.80 6.22** 1.00 0.44* -0.04 
Effort expectancy 6.04** 0.87 6.57** 0.68 0.25 3.36** 
Facilitating conditions  6.72** 0.54 6.75** 0.92 -0.03 0.25 
Affect 5.87** 1.00 5.90** 1.21 0.61* -0.13 
Self-efficacy 6.06** 0.89 6.22** 1.43 0.43* 0.68 
Trust 6.10** 0.82 6.21** 0.95 0.49* 1.06 
Behavioural intention 6.63** 0.54 5.93** 1.15 0.49* -4.50** 
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Self-management 6.27** 0.85 6.35** 0.80 0.47* 0.64 
Doctor 5.80** 0.72 6.20** 0.67 0.33* 3.68** 
Time 6.38** 2.48 6.41** 0.87 0.16 2.69** 
Creatinine 6.26** 0.46 6.18** 0.77 0.29* -0.66 
Blood pressure 6.69** 0.42 6.76** 0.35 0.34 0.85 
Feeling - - 4.43** 0.63 - - 
Note: H0:  = 4, *p < 0.05, **p < 0.01 for bootstrapping of t-test, or *the 95% CI does not include 0 for bootstrapping of 
correlation. 
 
Table 4. Correlations between each construct pair. 
 PE-insight PE-time EE FC AF SE TR BI 
Performance expectancy-insight 1.00 -0.02 0.19 -0.13 0.69* -0.02 0.64* 0.32* 
Performance expectancy-time -0.02 1.00 0.13 0.47 0.20* 0.18 0.13 0.40* 
Effort expectancy 0.19 0.13 1.00 0.01 0.30* -0.02 0.27 0.13 
Facilitating conditions -0.13 0.47 0.01 1.00 0.12 0.57* -0.02 0.57 
Affect 0.69* 0.20* 0.30* 0.12 1.00 0.35* 0.79* 0.51* 
Self-efficacy -0.02 0.18 -0.02 0.57* 0.35* 1.00 0.15 0.37 
Trust 0.64* 0.3 0.27 -0.02 0.79* 0.15 1.00 0.31* 
Note: *the 95% CI does not include 0. 
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Table 5. Controlled correlation between independent factors and behavioural intention (BI). 
Factors correlating with BI Control factors Correlation 
Performance expectancy-
insight 
Performance expectancy-time, trust, and affect 0.07 
Performance expectancy-
time 
Performance expectancy-insight, trust, and 
affect 
0.36 
Affect Performance expectancy-insight, performance 
expectancy-time, and trust 
0.39* 
Trust performance expectancy-insight, performance 
expectancy-time, and affect 
-0.19 
Note: *the 95% CI does not include 0. 
 
Table 6. Model coefficients. 
 Coefficients Bootstrap Coefficients 
Model 1 B Std. Err Beta t p Bias Std. Err p 
95% CI 
Lower Upper 
(Constant) 3.05 0.74  4.12 <.001 -0.21 0.96 0.002 0.50 4.26 




Kidney transplantation is the treatment of choice for patients with end stage renal disease, but does not 
free patients from needing medical care. As kidney transplant patients have to adhere to a strict medication 
regimen and need to be frequently monitored for signs of graft dysfunction, they are still considered 
chronically ill. Self-management, the process of managing symptoms, treatment, physical and psychosocial 
consequences by patients themselves in daily life, has been proposed to be useful when dealing with chronic 
illness [4]. A self-management support system (SMSS) aimed at empowering patients by giving them more 
control of their care process and daily activities, can help to implement self-management in daily life [5]. 




Results show that patients were on average positive towards using the SMSS, both in advance of use and 
after having used the SMSS for four months. The behavioural intention to start or continue using the SMSS 
could mostly be explained by patients’ affect towards the SMSS (26% explained variance, supporting H5). 
The analysis also found performance expectancy on insight and on time, and trust to be correlated with 
behavioural intention, supporting H1 and H7 respectively. Still, these factors were not able to explain 
variation in behavioural intention beyond the affect factor. No support was found for the other hypotheses 
(H2, H3, H4, and H6). This result is different than what is usually found when using TAM or UTAUT [27], with 
effort expectancy being traditionally one of the most important factors explaining behavioural intention. 
Although 26% of explained variance is at the lower end of the range of 17% to 70% reported by other studies 
[27], the regression model included only one factor, which might be a reason for the relatively small R2. 
Although affect overlapped with performance expectancy to some extent, affect was the only remaining 
factor in the regression analysis being significantly associated with patients’ behavioural intention to 
continue using the system after four months of use. In the first few months post-transplantation, only a 
limited number of outpatient visits was replaced by a telephonic consult. Many patients, therefore, visited 
their doctors in the usual frequency, putting less need on using the system to be informed on their kidney 
function. The fact that there was no absolute need to use the system, contrary to what happens when an 
entire organisation implements a new technology and replaces the old one, might explain why affect was 
found to be the most important factor related to behavioural intention. When patients are ‘free’ to choose, 
it seems logic that emotions are crucial. Comments made by patients at the end of study participation 
confirm the emotional aspect. Some patients mentioned that if possible they would like to continue using 
the SMSS after one year, as it gave them a feeling of safety. Others indicated that the first year after 
transplantation is of most risk and as they had safely reached this milestone, they no longer felt the need to 
use the SMSS.  
It was further found that some questionnaire items, especially the social ones such as social influence and 
facilitation related to the social environment, were rated as not applicable by a substantial part of the group. 
These participants might not have understood these questions or had not discussed the use of the system 
with their social environment and felt, therefore, unable to give an answer. Reformulation of these items or 
informing people that holding social related beliefs does not require actual discussion with the social 
environment might, therefore, be advisable in the future. 
The main scientific contribution of the current study is that it introduced affect as a new factor explaining 
kidney transplant patients’ behavioural intention to use or continue using a SMSS.  In practice, the finding 
suggests that the emotional experience of using a SMSS should be taken into account when designing and 
implementing a system to be used in healthcare. Several strategies have been put forward for this, for 
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example by empowering patients to interpret their measurements, instead of providing automatic 
interpretation from the system as a method to decrease patients’ stress of using the technology [57]. 
Furthermore, using warm colours rather than bright colours to get a calming effect, and cold colours for a 
more relaxing effect [58-60]. 
 
Limitations and Future Research 
To appreciate the study, awareness of its limitation is necessary. First, the study has a relatively small sample 
size considering the number of factors included in the study. Another limitation is the way of dealing with 
the ‘not applicable’ ratings. Although items indicated as not applicable by a substantial sub group were 
excluded in the analyses, others were treated as missing values, but they could have had a different 
meaning. A third limitation is pre-selection, as the data used in this study were derived from a group of 
patients that had already agreed to use the SMSS. The high intention at the beginning of the trial to use the 
system confirms this bias. Besides, among all 36 patients who declined to participate in the randomised 
controlled trial at first place, 17 patients declined because they expected additional burden and two because 
they expected no gain of using it, which belonged to the performance expectancy factor. Fourth, the SMSS 
has different components, such as the medical devices, MNI, and the eLearning modules, and the patients 
might have held different attitudes towards them. However, their intention to use each of these 
components and the corresponding influencing factors were not investigated in the questionnaire.  
This work can be extended in several directions. First, enlarging the sample size would increase the statistical 
power, and additional research would also help to mature the model, justifying the use of more 
sophisticated statistical techniques such as confirmatory factor analysis, or, when including other dependent 
variables such as observed usage and health indicators, structural equation modelling. Second, interviewing 
some respondents would provide essential insights in, for example, how they interpreted the items, 
especially the affect items, and the rational for considering items as not applicable. This could help in the 
re-formulation of some items. Third, it would be interesting to include patients who would not use the SMSS 
to understand them as well. Another direction could be to investigate patients’ acceptance of the different 
components of a SMSS.  
Conclusions 
This study builds a model to investigate the influencing factors for renal transplant patients to accept a self-
management support system. Trust and performance expectancy could explain variation in behavioural 
intention of using the SMSS, but not beyond the explanation given by patients’ affect towards the system. 
  
 
As behavioural intention is considered an indication for system acceptance, paying attention to the 
emotional experience of kidney transplant patients when using an SMSS seems important for successful 
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Appendix A. Questionnaire Items 
1. Acceptance factors as formulated at T1 
Performance expectancy 
PE1 With the ADMIRE system, I can monitor my health very well myself. 
PE2 Through the ADMIRE system I understand my condition and treatment better. 
PE3 The ADMIRE system gives me clear insight into my current health. 
PE4 With the ADMIRE system, I can detect problems with my renal function earlier. 
PE5 I think using the ADMIRE system puts my health at lower risk. 
PE6 With the help of the ADMIRE system, I can play a greater role in my own medical care. 
PE7 I think an advantage of ADMIRE is that I can travel to the hospital less often. 
PE8 I think an advantage of ADMIRE is that I have more time for other activities, since I have fewer 
outpatient appointments. 
Effort expectancy 
EE1 Working with the ADMIRE system gives me little trouble. 
EE2 The ADMIRE system is easy to use in my daily life. 
EE3 I think the use of the ADMIRE system gives no ambiguities. 
EE4 Learning to work with the ADMIRE system is easy for me. 
Social influence 
SI1 I think my family think that I should use the ADMIRE system. 
SI2 I think my friends think that I should use the ADMIRE system. 
SI3 I think my care-givers think that I should use the ADMIRE system. 
SI4 I think my peer patients think that I should use the ADMIRE system. 
Facilitating conditions 
FC1 My computer is good enough to use the ADMIRE system. 
FC2 My internet connection works perfectly. 
FC3 Where necessary, my family helps me to use the ADMIRE system. 
FC4 Where necessary, my friends help me to use the ADMIRE system. 
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AF1 I find using the ADMIRE system interesting. 
AF2-R* I experience using the ADMIRE system as annoying. 
AF3 I find using the ADMIRE system pleasant. 
AF4-R* Using the ADMIRE system makes me feel restless. 
*R: reversed. 
Self-efficacy 
SE1 I can use the ADMIRE system without the help of others.  
SE2 I can use the ADMIRE system without the help of the ADMIRE-team.  
SE3 I can use the ADMIRE system as long as there is someone available to help me.  
SE4 I can use the ADMIRE system as long as nothing abnormal happens. 
Trust 
Tr1-R* I think using the ADMIRE system puts my privacy at risk. 
Tr2 I am confident that the ADMIRE system works well. 
Tr3 I trust the information that the ADMIRE system provides me with. 




BI1 I will certainly measure at the specified time points and enter the data into the ADMIRE 
system. 
BI2 I will certainly look at the overview of my measurements carefully. 
BI3 I will certainly follow the instructions of the ADMIRE system after entering my measurements. 
BI4 I will certainly first consult the eLearning module if I have medical questions. 
BI5 I will certainly use the planning function within the ADMIRE system to keep track of my 





2. Different Aspects 
Training 
 The ADMIRE training teaches me useful things. 
 I am very pleased about the introduction given by a member of the ADMIRE-team. 
 I find the online learning module very informative. 
 I got sufficient knowledge and skills to work with the ADMIRE system through the online 
learning module. 
Self-management 
 With the help of the ADMIRE system, I will be able to play a greater role in my own medical 
care. 
 The ADMIRE system contains lots of interesting information. 
 I find it an advantage that changes in my condition will be quickly noticed due to the 
frequent home measurements. 
 I find it a disadvantage that through self-measuring I will be more occupied with my kidney 
disease. 
Doctor 
 I think that telephone contact with my doctor will be a full replacement for an outpatient 
appointment. 
 I find it a disadvantage that when my creatinine rises I will receive an automatic notification 
instead of a personal message from my doctor. 
 I find it an advantage that my doctor will have direct access to my measured values. 
 I find it a disadvantage that I will see a doctor less often due to my participation in ADMIRE. 
Time 
 I think that a disadvantage of ADMIRE is that I have to spend time on performing self-
measurements.  
 I think that a disadvantage of ADMIRE is that I have to be telephonically available at agreed 
time. 
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 I think that an advantage of using the ADMIRE system is that I need to travel to the hospital 
less often. 
 I think an advantage of using the ADMIRE system is that I have more time for other 
activities, because I have fewer outpatient appointments. 
 I think an advantage of using the ADMIRE system is that blood samples can be taken less 
frequently in the hospital. 
Creatinine 
Blood pressure  
 I am well able to use the creatinine meter. 
 I find it an advantage that I can measure my creatinine value. 
 I find it a disadvantage that I have to prick in my finger myself. 
 I think I will find it pleasant to use the creatinine meter. 
 I will find using the creatinine meter reassuring. 
 I will find using the creatinine meter frightening. 
 I will find using the creatinine meter useful. 
 I will find using the creatinine meter frustrating. 
 I have confidence in the accuracy of the creatinine meters. 
 I will be able to carry out the self-measuring at the agreed time. 
 I will be able to assess the self-measured results. 
 I will be able to judge at what time it is important to contact the hospital. 
 I find it a disadvantage that I myself will have to react as my creatinine value increases. 
 A good self-measuring result will reassure me as much as a good outcome from the hospital 
laboratory. 
 I find the self-measured values match the values measured in LUMC (T1 only). 
 I am able to use the blood pressure meter. 
 I find it an advantage that I can measure my blood pressure. 
 I think I will find it pleasant to use the blood pressure meter. 
 I will find using the blood pressure meter reassuring. 
 I will find using the blood pressure meter frightening. 
 I will find using the blood pressure meter useful. 




 I am often worried about whether I have carried out the measurements correctly. 
 After a good result of the self-measuring I am sufficiently reassured. 
 I am afraid of rejection when I measure my creatinine. 
 I regularly conduct an additional measurement to reassure myself. 
 I am not worried if I get a notification from the ADMIRE system that my creatinine has 
increased. 




 I have confidence in the accuracy of the blood pressure meter. 
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scores 1 2 3 4 5 
Affect (AF3) .83 .08 -.04 .25 -.11 .72 .76 
Trust (TR4) .79 .15 -.09 -.07 .18 .74 .69 
Performance expectancy - insight (PE3) .77 -.20 .04 .20 .10 .86 .69 
Trust (TR2) .77 .13 .21 .11 .15 .57 .69 
Affect (AF2) .75 .06 .22 .17 .23 .61 .69 
Trust (TR3) .72 .02 -.12 .04 .35 .75 .66 
Affect (AF1) .72 .16 -.15 -.11 -.24 .79 .64 
Performance expectancy - insight (PE2) .69 -.11 .01 -.02 -.15 .70 .51 
Performance expectancy - insight (PE1) .69 .02 -.06 .04 .37 .57 .61 
Self-efficacy (SE1) .06 .92 .09 .03 -.01 .73 .85 
Self-efficacy (SE2) .15 .84 .01 -.07 -.02 .58 .73 
Facilitating conditions (FC2) -.14 .72 .51 .01 .05 .49 .79 
Facilitating conditions (FC1) -.12 .71 .56 .03 .00 .52 .84 
Affect (AF4) .48 .52 .16 .30 .04 .79 .62 
Performance expectancy - time (PE8) .01 .16 .92 -.03 -.05 .47 .87 
Performance expectancy - time (PE7) .06 .21 .92 .00 .07 .55 .89 
Effort expectancy (EE1) .16 -.06 .04 .86 .20 .51 .81 
Effort expectancy (EE4) -.04 .15 -.15 .85 -.14 .29 .79 
Effort expectancy (EE2) .26 -.12 .15 .59 .41 .85 .62 
Trust (TR1) .14 .06 .01 .12 .91 .33 .86 
Eigenvalues 5.48 3.08 2.48 2.08 1.54   
% of variance 27.38 15.40 12.39 10.41 7.68   
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The StatSensor® Xpress-i™, a point-of-care system for blood creatinine measurement, offers patients 
the possibility of self-monitoring creatinine. In this study, the analytical performance of the 
StatSensor® for both detecting current renal function and monitoring renal (dys)function in kidney 
transplant patients was examined.  
Accuracy of the StatSensor® with capillary and venous whole blood was evaluated and compared to 
an isotopic dilution mass spectrometry (IDMS)-traceable enzymatic creatinine test in venous serum 
(n=138). Twenty Li-heparin samples were compared to the IDMS reference method performed by a 
Joint Committee for Traceability in Laboratory Medicine (JCTLM)-listed reference laboratory (RfB, 
Bonn, Germany). To evaluate StatSensor®’s suitability to monitor kidney function, both venous and 
capillary samples were obtained in 20 hospitalized transplantation patients. Venous samples were 
analyzed with an IDMS-traceable enzymatic test, capillary samples were measured using the 
StatSensor®. For all 2-day intervals, percentage change in creatinine was compared between both 
methods. 
The StatSensor® did not meet total allowable error criterion of 6.9%. Average overall CV for the 
StatSensor® was 10.4% and 5.2% for capillary and venous whole blood results, respectively. Overall 
CVa for the central laboratory serum creatinine method was <1.5%. For monitoring renal (dys)function, 
total agreement of the StatSensor® with an IDMS-traceable enzymatic test was 68% using a 10% 
Δchange. No significant differences were found between the changes observed by both methods. 
Capillary blood testing with the StatSensor® is not advisable for determining current renal function 
with a single creatinine measurement in kidney transplant patients, mainly due to excessive analytical 
imprecision. However, our results suggest that capillary blood testing with the StatSensor® can be used 






In the last decade significant improvements in kidney transplant outcome have been achieved thanks 
to advances in the management of immunosuppression [1]. However, patients continue to be at risk 
for rejection, mainly in the first year after transplantation. The most important parameter for rejection 
is deterioration of the renal function, measured by the serum creatinine concentration. As early 
detection of a rejection episode is mandatory to minimize permanent damage to the kidney graft, 
kidney transplant patients have their serum creatinine checked on average 20 times during the first 
year post-transplantation. If patients were enabled to monitor kidney function at home, this would 
have important advantages. 
First, home monitoring could improve speed of rejection detection. Second, the high number of 
necessary outpatient visits could be reduced. This would be an advantage, as the frequent visits are a 
burden to the recovering patient. Further, it would be beneficial for healthcare as decreasing number 
of outpatient appointments alleviates the burden to healthcare capacity. Third, transferring part of 
care to the home setting corresponds to the idea of 4 P Medicine [2]. 4 P Medicine aims at 
decentralizing healthcare by means of delivering Predictive, Preventive, Personalized and Participatory 
medicine. It has repeatedly been shown that self-monitoring is of clinical benefit for patients with 
hypertension [3, 4] and thrombosis [5–7]. Further, several studies in different disease populations 
show that patients prefer self-monitoring to regular care [7–14] and that patients who self-monitor 
experience higher levels of quality of life [8, 10, 13, 15] and more empowerment [7, 8, 11, 12, 14] than 
patients who do not.  
Recently, a handheld creatinine meter (StatSensor® Creatinine Xpress-i™) has become available. It is 
cleared by the US FDA for hospital use by healthcare professionals and the device is used among 
radiology patients to detect contrast-induced nephropathy [16–18]. In the future, the availability of 
this device may offer kidney transplant patients the possibility to self-monitor their blood creatinine 
levels at home. 
However, before an in vitro diagnostic (IVD) device can be advocated for adequate home-based patient 
care, it must be thoroughly tested to guarantee its robustness and clinical reliability. Two previous 
studies on the performance of the StatSensor® creatinine meter concluded that its’ results can deviate 
from centralized enzymatic method values to a small [19] or even large amount [20]. However, in both 
articles the possible value of StatSensor® for use in clinical practice is recognized, depending on the 
specific test purpose. The importance of taking the purpose of a test into consideration when 
evaluating its’ performance has recently been advocated by a multidisciplinary group of the European 
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Federation of Clinical Chemistry and Laboratory Medicine (EFLM) [21]. For kidney function, one can 
distinguish between diagnosing and monitoring purposes, recognizing that both may require different 
levels of robustness as well as different criteria for performance assessment. 
The aim of this study was two-fold. First, to assess the suitability of the StatSensor® for detecting 
current renal function of kidney transplant patients with a single creatinine measurement, by 
evaluating the metrological traceability and exchangeability of StatSensor® results compared to an 
isotopic dilution mass spectrometry (IDMS) traceable enzymatic creatinine central laboratory method. 
Second, to assess the suitability of the StatSensor® for monitoring creatinine trends in kidney 
transplant patients with serial creatinine measurements, by evaluating the concordance of sequential 
StatSensor® results to sequential results of the reference laboratory method around the cut-off level 
used for early identification of kidney rejection in kidney transplant patients. 
 
MATERIALS AND METHODS 
 
Ethics approval 
This study was performed at the Leiden University Medical Centre (LUMC). It was part of the pilot study 
Teletransplant which protocol was approved of by the LUMC Medical Ethics Committee. 
 
Materials 
The StatSensor® Xpress-i™ Creatinine Hospital Meter (Nova Biomedical, Waltham, MA, USA) is a 
handheld point-of-care (POC) device developed for measuring creatinine in capillary (finger prick) 
whole blood as well as venous and arterial whole blood. Serial numbers of the StatSensor® devices 
used were 149010610225, 149024910321, 149025210321, 149025910321, 149027410321 and 
149027610321. The StatSensor strip technology utilizes a gold-based multiwell, multilayer technology 
that corrects for the influence of interfering substances that can be present in the whole blood matrix 
of hospitalized patients. Creatinine is measured enzymatically with signal detection method based on 
amperometry. 
According to the product insert, test results are traceable to National Institute of Standard and 
Technology (NIST) SRM 967. Two batches of strips with LOT numbers 4910348249 and 4911013249 
were used. During the evaluation study, five levels of calibrators were used (n=2) which were analyzed 
on six different StatSensor® devices with two batches of strips (see Supplemental Data, 1 that 
accompanies the article http://www.degruyter.com/view/j/cclm.2015.53.issue-10/cclm-2014-
  
 
0932/cclm-2014-0932.xml?format=INT ). Serum creatinine in the hospital central laboratory is 
performed with an IDMS-traceable enzymatic method on the Roche Modular P800, Cat Nr. 
11875566216 (Reagent 1) and 11875582216 (Reagent 2) for the Creatinine Plus assay and Cat Nr. 




Evaluation of StatSensor®’s performance for detecting current renal function of kidney transplant 
patients  
The analytical performance of the StatSensor® was evaluated and compared to the performance of an 
IDMS traceable enzymatic creatinine central laboratory method using specimens of kidney transplant 
patients who had their regular outpatient hospital appointment in July 2011. All patients received a 
letter about the study and the informed consent procedure. We used a ‘yes, unless’ principle, with all 
invited patients enrolled unless they declined participation. 
Participation comprised of the donation of an extra tube of blood and the performance of two capillary 
creatinine measurements. After collecting venous blood samples for routine analyses (including 
analysis of serum creatinine concentration), an additional lithium heparin tube was taken. Participating 
patients then visited a doctors’ assistant to measure capillary whole blood creatinine with the 
StatSensor® on the spot. Five different StatSensor® devices were randomly used. Capillary punctures 
were performed in duplicate (middle and ring finger). Based on the average of the duplicate 
StatSensor® measurements, patients were grouped into three creatinine categories: 50–100, 100–200 
and >200 µmol/L. The first 30 patients allocated to one of these categories were selected for further 
analysis. In addition, eight patients with large differences between the duplicate measurements were 
selected for further assessment. In our central laboratory, creatinine was repetitively measured (2- 
and 5-fold) by an experienced technician in lithium heparinized blood on the patient-specific 
StatSensor® meters, i.e., the ones used for testing the capillary finger pricks. Residual lithium 
heparinized whole blood was centrifuged at 2750 g for 15 min at room temperature (RT). The obtained 
plasma was used to determine creatinine according to the central laboratory method. Residual plasma 
was stored at –80 °C. All lithium heparinized blood was analyzed within 4 h from blood drawing. 
A subset of 20 stored plasma samples was sent to the Reference Institute for Bioanalytics (RfB) in Bonn, 
Germany for objective evaluation of StatSensor® bias as compared to the Joint Committee for 
Traceability in Laboratory Medicine (JCTLM)-listed IDMS reference method (www.bipm.org/BIPM 
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database). Selection of 20 samples occurred based on sampling across creatinine devices used for 
capillary creatinine testing (n=5 for 149010610225, 149024910321, 149025210321 and 
149025910321) and capillary creatinine test results, with all levels represented. 
 
Evaluation of StatSensor®’s performance for monitoring creatinine trends in kidney transplant patients 
To evaluate the suitability of the StatSensor® device for trend self-monitoring, tightly monitored 
patients with expected changes in levels of creatinine have to be selected. In theory, dialysis patients 
are an ideal population, considering the raise in creatinine during the days immediately following a 
dialysis session. However, their high levels of serum creatinine pose a problem, as earlier studies 
showed a significant negative bias of the StatSensor® at high creatinine concentrations [19, 20]. 
Another group of kidney patients in which changes in levels of creatinine can be expected, are recently 
transplanted patients. During the first days after kidney transplantation, the serum creatinine usually 
decreases rapidly due to the well-functioning kidney graft. Although only an increase of creatinine 
levels is relevant for the detection of kidney deterioration, it does not matter for the analysis whether 
creatinine levels rise or fall. Therefore, we can use this population for validating creatinine trend 
monitoring. For this analysis, 20 newly transplanted patients still being under hospital management 
were recruited for assessing the ability of StatSensor® for detecting changes in levels of creatinine over 
time (trend monitoring). 
StatSensor® capillary creatinine measurements were performed twice per day (at 6.00 a.m. and 20.00 
p.m.) on consecutive days following transplantation. According to routine clinical practice, serum was 
collected once a day for creatinine measurement by the central laboratory method. Both venous and 
capillary punctures were performed by professional nurses working at the transplantation ward. 
 
Data analysis 
For the analytical performance study, analytical coefficients of variation (CV) for StatSensor® were 
calculated from replicate determinations. Predefined quality requirements that we aimed at were 
based on desirable performance criteria derived from biological variation [22]. A split sample 
comparison was planned in order to study traceability of StatSensor® test results to NIST SRM 967. 
Equivalence of StatSensor® and central laboratory test results was evaluated using a two-instrument 
comparison procedure (EP Evaluator, Rhoads). Methods produce clinically exchangeable results if (Y-
X) <total allowable error (TEa) for at least 95% of the results. In addition, reference change values 
  
 
(RCVs) were calculated as 2.8 * (CVa +CVb ), where CVa means desirable analytical CV, and CVb means 
intra-individual biological CV (CVa =2.2%; CVb =4.3%; TEa =6.9%) [22].  
For the evaluation of StatSensor®’s performance for determining creatinine trends in kidney transplant 
patients, a >10% increase in serum creatinine was considered to be clinically relevant. A general 
guideline is that an abrupt increase in the serum creatinine of greater than 50 percent should be 
promptly evaluated [23]. However, from professional experience, we know that an increase of 10% 
may indicate early symptoms of graft failure warranting further analysis or intensified follow-up of 
recently transplanted kidney patients. To calculate the degree of creatinine change, linear regression 
analysis was applied to analyze creatinine results generated during every 2-day interval with a 
maximum of five consecutive StatSensor® capillary creatinine measurements. The percentage 
creatinine change per day was obtained by dividing the slope by the average value (Figure 1). This 
calculation was also performed for the serum creatinine values determined by the central laboratory 
within the same time intervals. Only intervals which had at least four capillary creatinine values and 
three serum creatinine values available were selected. Agreement in levels of change as measured by 
the two methods was investigated by calculating the correlation between the percentage change in 




StatSensor®’s performance for detecting kidney function in kidney transplant patients 
A total of 133 kidney transplant patients were included and 138 StatSensor® measurements were 
performed in duplicate (some patients visited the outpatient clinic twice during the period of 
inclusion). A mean difference of 20.21 µmol/L was found between the StatSensor® whole blood 
creatinine and the Roche Modular P800 serum creatinine (n=138) across the measuring range, with 
limits of agreement (defined as mean ±1.96 SD) varying between –58.8 and +34.1 µmol/L (see Sup- 
plemental Data, Figure 1). 
To investigate equivalence of test results produced by StatSensor® and the central laboratory, 30 
patients with StatSensor® creatinine results fitting into one of three categories (50–100, 100–200, >200 
µmol/L) were selected. In addition, eight patients with the most marked differences between the 
duplicate capillary measurements (mean difference 42.5 ± 9.93, range 29 µmol/L) were selected. For 
each patient, a StatSensor® capillary whole blood creatinine result, a StatSensor® venous lithium 
heparin whole blood creatinine result, a venous lithium heparin plasma creatinine result as measured 
with the central laboratory method and a serum creatinine result as measured with the central 
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laboratory method was available. For the capillary blood measurements, the mean creatinine level was 
161 ± 86 µmol/L. For the lithium heparin samples, the mean creatinine level was 150 ± 80 µmol/L for 
StatSensor® measurements and 154.4 ± 81.1 for the central laboratory methods. The cor- responding 
mean serum creatinine level according to the central laboratory method was 172 ± 82 µmol/L.  
The average error index(Y-X)/TEa between the StatSensor® capillary result and central laboratory 
serum creatinine result was –0.96 with a range of –6.61 to 5.42. The difference between the 
StatSensor® and the central laboratory method was within the TEa for only 15 out of 38 (39.5%) 
specimens. The largest error index occurred at a concentration of 107.5 µmol/L (see Figure 2A).  
Average overall CVa for StatSensor (n=38) was 10.4% and 5.2% using the capillary respectively venous 
whole blood results (Table 1), which is far above the desirable imprecision of 2.2% [22]. For the central 
laboratory serum creatinine method, overall CVa is <1.5%, and thus well below the desirable 
imprecision. As RCVs depend on the analytical imprecision of the method used, different RCVs will be 
found depending on the method used. RCVs for StatSensor® in capillary and heparinized venous whole 
blood are 35% and 23%, respectively, compared to 15.5% for the central laboratory method. 
 
 
Figure 1: Regression line was calculated for every 2-day period (day 1– 3, day 2– 4, day 3– 5, etc.).  
Percentage change was calculated by creatinine change per day (creatb-creata)/(Tb-Ta) divided by 
the mean of the creatinine values (cr1+ cr2+ cr3+ cr4 + cr5)/5. This calculation was also performed 






Figure 2: Routine method comparison. 
Method comparison between creatinine measured in finger prick (FP) whole blood using StatSensor® 
and creatinine in serum using an IDMS-traceable Modular P800 assay (Roche) (left) with corresponding 
error indices (right). Blue dots meet the TEa criterion of 6.9%; red dots do not meet the TEa criterion. 
 
Metrological traceability 
Twenty plasma creatinine samples over a range of 60.0–317.9 µmol/L were analyzed by the German 
Reference laboratory RfB, using a JCTLM-listed, internationally recognized creatinine IDMS reference 
method, and by StatSensor® (mean of duplicate measurements). Linear regression and difference plots 
were calculated from the RfB IDMS plasma creatinine target values (X) and the StatSensor® capillary 
test results (Y): Y=0.7942*X+14.637, R2 =0.9096 (see Figure 3A, left). The mean difference between the 
two methods was –16.1 µmol/L, with an upper limit of agreement [+2SD] of 28.07 µmol/L and a lower 
limit of agreement [–2SD] of –60.30 µmol/L (see Figure 3A, right). When plotting the central laboratory 
serum creatinine test results (Y) against the RfB IDMS plasma creatinine results (X) the linear regression 
was: Y=0.9981*X+1.886, R2 =0.9981 (Figure 3B, left). The difference plot revealed a mean bias of 1.6 
µmol/L, with a lower limit of agreement [–2SD] of –2.30 µmol/L and an upper limit of agreement [+2SD] 
of 5.50 µmol/L (Figure 3B, right). Whereas the central lab method meets the allowable bias of 3.4%, 
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laboratory method was available. For the capillary blood measurements, the mean creatinine level was 
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Figure 1: Regression line was calculated for every 2-day period (day 1– 3, day 2– 4, day 3– 5, etc.).  
Percentage change was calculated by creatinine change per day (creatb-creata)/(Tb-Ta) divided by 
the mean of the creatinine values (cr1+ cr2+ cr3+ cr4 + cr5)/5. This calculation was also performed 






Figure 2: Routine method comparison. 
Method comparison between creatinine measured in finger prick (FP) whole blood using StatSensor® 
and creatinine in serum using an IDMS-traceable Modular P800 assay (Roche) (left) with corresponding 
error indices (right). Blue dots meet the TEa criterion of 6.9%; red dots do not meet the TEa criterion. 
 
Metrological traceability 
Twenty plasma creatinine samples over a range of 60.0–317.9 µmol/L were analyzed by the German 
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was: Y=0.9981*X+1.886, R2 =0.9981 (Figure 3B, left). The difference plot revealed a mean bias of 1.6 
µmol/L, with a lower limit of agreement [–2SD] of –2.30 µmol/L and an upper limit of agreement [+2SD] 
of 5.50 µmol/L (Figure 3B, right). Whereas the central lab method meets the allowable bias of 3.4%, 






Table 1. Analytical imprecision (CVa) and critical differences (RCV) using a StatSensor® whole blood 
creatinine device as compared to a serum central lab test performed on Modular P800 (Roche 
Diagnostics).  
 StatSensor® Modular P800 
Capillary MF+RFa 
Whole Blood (n=2) 
Mean (SD) 
Venous Li-Hepb 
Whole Blood (n=2) 
Mean (SD) 
Venous Li-Hepb 





Creatinine µmol/l  160.5 (85.7) 149.7 (79.6) 154.4 (81.1) 171.8 (82.0) 
CVa %  10.4 (10.2) 5.2 (4.4) 6.0 (2.3) 1.3 (1.0) 
RCV %  35.3 (25.2) 22.5 (8.9) 22.7 (4.8) 15.5 (0.9) 
a Middle and ring finger (MF and RF) capillary pricks were taken from 38 stable post-kidney transplant patients with 
creatinine values ranging between 50 - 450 µmol/l. b Venous blood was sampled in lithium heparin tubes (Venous Li-Hep) 
and in serum separation tubes (SST) for central lab analysis on both StatSensor® devices respectively Modular P800 
according to manufacturers’ instructions. 
 
Evaluation of StatSensor®’s performance for monitoring creatinine trends in kidney transplant 
patients 
Both capillary (twice per day) and venous blood samples were obtained from 20 kidney transplant 
patients for 6.28 (±2.99) consecutive days post-surgery. Some examples of post-transplantational 
creatinine courses measured by both StatSensor® and the central laboratory method (P-Modular) are 
shown in Figure 4. Eighty-two 2-days period trends (with 3 consecutive serum creatinine and at least 
4 StatSensor® creatinine measurements) were obtained. According to expert opinion, an elevation of 
>10% in two subsequent creatinine measures is considered relevant for detection of kidney rejection. 
From Table 2, it can be seen that 33 out of 82 available intervals showed a >10% difference between 
subsequent intervals. The StatSensor® correctly identified a difference of >10% in 70% of these cases. 
Forty-nine intervals showed a difference of ≤10%, of which 67% was correctly identified as such by the 
StatSensor®. Total agreement was 68%. Figure 5 shows the calculated creatinine changes in venous (X-
axis) and capillary blood (Y-axis). The correlation coefficient between both methods was 0.77 (95% CI 
  
 
0.625–0.910). Deming regression analysis showed a slope of 0.889 (95% CI 0.753–1.026) indicating no 













Figure 3: Reference standardization study. 
(A) Linear regression (left) and difference plot (right) of creatinine measured in finger prick (FP) whole blood 
using StatSensor® (Y) and in Li-heparin plasma using the IDMS reference method, RfB, Bonn (X). (B) Linear 
regression plot (left) and difference plot (right) of creatinine measured in venous serum using Roche Modular 
P800 (Y) and in Li-heparin plasma using IDMS reference method, RfB, Bonn (X).  
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>10% in two subsequent creatinine measures is considered relevant for detection of kidney rejection. 
From Table 2, it can be seen that 33 out of 82 available intervals showed a >10% difference between 
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axis) and capillary blood (Y-axis). The correlation coefficient between both methods was 0.77 (95% CI 
  
 
0.625–0.910). Deming regression analysis showed a slope of 0.889 (95% CI 0.753–1.026) indicating no 













Figure 3: Reference standardization study. 
(A) Linear regression (left) and difference plot (right) of creatinine measured in finger prick (FP) whole blood 
using StatSensor® (Y) and in Li-heparin plasma using the IDMS reference method, RfB, Bonn (X). (B) Linear 
regression plot (left) and difference plot (right) of creatinine measured in venous serum using Roche Modular 





Figure 4. Examples of post-transplantational creatinine trends measured by StatSensor® (open) and 
Modular P800 (closed). 
 
Table 2. Total agreement between serum creatinine on Modular P800 and finger prick whole blood 
creatinine on StatSensor® considering changes of >10% and ≤10% in serum creatinine in subsequent 
2-day intervals.  
  Modular P800  
  Delta >10% Delta ≤10% Total 
StatSensor® 
Delta >10% 23 16 39 
Delta ≤10% 10 33 43 





Figure 5: Agreement between blood creatinine changes in capillary finger prick (FP) whole blood 
measured with the StatSensor® (Cr change) and in venous serum measured with the Modular P800 
(sCr change) has been evaluated. Both a Deming regression plot (left) and the corresponding difference 




In the current study, we examined the suitability of the StatSensor® Xpress-i™, a handheld POC system 
for creatinine measurement. We analyzed its performance for both detecting current renal function of 
kidney transplant patients with a single creatinine measurement and monitoring creatinine trends with 
serial creatinine measurements. From the reference standardization study it becomes clear that the 
traceability of capillary StatSensor® creatinine results to the creatinine reference system is inadequate. 
The split-sample comparison study showed that CVa of the StatSensor® is excessive compared to the 
predefined desirable CVa criterion based on biological variation [22], leading to 2.25-fold increased 
RCVs as compared to the central laboratory method (Table 1). Therefore, the StatSensor® device does 
not fulfill desirable nor minimum analytical performance criteria in case of using capillary blood. As 
such, the StatSensor® is not suitable for detecting current renal function of kidney transplant patients 
with a single creatinine measurement. These findings are in agreement with previous studies which 
showed insufficient analytical validity of the StatSensor® [19, 20] compared to IDMS-standardized 
enzymatic methods in the central laboratory. Improving the analytical performance of the StatSensor®, 
in line with IVD 98/79/EC directive and the ISO 15189 guideline, could improve the potential for using 
StatSensor® creatinine capillary testing for kidney diagnostic use. Figure 3B illustrates the perfect 
91
4




Figure 4. Examples of post-transplantational creatinine trends measured by StatSensor® (open) and 
Modular P800 (closed). 
 
Table 2. Total agreement between serum creatinine on Modular P800 and finger prick whole blood 
creatinine on StatSensor® considering changes of >10% and ≤10% in serum creatinine in subsequent 
2-day intervals.  
  Modular P800  
  Delta >10% Delta ≤10% Total 
StatSensor® 
Delta >10% 23 16 39 
Delta ≤10% 10 33 43 





Figure 5: Agreement between blood creatinine changes in capillary finger prick (FP) whole blood 
measured with the StatSensor® (Cr change) and in venous serum measured with the Modular P800 
(sCr change) has been evaluated. Both a Deming regression plot (left) and the corresponding difference 




In the current study, we examined the suitability of the StatSensor® Xpress-i™, a handheld POC system 
for creatinine measurement. We analyzed its performance for both detecting current renal function of 
kidney transplant patients with a single creatinine measurement and monitoring creatinine trends with 
serial creatinine measurements. From the reference standardization study it becomes clear that the 
traceability of capillary StatSensor® creatinine results to the creatinine reference system is inadequate. 
The split-sample comparison study showed that CVa of the StatSensor® is excessive compared to the 
predefined desirable CVa criterion based on biological variation [22], leading to 2.25-fold increased 
RCVs as compared to the central laboratory method (Table 1). Therefore, the StatSensor® device does 
not fulfill desirable nor minimum analytical performance criteria in case of using capillary blood. As 
such, the StatSensor® is not suitable for detecting current renal function of kidney transplant patients 
with a single creatinine measurement. These findings are in agreement with previous studies which 
showed insufficient analytical validity of the StatSensor® [19, 20] compared to IDMS-standardized 
enzymatic methods in the central laboratory. Improving the analytical performance of the StatSensor®, 
in line with IVD 98/79/EC directive and the ISO 15189 guideline, could improve the potential for using 




agreement and negligible bias of 1.60 (–2.3– 5.5) µmol/L between central laboratory/Modular P800 
and IDMS reference method, contrasting with the large scatter and excessive bias of –16.1 (–60.3–
28.1) µmol/L for StatSensor® compared to IDMS reference methods as presented in Figure 3A. In the 
case of trend monitoring, the uncertainty of a single capillary blood creatinine test result is less critical. 
Detection of rejection episodes after kidney transplantation reflects a monitoring purpose for which 
the device should be able to detect trends in sequential measurements. In the present study, we 
examined the suitability of StatSensor® capillary blood testing to monitor changes in renal function. 
For recently transplanted patients, clinicians are especially interested in sudden increases in serum 
creatinine of >10% as this requires further analysis and/ or intensified follow-up. Therefore, the aim of 
this study was to assess whether a >10% change in serum creatinine (as measured by the central 
laboratory method) can also be detected when using StatSensor® for trend monitoring. For validating 
trend detection, it does not matter whether creatinine increases or decreases. Newly transplanted 
patients are a suitable population group, as their creatinine levels usually decrease rapidly during the 
first days after kidney transplantation. A reasonable correlation (R=0.77) between changes detected 
by the central laboratory and the StatSensor® was found. False-negative results lead to a delayed 
detection of rejection and should not or hardly occur. Although false-positive findings are less 
problematic, they lead to extra diagnostic interventions. In this study, the StatSensor® correctly 
identified a difference of >10% (true positive) in 70% and a difference of ≤10% (true negative) in 67% 
of all cases (total agreement 68%) within the time period monitored. Although these results indicate 
that StatSensor®’s ability to detect changes in kidney function needs improvement, the absence of a 
significant difference between changes observed by the central laboratory analyzer and the 
StatSensor® shows that it does have potential for monitoring creatinine.  
To strengthen StatSensor®’s performance, an important step should be the improvement of its 
analytical performance as this will impact its clinical (diagnosing and monitoring) performance too. In 
the meantime, two manoeuvres could offer a provisional solution. First, to decrease the number of 
false negative results, one could choose a cut-off percentage which is lower for StatSensor® results. 
For example, by lowering the StatSensor® cut-off percentage to >5%, the number of correctly identified 
relevant changes (>10% increase as determined by the central laboratory method) increases from 70% 
to 82%. However, this approach would result in an increased number of false positives. Second, with 
increasing the frequency of StatSensor® measurements, a more reliable trend will be obtained, as the 
confidence interval decreases proportionally to the square root of the number of performed 
measurements, given a normal distribution. At home, patients can measure their creatinine daily. By 
doing so, the chances of detecting rejection are increased and theoretically, the number of outpatient 
  
 
visits can be safely reduced. To investigate this approach, we have implemented a randomized 
controlled trial (RCT) with StatSensor®’s monitoring performance being tested in a clinical setting. One 
of the other outcomes of this study will show whether the results produced by patients at home, will 
yield the same clinically acceptable results for monitoring creatinine trends as observed when hospital 
professionals perform the measurements. 
Besides offering the possibility of lowering the number of outpatient visits, self-monitoring kidney 
function after kidney transplantation is expected to have other benefits. Studies in other patient 
populations show that patients monitoring and/or managing their own disease results in more cost-
effective healthcare systems by enabling the management of chronic diseases outside institutions [24–
29], improved health outcomes [4, 6, 7, 9, 30, 31] and higher patient satisfaction [7–15, 32–34]. 
Whether the possible benefits also apply to kidney transplant patients, has yet to be investigated. 
In conclusion, the analytical validity assessment and comparison to an international JCTLM-listed IDMS 
reference method indicate that the StatSensor® is not suitable for detecting kidney (dys)function of 
kidney transplant patients in case of singlicate capillary blood measurements, i.e., more variation is 
observed with StatSensor® capillary blood results compared to StatSensor® venous blood results and 
plasma or serum central laboratory results. Further investigation is required to determine the nature 
of the variation in capillary blood. Nevertheless, our results show that the device has potential for 
trend monitoring in the context of daily follow-up for kidney function after kidney transplantation. In 
an ongoing RCT, the safety and clinical performance of the StatSensor® POC system for monitoring 
creatinine trends is further investigated.  
The different conclusions concerning the suitability of the StatSensor® for detecting current kidney 
function with a single creatinine measurement versus monitoring creatinine trends with serial 
creatinine measurements in kidney transplant patients illustrate the importance of the interplay of the 
different components of the cyclical framework for the evaluation of medical tests and IVDs, which 
was described recently by a multidisciplinary group of the EFLM [21]. They state that the key 
components of test evaluation should be driven by the test purpose and test role in the clinical 
pathway, and that clinical effectiveness data should be fed back to refine analytical and clinical 
performances. This implies that the intended clinical applications and outcomes of the new test should 
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Table 1. Calibration performance of the creatinine Statsensor® device as determined by a clinical 
chemistry technician during the evaluation study. To that end, 5 calibrator levels were measured in 
duplicate on 6 different StatSensor® devices with two batches of strips. Averages, SD and overall CVs 
were calculated using basic statistics. 














Level1 5511017241 71-150 141 5 3.2 131 9 6.5 
Level2 5511017242 133-248 207 11 5.2 200 12 6.2 
Level3 5511017243 256-442 391 26 6.8 382 21 5.6 
Level4 5511017244 433-698 558 20 3.6 564 46 8.2 
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Self-monitoring creatinine could decrease the frequency of outpatient visits and improve rejection 
detection after kidney transplantation. In this non-inferiority trial, the safety and feasibility of self-
monitoring creatinine supported by an online self-management system in the first year post-
transplantation was investigated.  
119 kidney transplant patients were randomized to standard care (N=65) or to self-monitoring 
creatinine with part of outpatient visits replaced by telephone consults (N=54). Primary outcome was 
kidney function (eGFR), secondary outcomes included number of visits. Twenty intervention patients 
were interviewed on their experience with self-monitoring.  
No differences were found between intervention and control group for the development of eGFR over 
time (p. 544). Number of outpatient visits was significantly reduced (p .007), but the degree of 
reduction was suboptimal. Self-monitoring enhanced early rejection detection in 3 out of 5 cases, none 
were missed. Satisfaction was high; 95% of the interviewed patients would recommend self-
monitoring.  
Taking into account the non-inferiority to standard care, the reduction in visits and the high level of 









Several studies have shown that patient self-monitoring can have significant clinical benefits for 
different chronic diseases, including reductions in HbA1c[1-4], improvements in blood pressure 
control[5-9], improved asthma control[10] and reductions in thromboembolic events[11, 12]. Self-
monitoring has further been shown to lead to a higher quality of life[13-16] and more patient 
empowerment[16-19]. In addition, patients seem to prefer self-monitoring above regular care[8, 13, 
14, 16, 17, 19].  
Self-monitoring may also be a promising approach for follow-up of kidney transplant patients, with the 
frequent outpatient appointments constituting a high burden to healthcare systems and to patients. 
As many of these appointments are routine visits to monitor kidney function, self-monitoring 
creatinine and blood pressure at home has the potential to replace part of these visits by telephone 
contacts[20]. Further, as self-monitoring allows for measurements to take place more frequently, 
speed of rejection detection may be improved which could in the long run lead to improved kidney-
graft survival[21-26].  
To the best of our knowledge, there are no studies available that report on the usability of self-
monitoring kidney function. Results from a pilot study of our own group did show that self-monitoring 
of creatinine and blood pressure is very well accepted by patients[27]. Our objective therefore was to 
investigate whether self-monitoring kidney function supported by a Self-Management Support System 
(SMSS) can lead to a reduction in number of outpatient visits in the first year post-transplantation 
without compromising on quality of care. To this end, we conducted a randomized controlled trial, 
comparing quality of care (eGFR, blood pressure, satisfaction, quality of life) and number of outpatient 




The ADMIRE study (Assessment of a Disease management system with Medical devices In RENal 
disease) was a randomized controlled trial (RCT) among kidney transplant patients performed at the 
University Medical Centre of Leiden (LUMC), The Netherlands. The study protocol was reviewed and 
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2.1. Participant recruitment and assignment 
Power calculation used the within-group standard deviation for differences in renal function of two 
historic kidney transplant cohorts (3.8 ml/min). The tolerance limit for differences between groups was 
set to 3.0 ml/min. With a robust beta (power of 95%), an alpha of .05 and 2-tailed testing, a sample 
size of at least 42 per group was needed.  
Patients were eligible for participation if their living donor transplantation was scheduled or if they 
were still hospitalized after having received a kidney from a deceased donor within period of inclusion 
(March 2012 - May 2014), were ≥18 years of age, mastered the Dutch language sufficiently, had 
sufficient computer skills and access to Internet, could perform the required actions independently 
and had a creatinine level of ≤300 µmol/l within 4 weeks post-transplantation (due to lower reliability 
of the creatinine device for values >300 µmol/l). Patients were excluded if they had insufficient 
understanding of the treatment and/or had a history of incompliance.  
During a pre-transplant appointment with a nurse-practitioner aimed at informing patients about the 
transplantation procedure in the LUMC, patients were shortly introduced to the study and received a 
detailed description of the study design and informed consent form. If a signed informed consent form 
was not returned within 2 weeks from the appointment, patients were contacted by the primary 
investigator to inform whether they were (still) interested in participation. Each participant was 
assigned a study number in consecutive order. Study numbers were allocated to either the 
intervention or control group according to a pre-set randomization schedule with a 1:1 ratio. The 
randomization list was produced by means of random permutations of therapies within blocks of 
length 10 with 5 occurrences of each of the two therapies per block. A Statistical Package for the Social 
Sciences (SPSS) program (syntax) was written for this purpose by the statistician. For the last 6 months 
of inclusion, a new randomization list was created by the statistician with a 2:1 ratio as the 
intervention-control distribution became skewed. The randomization procedure was blinded for the 
project members directly involved in patient recruitment. 
 
2.2. Materials 
Patients received a StatSensor® Xpress-i™ Creatinine Hospital Meter (Nova Biomedical, Waltham, USA) 
and measurement accessories (i.e. test strips, control solution and safety lancets for capillary blood 
sampling) to self-monitor creatinine. Further, they received a Microlife WatchBP® Home (Microlife, 
Heerbrugg, Switzerland), an oscillometric device for blood pressure self-measurement on the upper 
arm. Both devices had a memory function and the option to download stored values to a computer. 
Test results were registered in an Internet-based self-management support system (SMSS). For 
  
 
creatinine, a feedback system was available. The feedback appeared directly after registration of a new 
creatinine value and consisted of a traffic light with corresponding text to support interpretation (see 
figure 1). Values registered in the SMSS were automatically sent to the electronic hospital system and 
thus visible for the treating nephrologist(s).  
The SMSS further entailed an eLearning module with measurement instructions and information on 
kidney anatomy, the transplantation procedure, medication and lifestyle.  
 
2.3. Intervention procedure 
After being instructed through eLearning, all intervention patients received the self-monitoring devices 
and supplementary instructions. Patients were carefully instructed that they were supposed to take 
action themselves upon the system’s feedback, as their nephrologist(s) would not systematically check 
registered home-based values. Patients were encouraged to practice using the creatinine and blood 
pressure devices during the remainder of their hospital stay. Home-based measurements had to be 
performed according to a fixed frequency, being daily during the first 4 weeks (phase 1), every other 
day for week 5-9 (phase 2), twice a week for week 10-15 (phase 3) and weekly from week 16 onwards 
(phase 4). This scheme was based upon the usual frequency of laboratory testing, which gradually 
decreases after time.  
For intervention patients, every other face-to-face (ftf) visit with regular hospital-based laboratory 
analysis was replaced by a telephonic consult to discuss self-monitored creatinine and blood pressure 
from week eight after transplantation on. A reminder for nephrologists to schedule a telephone 
consult instead of a ftf visit was shown repetitively in the patients’ electronic hospital file. The treating 
nephrologist eventually decided whether a patients’ clinical condition allowed for a ftf consult to be 
replaced by a telephonic one. The control group received standard care, excluding the use of a 
creatinine device at home. All their follow-up appointments took place in the outpatient clinic of the 
LUMC.  
In addition, 20 patients were interviewed concerning their experiences and satisfaction with self-
monitoring kidney function after transplantation using a semi-structured protocol (see appendix). Over 
time both intervention and control patients completed questionnaires, a baseline questionnaire at day 
of discharge and twelve months after discharge.  
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Figure 1. SMSS feedback system. 
 
2.4. Measures 
Serum creatinine (µmol/l) values measured around baseline (0-30 days post-discharge) and 12 month 
follow-up (301 -426 days post-discharge) were obtained from the electronic hospital file. The width of 
these timeframes was determined by the availability of at least 1 creatinine value per patient. The 
same timeframes were used to obtain systolic and diastolic blood pressure (mmHg). A mean serum 
creatinine and systolic and diastolic blood pressure was calculated for baseline and follow-up using the 
available measurements within the two timeframes. Kidney function (eGFR) was calculated with the 
Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula[28]. Number of outpatient 
contacts, serious adverse events (SAEs, i.e. hospitalizations) and rejection episodes within 365 days 
from discharge were obtained from the electronic hospital file. To investigate whether replacing ftf 
visits with telephonic consults led to a decrease in total healthcare consumption, total number of 
minutes spent per patient in the first 365 days from discharge was calculated including all ftf visits (10 
minutes), telephonic consults (5 minutes) and separate laboratory analyses (5 minutes). Self-
monitored values registered online were obtained from the SMSS.  
Both the intervention and control group completed the Short Form-12 (SF-12) [29] to measure quality 
  
 
of life. This questionnaire contains 12 multiple-choice items covering Physical Component Summary 
(PCS), and the Mental Component Summary (MCS). The Partners in Health scale[30] (PiH) was used to 
measure self-efficacy regarding self-management behaviour. The PIH contains 12 items on a nine-point 
scale. The Client Satisfaction Questionnaire(CSQ-8) [31] was used to measure satisfaction with care 
and consists of 8 items that are rated on a four-point scale. All questionnaires were completed at 
baseline and 12-month follow-up. 
The interviews were recorded and transcribed in full. Answers to questions relating to satisfaction with 
self-monitoring after kidney transplantation (1. If possible, would you like to continue self-monitoring 
supported by the SMSS? Why (not)?, 2. Would you recommend self-monitoring kidney function 
supported by the SMSS to other kidney transplant patients? Why (not)?) were extracted from the data 
and categorized.  
 
2.5. Data analysis 
Baseline continuous variables are reported as mean (SD, standard deviation) or median (IQR, 
interquartile range) in case of skewed data. Categorical variables are reported in percentages. The 
baseline characteristics of the intervention and control group were compared using independent t-
tests for continuous variables and chi-square tests for categorical variables. Linear mixed modelling 
was used to compare intervention and control patients concerning the change in kidney function 
(eGFR), blood pressure, QoL (physical and mental component scale), level of satisfaction with care and 
self-management behaviour over time. Linear mixed modelling is the recommended method for 
analysing repeated measures, as it accounts for correlation between repeated measurements of the 
same patient.  
To analyse the difference between intervention and control patients for number of ftf and telephonic 
consults, total number of reimbursable minutes spent over 365 days post-discharge (including ftf visits, 
telephonic consults and laboratory analysis only) and number of SAEs, univariate linear regression was 
used.  
Besides univariate linear mixed models and linear regression analyses, sensitivity analyses were 
performed using multivariate models adjusting for significant baseline difference(s) between the two 
study groups. Missing baseline data were imputed using multiple imputations (n=10). 
For the variables with a hypothesized non-inferior outcome (eGFR, blood pressure, quality of life, 
satisfaction, number of SAEs), only the per protocol population was included in the analyses. Including 
intention-to-treat patients would dilute the potential difference between intervention and control 
patients, facilitating a non-inferior result. For the variables with an expected difference between the 
  
 
Extremely non-adherent: measurements performed during less than 25% of the requested days 
1. Non-adherent: measurements performed during 25-74% of the requested measurement days 
2. Adherent: measurements performed during 75-100% of the requested measurement days 
3. Over-adherent: measurements performed more frequently than requested (i.e. > 100%).  
This same procedure was used to calculate level of adherence to registration of measurement in the 
SMSS, i.e. whether patients registered measurements on the requested number of days.  
 
 
Figure 1. Possible feedback combinations in the SMSS.  
 
Moment of registration 
Date of measurement (derived from device logged data) was compared to the date of registration of 
this measurement (derived from SMSS logged data). Per patient the average number of days delay 
between measurement and registration was calculated. Further, we investigated whether delayed 
registration was related to stability of creatinine level by comparing feedback that was generated by 
the SMSS in case of registration on day of measurement with feedback that was generated when 
registration was delayed. 
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intervention and control group (number of outpatient visits, number of telephonic consults and 
amount of self-management behaviour), both intention-to-treat and per protocol analyses were 
performed. 
For intervention patients only, self-monitored creatinine trends were compared to laboratory trends 
in case the latter showed an increase of >10%. Time frames with a >10% laboratory increase and at 
least 3 available self-monitored creatinine values within the same time frame were taken into account 
(see figure 2). Number of cases in which both laboratory and self-monitored creatinine trends showed 
an increase of >10% were selected and divided by total number of laboratory-based creatinine 
increases of >10%.  
All statistical analyses were performed with SPSS 23 for Windows (IBM Corp, Armonk, NY). P-values of 
<0.05 were considered significant.  
 
 
Figure 2. Method of comparing creatinine trends as analysed by the laboratory (dots) and measured 




Within period of inclusion, in total 217 patients received a kidney transplant of which 155 were 
considered eligible for participation. The main reasons for ineligibility were insufficient mastery of the 
Dutch language (N=25, 40%) and no access to a computer or too limited computer skills (N=16, 26%). 
  
 
Within the eligible population, 119 patients (77%) signed an informed consent. The main reason for 
not wanting to participate was the anticipated additional burden of self-monitoring (N=17, 47%). Sixty-
five patients were randomized to the intervention group. After randomization, 3 patients dropped out 
because of graft dysfunction, death and cancellation of transplantation (none was study related). Four 
patients cancelled their participation before starting to self-monitor kidney function at home, because 
of limited trust in the creatinine device, difficulties when logging on the SMSS, business rush or a 
worsened condition post-transplantation. The number of patients eligible for intention-to-treat 
analysis was 62 in the intervention and 51 in the control group. See figure 3 for the study flow-chart.  
Sample characteristics are shown in table 1 for both the intention-to-treat and per protocol 
population. Intervention and control group were similar on all variables, except for diabetes. The 
intervention group contained significantly more patients with diabetes, which pertained to both the 
intention-to-treat and per protocol population (p .03 and .01, respectively). Sensitivity analyses 
adjusting for diabetic status were therefore performed. The interviewed population was a 
representative sample of all intervention patients with a mean age of 51 years, a 70/30 male/female 
ratio, 50% pre-emptive and 85% living donor transplantations. 
 
3.1. Self-monitoring kidney function after transplantation is non-inferior to regular care 
Figure 4 shows the development over time of eGFR, quality of life and blood pressure. Significant 
improvements over time were found for eGFR (p .025, 95% CI [.546 – 8.066]), systolic (p .009, 95% CI 
[-11.481 – -1.673]) and diastolic blood pressure (p .018, 95% CI [-6.499 – -.623]) and physical (p .000, 
95% CI [14.855 – 32.384]) and mental QoL (p .004, 95% CI [3.809 – 19.408]), independent of study 
group (see table 2). Mean number of SAEs for both the intervention and control group is shown in 
figure 5. Total number of SAEs was similar for intervention and control patients (p .117, 95% CI [-1.012 
– .114]), see table 3. Sensitivity analyses controlling for diabetes led to a loss of the statistically 
significant improvement over time for eGFR, blood pressure and quality of life (data not shown). 
Number of SAEs was significantly lower for the intervention compared to the control group when 
controlling for diabetes (p .046, 95% CI [-1.178 – -.010]).  
Level of general satisfaction about care remained stably high over time in both study groups with a 
mean score of around 29 on a scale with a maximum of 32 (see figure 4 and table 2). During the 
interviews, intervention patients also reported high levels of satisfaction with self-monitoring (N=20). 
Nineteen out of 20 interviewees (95%) would recommend self-monitoring to other kidney transplant 
patients. Further, 15 out of 20 (75%) indicated they would have liked to continue self-monitoring 
beyond the first year post-transplantation.  
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Figure 3. Study flowchart.  
  
 
                       Table 1. Baseline characteristics 
 
 
  Intention-to-treat population Per protocol population 









Sex, male N (%)  40 (65) 27 (53) .25 37 (64) 27 (54) .33 
Age at tx (mean, SD)  52 (14) 51 (13) .51 52 (14) 50 (14) .68 
Living together/married (N, %)  44 (71) 36 (71) >.99 43 (74) 35 (70) .67 
Educational level (%)1    .59   .49 
 Low 17 (27) 13 (25)  17 (29) 12 (24)  
 Middle 12 (19) 15 (29)  12 (21) 15 (30)  
 High 17 (27) 20 (39)  17 (29) 20 (40)  
Paid job, yes (N, %)1  24 (39) 23 (45) .84 24 (41) 23 (46) >.99 
Origin, Dutch (N, %)  56 (90) 46 (90) >.99 53 (91) 45 (90) >.99 
Underlying disease (N, %)    .47   .43 
 Familial/hereditary 
diseases 
15 (24) 12 (24)  13 (22) 11 (22)  
 Primary 
glomerulonephritis 
9 (15) 10 (20)  8 (14) 10 (20)  
 Pyelonephritis 3 (5) 6 (12)  3 (5) 6 (12)  
 Secondary glomerular/ 
systemic diseases 
10 (16) 8 (16)  10 (17) 8 (16)  
 Vascular diseases  13 (21) 6 (12)  13 (22) 6 (12)  
 Other/unknown 12 (19) 9 (18)  11 (19) 9 (18)  
Diabetes, yes (N, %)  13 (21) 3 (6) .03 13 (22) 2 (4) <.01 
BMI (mean, SD)  25 (4) 25 (4) .24 26 (4) 24 (4) .15 
Former transplantation, yes (N, %)  7 (11) 8 (16) .58 6 (10) 8 (16) .40 
Dialysis dependency pre-
transplantation (N, %) 
 33 (53) 27 (53) >.99 32 (55) 26 (52) .85 
PRA, median (median, IQR)  4 (1) 4 (4) .30 4 (1) 4 (4) .25 
Living donor (N, %)  54 (87) 45 (88) .81 50 (86) 44 (88) .80 
HLA incompatibility (mean, SD)  3 (2) 3 (2) .15 3 (2) 3 (2) .15 
Primary graft function (N, %)  56 (90) 45 (88) .77 52 (90) 44 (88) >.99 
eGFR (CKD-epi) (mean, SD)  49 (16) 53 (17) .22 49 (16) 52 (17) .27 
No. anti-hypertensive medications 
(mean, SD) 
 1 (1) 1 (1) .70 1 (1) 1 (1) .96 
Blood pressure (mean, SD) Systolic 138 (14) 135 (13) .34 137 (14) 135 (13) .36 
 Diastolic 82 (9) 83 (8) .78 82 (9) 83 (8) .71 
1 Imputed data 
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Table 2. Additional decline or additional increase of the intervention group compared to standard 
care using linear mixed model analyses. 
1 Per protocol analysis only due to the hypothesized non-inferiority of self-monitoring to regular care; 2 Not applicable  
 
Table 3. Difference in outcome of the intervention group compared to regular care using linear 
regression analyses.  
 Intention-to-treat analysis Per protocol analysis 
 Estimate 95% CI p Estimate 95% CI p 
Upper Lower  Upper Lower  
No. of ftf consults -2.39 -4.14 -.64 .007 -2.62 -4.32 -.92 .003 
No. of telephonic consults 1.44 .36 2.52 .009 1.53 .42 2.64 .007 
Total no. of minutes  -33.48 -63.97 -2.99 .032 -38.84 -69.69 -7.98 .014 
No. of SAEs1,2 NA NA NA -.45 -1.01 .11 .117 
1 Per protocol analysis only due to the hypothesized non-inferiority of self-monitoring;  
2 Serious Adverse Events, complications requiring an overnight stay in the hospital 
 
  
 Intention-to-treat analysis Per protocol analysis 
Estimate 95% CI p Estimate 95% CI p 
Upper Lower  Upper Lower  
eGFR1 NA2 NA NA 1.41 -3.74 6.56 .544 
Systolic blood pressure1 NA NA NA 4.37 -2.20 10.94 .189 
Diastolic blood pressure1 NA NA NA .81 -3.13 4.74 .685 
Quality of life- physical1 NA NA NA 2.69 -9.67 15.04 .667 
Quality of life- mental1 NA NA NA 3.20 -7.72 14.12 .562 
Satisfaction1 NA NA NA .42 -.54 1.38 .381 
Self-management behaviour .46 -5.03 5.95 .867 .69 -4.86 6.23 .806 
  
 
3.2. Significant reduction in number of outpatient visits 
Mean number of ftf consults, telephonic consults and total number of minutes spent of both the 
intervention and control group are shown in figure 5. Self-monitoring led to a significant decrease in 
number of outpatient visits for the intention-to-treat population, with 16.02 (SD 4.93) and 18.35 (SD 
3.91) ftf visits for the intervention and control group, respectively (p .007, 95% CI [-4.023 – -.651]), see 
table 2. Total number of reimbursable minutes spent per patient (including ftf, telephonic consults and 
laboratory analysis) was significantly lower for self-monitoring patients, with 286.13 (SD 90.96) 
minutes for the intervention versus 319.61 (67.91) minutes for the control group (p .032, 95% CI [-
63.967 – -2.991]). Sensitivity analyses with patients treated per protocol only and controlling for 
diabetes gave no substantially different results (data not shown).  
 
3.3. Physician’s interaction with SMSS and self-monitoring  
Following our protocol (i.e. replacing half of the ftf visits by a telephonic one after the first period of 
eight weeks after transplantation), the expected difference in number of ftf visits between 
intervention and control patients should have been 6 (given that a patients’ clinical condition allowed 
for visits to be replaced). As the actual difference between intervention and control group was 2.3 
visits, we further investigated doctors’ involvement with the study protocol. Per doctor (N=15), total 
number of ftf appointments and telephonic consults for patients in the intervention group was 
calculated and compared to total number of logons to the SMSS. For this purpose, only patients that 
performed and registered measurements during the full study period were considered (N=36). For 10 
doctors (67%), the number of logons to the SMSS equalled at least the number of telephonic consults 
with self-monitoring patients. Comparing number of logons to total number of consults (either ftf or 
telephonic), 10 doctors (67%) had checked the values in the SMSS in less than half of their 
appointments. Three of them had never logged on to the SMSS although having had multiple 
(telephonic) consults.  
 
3.4. Level of self-efficacy regarding self-management behaviour similar in both study groups 
Self-reported self-management behaviour increased significantly over time for both the intervention 
and control group (p .030, 95% CI [.419 – 8.239]) No difference between intervention and control group 
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Figure 4. Mean score on variables measured repeatedly over time. Blue diamond = intervention 
group, red square = control group.  
 
1 Per protocol population; 2 Intention to treat population. 
 
3.5. Detection of rejection episodes and other relevant creatinine increases (>10%)  
In total 12 rejection episodes took place, five of which concerned intervention patients. In three cases, 
rejection was detected earlier thanks to the creatinine values measured at home. In one case rejection 
could not have been detected earlier as the concerning patient did not perform any measurements in 
the period preceding the rejection episode. In the fifth case, the individual measurements did show an 
increasing trend, but not enough for the system to generate the advice to contact the hospital.  
For 71 laboratory-based creatinine trends, a steady increase of more than 10% was found. In half of 
the concerning timeframes (N=36), the minimum required number of three self-monitored and 
registered creatinine values between two laboratory measurements was available for comparison to 
  
 
laboratory-based creatinine trends. Home-based creatinine trends were similar to laboratory-based 
creatinine trends in 78% of the 36 analysable timeframes. 
 
 




In the first year after kidney transplantation intensive monitoring of kidney function is required to 
detect potential rejection episodes and other causes of kidney function at an earliest stage. In this 
study, self-monitoring kidney function after transplantation led to a significant decrease in number of 
ftf visits and total number of minutes contact time spent per patient. This was achieved without 
compromising on quality of care, indicated by the absence of differences between intervention and 
control patients for kidney function, blood pressure, quality of life and general satisfaction over time. 
Furthermore, results suggest that self-monitoring is safe with regard to discovering deteriorations in 
kidney function. As the accuracy of the creatinine device used is insufficient for detecting current renal 
function with a single creatinine measurement[32-34], several measurements are needed to obtain a 
reliable trend[34]. For the detection of clinically relevant increases in creatinine (>10%), we found a 
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similar trend for home-based and laboratory-based creatinine levels in 78% of all available cases, which 
is 10% higher than what has been reported before[34]. Five intervention group patients experienced 
a rejection episode. In three cases, the developing rejection was detected before the scheduled control 
appointment due to the creatinine measurements performed at home, while no rejection episode was 
missed.  
This study shows that self-monitoring kidney function at home can safely reduce the high number of 
outpatient visits post-transplantation. This is beneficial for both patients and the health care system. 
Patients can save time and effort during their recovery from the transplantation and in the longer term, 
having to pay less visits to the hospital limits the interference of post-transplant follow-up with daily 
life. Further, the lower amount of outpatient appointments will reduce the burden on health resources 
and healthcare budgets. The actual difference in number of outpatient visits between the intervention 
and control group was, however, smaller than expected. Other studies have also reported that 
reductions in regular care using telehealth were lower than expected[35, 36]. Leimig et al.[36] state 
that this is most likely due to patients’ hesitancy to lose ftf contact with healthcare professionals and 
hesitancy of the clinic personnel to use the telehealth equipment[36]. Our data are in concordance 
with this description, but only regarding the health care professionals. We observed a hesitance in the 
doctors to replace ftf visits with telehealth, despite the fact that these professionals were fully trained 
in the protocol. Two potential causes for the limited SMSS use by doctors can be distinguished. First, 
some of the doctors were critical about the accuracy of the creatinine device that was used. It has been 
concluded before that doctors need to feel confident in order to share control with patients[37] and 
that diagnostic confidence is key to incorporating telehealth into a transplant clinic[36]. Second, during 
the kick-off meeting for this study, several doctors stated that ‘outpatient care of kidney transplant 
patients goes beyond checking creatinine and blood pressure’. Doctors generally feel highly 
responsible for ensuring that high-quality care is achieved[37-39] and using self-reported and patient 
acquired creatinine and blood pressure data may interfere with their perception of their professional 
responsibility. It is therefore important to emphasize that self-monitoring and telehealth can support 
doctors in their delivery of healthcare instead of competing with it[40].  
The hesitations regarding self-monitoring did not seem to apply to patients. Patients were very positive 
about self-monitoring kidney function after transplantation, taking into account the near unanimous 
recommendation of self-monitoring to other kidney transplant patients. High levels of satisfaction with 
self-monitoring have been found before[8, 15-17, 41]. In these studies, however, self-monitoring 
patients also reported a higher level of general satisfaction than their fellow patients receiving regular 
care. This was not confirmed in the current study. Level of satisfaction measured with the CSQ was 
  
 
already high at the first measurement for both intervention and control patients, leaving little room 
for improvement over time. Two other factors may have further contributed to the equal levels of 
satisfaction with care. First, the CSQ may have been too general to capture more subtle differences in 
satisfaction as it referred to ‘all’ care patients had received. Second, as the number of ftf visits that was 
replaced by a telephonic consult was lower than expected, intervention and control patients received 
more similar care, potentially resulting in equal levels of satisfaction.  
To the best of our knowledge, this is the first study to investigate the potential of self-monitoring 
kidney function to replace part of the highly frequent outpatient visits after kidney transplantation. 
The fact that we used an RCT design is an important strength, as an RCT is the most robust design when 
studying intended treatment effects, eliminating potential confounding by indication. Further, due to 
the use of linear mixed modelling and multiple imputations, both addressing the issue of missing data, 
all patients could be included in the analyses. The reported results concerning the involvement of 
doctors in the self-monitoring protocol adds to the clinical relevance of this paper.  
Our findings must also be evaluated within the context of the limitations of this study. First, all 
participants were recruited from a single centre. Second, nearly 90% of our study participants were 
transplanted with a kidney from a living donor. Third, from all kidney transplantations that were 
performed during period of inclusion, 44% of the transplant patients were ineligible for participation 
or did not want to participate. This could suggest that self-monitoring kidney function after 
transplantation is suitable for a selected group of kidney transplant recipients only.  
In conclusion, this study shows that self-monitoring kidney function after transplantation has the 
potential to increase patient satisfaction and accelerate the detection of kidney function deterioration 
while reducing healthcare consumption at the same time. With the growing availability of other 
techniques, for example dried blood spot techniques (DBS), even more analyses can now be performed 
with capillary samples obtained at home. It has recently been shown that DBS techniques can 
successfully be applied for the analysis of immunosuppressant medication concentration and 
creatinine[42, 43], the most important parameters to be monitored after kidney transplantation. Using 
a system in which all home measurement results are combined, reference values that are tailored to 
an individual patient and to which both patients and healthcare professionals have access, self-
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The high frequency of outpatient visits after kidney transplantation is burdensome to both the 
recovering patient and healthcare capacity. Self-monitoring kidney function offers a promising strategy 
to reduce the number of these outpatient visits. The objective of this study was to investigate whether 
it is safe to rely on patients’ self-measurements, using data from a self-management RCT.  
During the first year post-transplantation 54 patients registered their self-measured creatinine values 
in an online Self-Management Support System (SMSS) which provided automatic feedback on the 
registered values (e.g. seek contact with hospital). Values registered in the SMSS were compared to 
those logged automatically in the creatinine device to study reliability of registered data. Adherence 
to measurement frequency was determined by comparing the number of requested with the number 
of performed measurements. To study adherence to provided feedback, SMSS logged feedback and 
information from the electronic hospital files were analysed. 
Level of adherence was highest during month 2-4 post-transplantation with over 90% of patients 
performing at least 75% of the requested measurements. Eighty-seven percent of all registered 
creatinine values was entered correctly, although values were often registered several days later. If 
(the number of) measured and registered values deviated, the mean of registered creatinine values 
was significantly lower than what was measured, suggesting active selection of lower creatinine values. 
Adherence to SMSS feedback ranged from 53-85% depending on the specific feedback. 
Patients’ tendency to postpone registration and to select lower creatinine values for registration and 
the suboptimal adherence to the feedback provided by the SMSS might challenge safety. This should 
be well-considered when designing self-monitoring care systems, for example by ensuring that self-








After kidney transplantation, an early detection of transplant failure is mandatory to minimize 
permanent damage to the transplanted organ. For kidneys, blood level of creatinine is considered the 
most important indicator of kidney function[1]. Patients therefore have their serum creatinine checked 
on average 20 times during the first year post-transplantation. As hypertension is both a potential 
indicator of decreased kidney function and an important risk factor for kidney graft failure[2-5], blood 
pressure needs extensive monitoring too. If patients were enabled to monitor both parameters at 
home, this would have important advantages. Self-monitoring could improve speed of rejection 
detection as measurements can take place more frequently while at the same time the high number 
of outpatient visits could be reduced and replaced by telephonic consults. Further, giving patients a 
more active role in their own care through self-monitoring has been shown to be of clinical benefit for 
a wide range of patients with chronic disease[6-15] and to lead to a higher quality of life[16-19]and 
more patient empowerment[7, 19-22].  
A pilot study of our own group showed that self-monitoring of both blood pressure and creatinine is 
very well accepted among patients, suggesting that at-home monitoring after transplantation offers a 
promising strategy[23]. For self-monitoring to be a safe alternative to regular face-to-face follow-up, 
however, patients need to adhere to a monitoring schedule, report test results accurately and act upon 
test results if these suggest graft failure may occur. This is important for all patients who engage in 
self-monitoring, but especially for patients who are transplanted. As most patients who develop graft 
rejection are asymptomatic and present with an increased serum creatinine only, frequent measuring 
is essential to make the difference between treatment in time and damage to or even loss of the kidney 
transplant. Level of adherence to a self-monitoring schedule has been shown to vary widely in other 
disease populations [24-28]. Further, for self-measured values to be clinically useful, they need to be 
reported accurately. Several studies in different study populations have shown that caution is 
warranted when using patient reported data for making clinical decisions as a considerable number of 
patients report values that do not sufficiently represent their actual measurements[29-34].  
To the best of our knowledge, no studies have assessed the reliability and accuracy of patient 
generated creatinine data or looked at level of adherence to a protocol of self-monitoring creatinine. 
This is unfortunate, as the introduction of self-monitoring offers a good opportunity to improve post-
transplantation care. Our first research goal was to investigate the level of adherence of kidney 
transplant patients to a creatinine monitoring schedule. Our second research goal was to determine 
the reliability of the creatinine values that were registered in an online self-management support 
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The high frequency of outpatient visits after kidney transplantation is burdensome to both the 
recovering patient and healthcare capacity. Self-monitoring kidney function offers a promising strategy 
to reduce the number of these outpatient visits. The objective of this study was to investigate whether 
it is safe to rely on patients’ self-measurements, using data from a self-management RCT.  
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in an online Self-Management Support System (SMSS) which provided automatic feedback on the 
registered values (e.g. seek contact with hospital). Values registered in the SMSS were compared to 
those logged automatically in the creatinine device to study reliability of registered data. Adherence 
to measurement frequency was determined by comparing the number of requested with the number 
of performed measurements. To study adherence to provided feedback, SMSS logged feedback and 
information from the electronic hospital files were analysed. 
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performing at least 75% of the requested measurements. Eighty-seven percent of all registered 
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(the number of) measured and registered values deviated, the mean of registered creatinine values 
was significantly lower than what was measured, suggesting active selection of lower creatinine values. 
Adherence to SMSS feedback ranged from 53-85% depending on the specific feedback. 
Patients’ tendency to postpone registration and to select lower creatinine values for registration and 
the suboptimal adherence to the feedback provided by the SMSS might challenge safety. This should 
be well-considered when designing self-monitoring care systems, for example by ensuring that self-








After kidney transplantation, an early detection of transplant failure is mandatory to minimize 
permanent damage to the transplanted organ. For kidneys, blood level of creatinine is considered the 
most important indicator of kidney function[1]. Patients therefore have their serum creatinine checked 
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pressure needs extensive monitoring too. If patients were enabled to monitor both parameters at 
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disease populations [24-28]. Further, for self-measured values to be clinically useful, they need to be 
reported accurately. Several studies in different study populations have shown that caution is 
warranted when using patient reported data for making clinical decisions as a considerable number of 
patients report values that do not sufficiently represent their actual measurements[29-34].  
To the best of our knowledge, no studies have assessed the reliability and accuracy of patient 
generated creatinine data or looked at level of adherence to a protocol of self-monitoring creatinine. 
This is unfortunate, as the introduction of self-monitoring offers a good opportunity to improve post-
transplantation care. Our first research goal was to investigate the level of adherence of kidney 
transplant patients to a creatinine monitoring schedule. Our second research goal was to determine 




system (SMSS). As this SMSS automatically provided instructions for further actions (e.g. continue 
regular schedule or contact the hospital) upon registration of a new creatinine value, our final research 




Patients and study design 
The data used in this study was obtained from the ADMIRE project (Assessment of a Disease 
management system with Medical devices In RENal disease), a cooperation between the Leiden 
University Medical Centre, the Technical University of Delft and the Dutch Organisation for Applied 
Scientific Research (TNO). This extensive project comprised the technical development of a SMSS in 
which several studies were performed to optimise the system to suit patient’s needs and wishes, as 
well as a prospective randomized controlled trial (RCT) to study whether self-monitoring kidney 
function supported by a SMSS can replace part of regular outpatient care without compromising on 
the quality of care. The study protocol was approved by the Medical Ethics Committee of the LUMC. 
Patients were eligible for participation in the RCT if they were about to receive a donor kidney or 
recently received one, were ≥ 18 years of age, mastered the Dutch language sufficiently, had access to 
Internet and had a creatinine level of ≤ 300 µmol/l within 4 weeks post-transplantation. Patients were 
excluded if they were visually impaired or were considered ineligible by their treating physician (e.g. 
due to mental retardation, a history of non-compliance to treatment). We therefore had a selection of 
patients that seemed most capable for engaging in self-monitoring 
Recruitment of living donor recipients took place during a pre-transplant consultation with a nurse-
practitioner. Recipients of a post mortem kidney were recruited during their post-transplantational 
stay in the hospital by the primary investigator (CvL). After this face-to-face introduction, patients 
received a written explanation of the study with an informed consent form. If a signed informed 
consent was not returned within two weeks from the recruitment date, patients were contacted 
telephonically to inquire whether they were interested in participating. After signing informed 
consent, each participant was assigned a study number. Incoming informed consents were treated in 
consecutive order. Study numbers were allocated to either the intervention or control group according 
to a pre-set randomization schedule which was created by a medical statistician. The randomization 
procedure was blinded for the project members directly involved in patient recruitment.  
  
 
For the current study, only participants randomized to the intervention group were included. 
 
Intervention 
Devices and Self-Management Support System (SMSS) 
For self-monitoring creatinine, each participant received a StatSensor® Xpress-i™ Creatinine Meter 
(Nova Biomedical, Waltham, USA) and related test material (i.e. test strips, control solution to test the 
quality of the strips, and safety lancets for capillary blood sampling. Based on a drop of blood of 1.2 
μL, the StatSensor® can show either current level of creatinine or eGFR. As at our medical centre 
clinicians usually communicate level of creatinine to kidney transplant patients, the device was set to 
show creatinine.  
For self-monitoring blood pressure, each participant received a Microlife WatchBP® Home (Microlife, 
Heerbrugg, Switzerland), an oscillometric device for blood pressure self-measurement on the upper 
arm. Both devices had a memory function and the option to download stored values to a computer.  
An online self-management support system (SMSS) was available for all patients in the intervention 
group. This SMSS entailed an eLearning module instructing patients on how to use the SMSS system, 
that is (a) how to perform creatinine measurements at home, (b) how to register self-measured values 
in the SMSS (both creatinine and blood pressure), and (c) how to respond to messages from the 
automatic feedback system to support patients’ interpretation of the creatinine trends. Figure 1 
provides an overview of the feedback process. The feedback appeared directly after registration of a 
new creatinine value online and consisted of a traffic light with corresponding text. Per day, a 
maximum of two creatinine values could be registered. After registration of the first value of the day, 
a green light indicated that there was no reason for concern and was associated with the advice to just 
continue regular measurement frequency. This was termed the day conclusion, as no further actions 
were required for the concerning day. The appearance of an orange or red light (in case the newly 
registered value was respectively >15% or >20% higher than mean of the previous five values) directly 
after registration of the first value of the day indicated that there was some reason for concern. The 
system’s advice was then to perform and register a second measurement to confirm the first 
measurement. This was termed action feedback, as it required an immediate action. After registration 
of a second measurement, an appearing green light indicated that there was no further reason for 
concern. In this case, patients were advised to continue their regular monitoring frequency. 
Alternatively, an orange light indicated that there was some reason for concern and patients were 
advised to measure again tomorrow. Finally, a red light indicated that there was reason for concern 
and patients were advised to contact the hospital. Feedback given after the registration of a second 
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quality of the strips, and safety lancets for capillary blood sampling. Based on a drop of blood of 1.2 
μL, the StatSensor® can show either current level of creatinine or eGFR. As at our medical centre 
clinicians usually communicate level of creatinine to kidney transplant patients, the device was set to 
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For self-monitoring blood pressure, each participant received a Microlife WatchBP® Home (Microlife, 
Heerbrugg, Switzerland), an oscillometric device for blood pressure self-measurement on the upper 
arm. Both devices had a memory function and the option to download stored values to a computer.  
An online self-management support system (SMSS) was available for all patients in the intervention 
group. This SMSS entailed an eLearning module instructing patients on how to use the SMSS system, 
that is (a) how to perform creatinine measurements at home, (b) how to register self-measured values 
in the SMSS (both creatinine and blood pressure), and (c) how to respond to messages from the 
automatic feedback system to support patients’ interpretation of the creatinine trends. Figure 1 
provides an overview of the feedback process. The feedback appeared directly after registration of a 
new creatinine value online and consisted of a traffic light with corresponding text. Per day, a 
maximum of two creatinine values could be registered. After registration of the first value of the day, 
a green light indicated that there was no reason for concern and was associated with the advice to just 
continue regular measurement frequency. This was termed the day conclusion, as no further actions 
were required for the concerning day. The appearance of an orange or red light (in case the newly 
registered value was respectively >15% or >20% higher than mean of the previous five values) directly 
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measurement was also termed day conclusion, as no further values could be registered. See figure1 
for an overview of all possible feedback combinations.  
A link was created between the SMSS and the electronic hospital system in order for the registered 
creatinine values to be visible for the treating nephrologist(s). Nephrologists did not receive a copy of 
the supplied SMSS feedback. 
 
Procedure 
The time schedule for providing instructions depended on whether patients participated in the living 
donor program or whether they received a kidney from a deceased donor. Two weeks prior to a 
scheduled transplantation, patients received account details to log in to the SMSS and use the 
eLearning module to prepare for self-monitoring. Recipients of a kidney from a deceased donor 
received account details during their post-transplantational stay in the hospital. A laptop was available 
to use the eLearning modules. After being virtually instructed through eLearning, all patients received 
the creatinine device and supplementary face-to-face instructions. Special attention was paid to the 
fact that patients had to take action themselves upon the system’s feedback, as their nephrologist(s) 
would only check the home-based creatinine values in advance of or during an outpatient visit or 
telephonic consult. Patients were then encouraged to practice using the creatinine device during the 
remainder of their hospital stay.  
Home-based creatinine measurements had to be performed according to a fixed frequency, being daily 
during the first 4 weeks (phase 1), every other day for week 5-9 (phase 2), twice a week for week 10-
15 (phase 3) and weekly from week 16 onwards (phase 4). This scheme was based upon the usual 
frequency of laboratory testing, which decreases when time since transplantation increases. However, 
as the creatinine device tends to be less accurate than laboratory tests[35], the usual frequency of 
laboratory testing was multiplied with a factor seven to obtain a more reliable trend. After measuring, 
patients registered the results in the SMSS.  
In addition to conducting regular creatinine measurements, patients were advised to perform a test 
measurement when opening a new bottle of test strips. These measurements could be termed test 
measurements by pressing a designated button on the creatinine device.  
From week eight after transplantation on, every other face-to-face outpatient visit with regular 
hospital-based laboratory measurements was replaced by a telephonic consult to discuss self-
monitored creatinine and blood pressure. Although regular face-to-face visits also include other 
laboratory measurements (e.g. trough levels of immunosuppressive medication), these analyses do 
not need to be performed in the same frequency as for creatinine due to their (expected) little 
  
 
variation over a short period of time. It was therefore deemed unnecessary to replace these other 
laboratory measurements with a home-based alternative.  
To remind nephrologists of scheduling a telephone consult instead of a face-to-face visit, a short note 
asking for the next appointment to be a telephonic one was shown repetitively in a patients’ electronic 
hospital file. It was, however, up to the treating nephrologist to judge whether a patients’ condition 
allowed for a telephonic consult to take place or whether a face-to-face visit was requested.  
At the end of the intervention period of one year, all patients were invited to bring their creatinine 
device to download logged data. This data included test results, date and time of all performed 
measurements and, if applicable, an indication of whether a specific value was termed a test 
measurement. Further, data that was automatically logged in the SMSS was downloaded including the 
registered value(s), date of performed measurement (according to the patient), date of registration 
and the feedback that was supplied online after each registered creatinine value.  
 
Measures 
Patients completed a questionnaire at baseline to collect demographic characteristics.  
The read out data from the creatinine device and the data that was logged in the SMSS were combined 
using date of measurement. For the creatinine device, measurement date was the date of 
measurement performance that was registered automatically in the device memory. For the SMSS, 
measurement date was the date of measurement performance according to the patient. 
 
Statistical analyses 
Adherence to measurement frequency 
To assess whether patients adhered to the measurement protocol, we separated adherence according 
to device logged data (did patients perform the requested number of measurements?) and adherence 
to SMSS logged data (did patients register the requested number of measurements online?). If 
applicable, paired t-tests were conducted to compare means using SPSS 22.0. In these cases p<.05 was 
considered statistically significant.  
For adherence according to device logged data, we calculated the number of days with measurements 
per patient per phase and compared this to the number of requested measurement days. Number of 
requested measurement days was 28 during phase one (four weeks), 15 during phase two (five weeks), 
12 during phase three (six weeks) and 37 during phase four (37 weeks). To make it easier to interpret 
the results, level of adherence was divided in 4 subcategories for this study:  
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allowed for a telephonic consult to take place or whether a face-to-face visit was requested.  
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Extremely non-adherent: measurements performed during less than 25% of the requested days 
1. Non-adherent: measurements performed during 25-74% of the requested measurement days 
2. Adherent: measurements performed during 75-100% of the requested measurement days 
3. Over-adherent: measurements performed more frequently than requested (i.e. > 100%).  
This same procedure was used to calculate level of adherence to registration of measurement in the 
SMSS, i.e. whether patients registered measurements on the requested number of days.  
 
 
Figure 1. Possible feedback combinations in the SMSS.  
 
Moment of registration 
Date of measurement (derived from device logged data) was compared to the date of registration of 
this measurement (derived from SMSS logged data). Per patient the average number of days delay 
between measurement and registration was calculated. Further, we investigated whether delayed 
registration was related to stability of creatinine level by comparing feedback that was generated by 
the SMSS in case of registration on day of measurement with feedback that was generated when 
registration was delayed. 
  
 
Reliability: correctness and representativeness of registered data 
The reliability of registered data is determined by both the correctness and the representativeness of 
registered values. To study correctness of the registered data, we investigated the one on one 
correspondence between a registered and measured value on a given day. Three different categories 
were distinguished: 
1. Reliable SMSS registrations: in case a value that was registered in the SMSS corresponded to the 
device logged value on a given date. Only days with an equal number of measurements logged in 
the device and SMSS were taken into account. 
2. Non-correspondence, in case an SMSS registered value did not correspond to the device logged 
value on a given date. Only days with an equal number of measurements in the device logged and 
SMSS logged data were selected. All cases of non-correspondence were carefully checked for 
potential causes of the deviance (e.g. wrong combination of date and measured value, typo, 
rounding off). The cases where no potential cause was found were termed incorrect entries. For 
each patient, a mean level of creatinine was calculated for the values that were actually measured 
and for the values that were registered using cases of incorrect entry only. A paired t-test was 
performed to compare these means. Total and median number of non-corresponding values was 
calculated per patient. Patients with a high number of non-corresponding values were selected for 
further exploration. 
3. Phantom values, in case a value was registered in the SMSS on a given date while according to the 
data stored in the device no measurement was performed on that specific date. All potential 
phantom values were thoroughly checked for alternative explanations before it was concluded that 
there was no relation with values that had been measured by the patient. A paired t-test was 
performed using the mean of the phantom values versus the mean of all measured creatinine 
values per patient.  
 
Further, to get a reliable impression of a creatinine level over time (trend), the SMSS registered values 
need to represent what was actually measured. It is therefore important to know how often a 
measured value was not registered in the SMSS and whether the unregistered values differed in any 
way from the registered values. The measured values not being registered in the SMSS were split into 
two categories:  
1. Omissions, in case one or more measurements were performed on a given date, but no value was 
registered in the SMSS. Total and median number of omissions per patient was calculated. For each 
patient, we calculated a mean level of creatinine for the values that were both measured and 
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this measurement (derived from SMSS logge  d ta). Per patien  the average number of days delay 
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registration was delayed. 
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further exploration. 
3. Phantom values, in case a value was registered in the SMSS on a given date while according to the 
data stored in the device no measurement was performed on that specific date. All potential 
phantom values were thoroughly checked for alternative explanations before it was concluded that 
there was no relation with values that had been measured by the patient. A paired t-test was 
performed using the mean of the phantom values versus the mean of all measured creatinine 
values per patient.  
 
Further, to get a reliable impression of a creatinine level over time (trend), the SMSS registered values 
need to represent what was actually measured. It is therefore important to know how often a 
measured value was not registered in the SMSS and whether the unregistered values differed in any 
way from the registered values. The measured values not being registered in the SMSS were split into 
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registered in the SMSS. Total and median number of omissions per patient was calculated. For each 




registered and a mean level of creatinine for the values that were measured on days without any 
registration. A paired t-test was performed to compare these means. 
2. Selection of measurements, which is the case when the number of performed measurements that 
is stored in the device is higher than the number of registered measurements on a given date. 
Therefore only days with a difference between number of measured and number of registered 
creatinine values were selected (e.g. three measurements stored in the device and one value 
registered in the SMSS). We then calculated per patient the mean of all values stored in the device 
and registered in the SMSS and the mean of all values stored in the device, but not registered in the 
SMSS. A paired t-test was performed to compare these means.  
 
Adherence to feedback  
After registration of a creatinine value in the SMSS, patients received an automatically generated 
advice on the necessary action to take (see figure 1). To investigate level of adherence to the advice 
generated by the SMSS, we separated between adherence to action feedback (supplied after the 
registration of a first measurement when further action was required) and adherence to the day 
conclusion (supplied when no further actions were required after the first registration of a day or when 
a second and final measurement was registered on the same day).  
Action feedback could only appear in case the newly registered creatinine value was higher than the 
previous ones and required an additional measurement to confirm the first. In these cases, the 
feedback system of the SMSS showed an orange or red traffic light with the corresponding advice to 
repeat the measurement. From the SMSS logged data, we selected those cases where a second 
measurement was requested and checked whether the concerning patients indeed measured and 
registered a second creatinine value on the same day. 
To study adherence to the day conclusion, we only considered the cases in which patients again were 
confronted with an orange or red traffic light. In case of a request to perform another measurement 
tomorrow (orange traffic light), the SMSS logged data was checked to see whether the requested 
action was indeed performed. In case of a request to contact the hospital (red traffic light), patient 
hospital records were searched for telephonic and/or outpatient contacts on dates following the 
concerning feedback.  
 
Sensitivity analyses 
Two sensitivity analyses were performed to control for potential bias. First, as being hospitalized limits 
the possibility to keep up with requested measurement and registration frequency, level of adherence 
  
 
was analysed with patients that were hospitalized during the study both in- and excluded. The second 
sensitivity analysis concerned the test measurements patients were requested to perform when 
opening a new bottle of strips. Many patients either did not perform test measurements or did not 
indicate them as such. To prevent test values to be mistakenly considered creatinine measurements, 
all values that were stored in the device memory were checked. Potential test values were discussed 
and decided upon by the two main authors. The following criteria were used: 1. the value was not 
registered in the SMSS, 2. the value differed from the previous and following value, 3. the value fell 
within the test value range that was set by the manufacturer (133-239 µmol/l) and 4. the value 
followed or was followed by at least one SMSS-registered value measured on that same day (measured 
shortly after one another according to device logged data). After having thoroughly checked and 
discussed all potential test values, for 24 values it remained unclear whether they were test values or 
not. We therefore performed all analyses concerning the representativeness of registered creatinine 
data with these 24 values both in- and excluded.  
Further, we compared our findings concerning patient self-monitoring creatinine to a more broadly 
used and well-accepted form of patient-monitoring, being self-monitoring of blood pressure. For this 
purpose we performed two analyses with the self-monitored and self–reported blood pressure 
measurements in our study population. First, we looked at adherence to the blood pressure 
measurement protocol using the same procedure as for creatinine: number of days with 
measurements versus number of requested measurement days per patient per phase. The requested 
frequency of blood pressure measurements was equal to the measurement frequency of creatinine. 
As many patients used other blood pressure devices than the device we supplied for the study, we 
could not determine adherence to the measurement protocol in a reliable way. We therefore only 
could assess adherence to the registration protocol by comparing number of registered blood pressure 
measurements (SMSS logged data) to requested measurement frequency.  
Second, we looked at correspondence between measured and registered blood pressures. To prevent 
potential bias and misinterpretation, we 1. only used measurements from days with an equal number 
of measurements and registrations and 2. calculated a Mean Arterial Pressure (MAP, [(2 x 
diastolic)+systolic]/3)) for both measured and registered blood pressures per day. Using all cases of 
non-correspondence between measured and registered MAP, an overall mean arterial pressure was 
calculated per patient for both blood pressures that were actually measured and for blood pressures 
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Within period of inclusion, in total 217 patients received a kidney transplant of which 155 were 
considered eligible for participation. The main reasons for ineligibility were insufficient mastery of the 
Dutch language (N=25, 40%) and no access to a computer/lack of computer skills (N=16, 26%). One 
hundred nineteen patients (77%) signed an informed consent. The main reason for not wanting to 
participate was the anticipated burden of self-monitoring (N=28, 42%). Sixty-five patients were 
randomized to the intervention group. After randomization, 3 patients dropped out because of graft 
dysfunction, death and cancellation of transplantation (none was study related). Four patients 
cancelled their participation before starting to self-monitor kidney function at home, because they 
reported having little trust in the creatinine device, experienced difficulties when logging into the 
SMSS, experienced business rush or had a worsened condition post-transplantation. Fifty-eight 
patients were supplied with a creatinine and blood pressure device of which four never performed any 
measurement.  
To study level of adherence to requested measurement frequency, we included patients of whom 
measured values were available for at least one complete study phase (N=48). To study the reliability 
of registered data and adherence to system feedback, we included patients who performed and 
registered measurements during all study phases (N=43). The flow-chart in figure 2 gives a stepwise 
overview of the patient flow and for which selection of patients a specific analysis was performed. 
Patient characteristics are shown in table 1. The mean age of participants was 52 and 53 years for 
patients who received the monitoring devices (N=58) and patients who performed and registered 
measurements during all study phases (N=43), respectively. Number of patients with both a low and 
high educational level was slightly higher than in the average Dutch population[36]. Almost 90% of our 
participants had received a kidney from a living donor, while the ratio of transplantations with living 
vs. post-mortem kidneys was about equal in our centre during period of inclusion. This discrepancy is 
mainly due to a higher percentage of ineligibility among recipients of a post-mortem versus living 
kidney: 51% versus 16% respectively.  
No differences were found between patients who received the monitoring devices and patients who 
performed and registered measurements during all study phases for the characteristics we measured 





Adherence to requested measurement frequency 
Adherence to requested measurement frequency according to device logged data (did patients 
perform the requested number of measurements?) and adherence to SMSS logged data (if patients 
performed a measured, did they register the requested number of measurements?) is shown in figure 
3. During phase 1 (daily measurements) adherence to the requested number of creatinine 
measurements was lowest with 79%. Subsequently, adherence rose to over 90% during phase 2 
(measuring every other day) and 3 (measuring twice a week) and then decreased to 85% during phase 
4 (measuring weekly). Four patients performed less than 75% of the requested measurements 
throughout two or more phases. For registration of the requested number of creatinine measurements 
this same pattern is shown, although the percentage of non-adherent patients is higher during all 
phases. Eight patients were non-adherent during two or more phases regarding registration of the 
requested number of measurements.  
To control for the potential influence of hospitalization on level of adherence to measurement and 
registration protocol, we repeated our analysis with all hospitalized patients excluded. Total number 
of hospitalized patients was 11 during phase 1, three during phase 2, seven during phase 3 and nine 
during phase 4. Excluding these patients did not change our initial findings.  
 
Moment of registration 
When looking at date of measurement versus date of registration of measurements, a mean delay of 
4 days (SD 10) was found. The level of delay varied from 1 to 81 days. Seven patients (15%) always 
registered their test results on the day of measurement and 15 patients (31%) had an overall mean 
delay of less than one day between measurement and registration. Twenty-two patients (46%) had an 
overall mean delay of more than three days, ranging up to a mean difference of 29 days between date 
of measurement and date of registration. One could hypothesize that patients do not feel the need to 
register their measurement online if their level of creatinine is stable. However, the feedback that was 
generated by the SMSS for measurements registered on the day of measurement versus 
measurements that were registered with delay did not differ: in both situations, patients were 
requested to repeat the measurement in about 7% of all registrations.  
 
Reliability of registered data 
Of the 43 patients included in the reliability analysis, the total number of values stored in the creatinine 
devices was 5779 and the total number of values registered in the SMSS was 4606. To investigate 
correspondence between measurement and registration, only days with an equal number of 
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register their measurement online if their level of creatinine is stable. However, the feedback that was 
generated by the SMSS for measurements registered on the day of measurement versus 
measurements that were registered with delay did not differ: in both situations, patients were 
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Of the 43 patients included in the reliability analysis, the total number of values stored in the creatinine 
devices was 5779 and the total number of values registered in the SMSS was 4606. To investigate 




measurements in the device and registrations in the SMSS were selected. Total number of 
measurements performed and registered on these days was 3963. Figure 4 gives an overview of the 
reliability of the registered data, showing that 87% of these values was registered correctly.  
 
Non-corresponding registrations 
In 515 cases (13%) of all creatinine registrations, the registered value did not correspond to the value 
that was measured on that day. In 174 cases, we could determine the origin of the difference (e.g. 
wrong combination of date and measured value, typo, rounding off). The remaining 341 registrations 
(9% of all registered values) were used for further analysis. Median number of non-corresponding 
values per patient was 3 (IQR 8). Eleven patients (25%) made no mistakes at all, while another eleven 
patients made more than 10 mistakes. Two patients had an extremely high number of non-
corresponding registrations. The first one had 52 non-corresponding registrations, half of which were 
found to be exactly 10, 20, 30 or 40 µmol/l lower than what was actually measured. In total 83% of his 
non-corresponding entries was lower than what was measured. The other patient registered 92 non-
corresponding values, which were lower than the actual measured values in 93% of his cases.  
In case of non-correspondence, the difference between measured and registered ranged from 1 to 73 
mmol/l with a median of 9 mmol/l (IQR 13). The non-corresponding registrations were significantly 
lower than the actual measured ones: 123 mmol/l (SD 28) versus 130 mmol (SD 33), respectively (t = 
8.7, p=<.001).  
 
Phantom values 
In total 93 phantom values were found, which was 2% of all registered values. Thirteen patients (30%) 
registered at least one phantom value, six patients (14%) registered seven or more. Twenty phantom 
values resembled the measurements of surrounding days, which would suggest these phantom values 
were only registered to adhere to the registration protocol. However, this appeared not to be the case 
as 16 of these 20 resembling phantom values were registered by a single patient who would already 
have been overly adherent without these phantom values. Three patients registered creatinine values 
during months where no measurements were logged in the device. For example, one patient quit 
measuring in February, but registered three measurements during March and April. Phantom values 
were significantly lower than actually measured ones, respectively 107 (SD 26) and 123 (15) mmol/l (t 





Figure 2. Study flow-chart.  
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Table 1. Baseline patient characteristicsa  
 
 Received devices 
 
N=58 
Used devices and SMSS 
during all phases 
N=43 
p 
Sex, male (%) 37 (64) 27 (63) NSb 
Age at tx, M (SD) 51.6 (14) 52.5 (15) NS 
Living together/married (%) 43 (74) 33 (77) NS 
Children, yes (%) 39 (67) 29 (67) NS 
Educational level (%)   NS 
- Low 22 (38) 14 (33)  
- Middle 16 (28) 12 (28)  
- High 20 (34) 17 (39)  
Paid job, yes (%) 31 (53) 23 (53) NS 
Origin, native (%) 53 (91) 41 (95) NS 
Former transplantation (%) 6 (10.3) 4 (9.3) NS 
Dialysis dependence  
pre-transplantation (%) 
26 (44.8) 21 (49) NS 
Living transplantation (%) 50 (86.2) 38 (89) NS 
Kidney function (eGFR), M (SD) 49 (16.1) 50 (15) NS 
aFor a few patients data on marital status and education was missing. This data was imputed in SPSS using multiple 





Figure 3. Patient adherence to requested measurement and SMSS registration frequency per study 
phase. 
The X-axis refers to the different measurement frequencies requested throughout the study for both performed 
and registered measurements (daily, every other day, twice a week and weekly in phase 1, 2, 3 and 4, 
respectively) and the Y-axis shows the percentage of (over-)adherent and (extremely) non-adherent patients. 
 
Representation of registered creatinine values  
Of the 5779 measurements found in the creatinine device logged data, 1300 values (22%) were not 
registered in the SMSS. In 700 cases, one or more measurements were performed on a given date, but 
no value was registered in the SMSS (i.e. omission). Number of omissions per patient ranged from 0 to 
145. Five patients had no omissions at all and 11 patients had omitted 20 values or more. Median 
number of omissions was 8. The omitted values were significantly higher than the registered ones 
(mean of 139 (SD 31) vs. 130 (SD 32) µmol/l, respectively, t =-3.7, p=< .001).  
In several cases, more measurements were performed per day than values were registered. In these 
so-called measurement series, the number of performed measurements ranged from two to eight with 
a median of 2 (IQR 1) per day. The difference between number of measured and number of registered 
values was 1 and 2 in 74% and 18%, respectively. The total number of values that was measured within 
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(mean of 139 (SD 31) vs. 130 (SD 32) µmol/l, respectively, t =-3.7, p=< .001).  
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a median of 2 (IQR 1) per day. The difference between number of measured and number of registered 




a series of measurements, but was not registered in the SMSS was 600. The mean of the creatinine 
values that were both stored in the device and registered in the SMSS was significantly lower than the 
mean of the creatinine values that were stored in the device but not registered in the SMSS (unselected 
for registration): 137 (SD 35) vs. 143 µmol/l (SD 36), respectively (t =-2.5, p=.02).  
Repeating both analyses with the 24 values included that could either be test values or regular 
measurements did not change our findings (data not shown).  
 
Adherence to system feedback 
Results are given separately for adherence to the action code (requesting patients to perform a second 
measurement directly) and adherence to the day conclusion (feedback that only appeared in case a 
second measurement was requested and registered). An overview of the feedback procedure and level 
of adherence to the different kinds of feedback is shown in figure 5.  
 
Adherence to action code 
In 258 cases, patients were requested to perform a second measurement directly. In 137 cases (53%), 
patients actually performed and registered a second measurement. In 85 cases (33%) date of 
registration differed from date of measurement, suggesting that delayed registration was the main 
reason for not adhering to feedback, as this feedback was no longer up to date when shown to the 
patient. In 14 cases (5%), multiple measurements were performed in advance of registration. As these 
multiple measurements were probably representative of actual creatinine level already, patients might 
not have felt the need to perform another one.  
 
Adherence to day conclusion  
In 39 cases, patients were requested to measure again the next day. In 33 cases (85%), this feedback 
was adhered to. In three cases, the measurements were registered several days after measurement 
(delayed registration), suggesting that the feedback to measure again the next day was no longer up 
to date when shown to these patients. In one case, the requested measurement was performed, but 
was not registered in the SMSS. 
The advice to contact the hospital was given 24 times, which was followed up 14 times (58%). In the 
remaining 10 cases (concerning 10 individual patients) measurements were registered with several 
days delay. As feedback was no longer up to date when shown to them, this suggests delayed 
registration was the main reason for not adhering to the feedback to contact the hospital. If only cases 
  
 
with registration on the day of measurement were taken into account, adherence to contacting the 
hospital was 100%. 
 
 
Figure 4. Reliability of creatinine values registered in the Disease Management System.  
a These two values (1291 and 4606) do not add up to the total number of measurements in the device (5804) due to the 
presence of phantom values.  
 
Sensitivity analysis: adherence to and reliability of blood pressure measurements  
In total 31 blood pressure devices could be read out. The total number of values found in the 31 
available pressure devices was 4917, total number of values registered in the SMSS was 5637. The 
higher number of registered than measured blood pressures is due to patients using multiple blood 
pressure devices during study participation, while data of only one device was available. Adherence to 
registration of blood pressure measurements was comparable to creatinine registrations with 70%, 
88%, 87% and 81% of patients registering >75% of the requested number of measurements during 
phase one, two, three and four, respectively. Although the percentage of registrations not 
corresponding to the measured MAP was comparable to what we found for creatinine (14% vs. 13%, 
respectively), we could not replicate the significant difference between registered and actually 
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The advice to contact the hospital was given 24 times, which was followed up 14 times (58%). In the 
remaining 10 cases (concerning 10 individual patients) measurements were registered with several 
days delay. As feedback was no longer up to date when shown to them, this suggests delayed 
registration was the main reason for not adhering to the feedback to contact the hospital. If only cases 
  
 
with registration on the day of measurement were taken into account, adherence to contacting the 
hospital was 100%. 
 
 
Figure 4. Reliability of creatinine values registered in the Disease Management System.  
a These two values (1291 and 4606) do not add up to the total number of measurements in the device (5804) due to the 
presence of phantom values.  
 
Sensitivity analysis: adherence to and reliability of blood pressure measurements  
In total 31 blood pressure devices could be read out. The total number of values found in the 31 
available pressure devices was 4917, total number of values registered in the SMSS was 5637. The 
higher number of registered than measured blood pressures is due to patients using multiple blood 
pressure devices during study participation, while data of only one device was available. Adherence to 
registration of blood pressure measurements was comparable to creatinine registrations with 70%, 
88%, 87% and 81% of patients registering >75% of the requested number of measurements during 
phase one, two, three and four, respectively. Although the percentage of registrations not 
corresponding to the measured MAP was comparable to what we found for creatinine (14% vs. 13%, 




measured creatinine for blood pressure: 97 mmHg (SD 2) versus 96 mmHg (SD 9) for registered and 
measured MAP’s, respectively (t=.20, p=.84).  
 
 




Self-monitoring kidney function and blood pressure at home offers important advantages for patients 
after kidney transplantation. However, the value and safety of self-monitoring depends on how well 
patients actually adhere to their self-monitoring tasks, the reliability of the test results they report and 
whether they take appropriate actions based on their measurements. This study showed that level of 
adherence was generally good. Well above 90% of all patients performed the requested number of 
  
 
measurements during month 2-4 after transplantation. Adherence was lower during the first month 
when more measurements were requested and months 5-12 after transplantation when less 
measurements were requested, with about 75% and 85% of patients adhering to the requested 
number of measurements, respectively. Overall adherence to registration of measurements was about 
10% lower than adherence to performance of measurements during all phases. Two studies reporting 
on level of adherence to monitoring vital signs after lung transplantation found similar percentages of 
adherence being above 80% for the entire study period[24, 26]. For self-monitoring blood pressure, 
patients with uncontrolled hypertension were shown to be adherent for about 73% of the entire study 
period[25, 29]. In both studies, level of adherence was highest in the first few weeks and declined 
gradually over time. In sum, mean level of adherence that has been found in the current study 
corresponds to percentages that have previously been reported. In contrast, we did not find the 
highest levels of adherence in the first period. This may have been due to a strenuous measurement 
protocol. Patients had to measure every day in the first month. In these first weeks when patients have 
to recover and have to get used to life post-transplantation, performing measurements in such a high 
frequency might be too burdensome. Further, in this first period face-to-face visits were not yet 
replaced by telephonic consults and patients therefore visited the hospital at least weekly to monitor 
early signs of graft failure. Due to this high frequency of visits, patients may have felt a reduced need 
to perform measurements at home, as they did not have to rely on these measurements. The latter 
may also be an explanation for non-adherence during the whole study period.  
Further, for self-monitoring to be a safe alternative to regular face-to-face follow-up, patient-reported 
test results need to be accurate. In the current study, approximately 90% of both creatinine and blood 
pressure measurements was registered correctly in the SMSS. This percentage corresponds to what 
has previously been described for patient-reported blood pressure[29, 37] and anticoagulation[34] and 
is much higher than has been observed for patient-reported levels of blood glucose. A study by Kalergis 
and colleagues[30] for example, showed that slightly over half of the total group of patients with either 
diabetes type 1 or 2 was considered very reliable in their reporting. For patients with diabetes type 2 
and for pregnant women self-monitoring blood glucose, some studies even showed that the majority 
of patient-reported data was unreliable[31, 32].  
In cases of non-correspondence between measured and actually registered values, values that were 
eventually registered in the SMSS were significantly lower than those actually measured. These results 
seem to suggest that patients select, alter or add values in such a way that their creatinine profile looks 
more positive. This corresponds to what has been found in a population of patients with thrombosis, 
where the percentage of time patients’ level of anticoagulation was within the desired range was 
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significantly higher when using patient-reported data compared to data stored in the device[34]. For 
patients with diabetes or hypertension, it was found that inaccurate reporting increased with 
increasing levels of blood glucose[31] or blood pressure[37]. Why patients report values that look 
better than the actual measured values or add non-existent measurements has not yet been fully 
clarified. For diabetes, it has been suggested that patients report false glucose levels due to a feeling 
of guilt for not having achieved glycemic goals[32] or add phantoms values in an attempt to fill up 
logbooks and satisfy their healthcare providers[30]. Both situations seem to represent an attempt to 
be a ‘good’ patient. However, altering and selecting data that is not representative of the actual clinical 
situation or adding phantom values in any case may be dangerous. This can lead to suboptimal 
treatment and, eventually, to worsened patient outcomes[30, 37]. In a study by Kendrick and 
colleagues it was found indeed that women with pregnancy-derived diabetes received suboptimal 
treatment due to a large difference between their reported glucose values and what they had 
measured[32]. Results of another study showed that diabetic patients who were more reliable in their 
reporting had a significantly better glycemic control. It was suggested that this may be due to the ability 
of clinicians to adjust therapy more precisely if measurements are reported accurately[30]. To prevent 
incorrect reporting, it has been recommended to rely on the memory capacity of measurement 
devices, preferably by using devices that can transfer data automatically[30, 31, 33, 34].  
Besides eliminating the occurrence of both intentional and unintentional errors, the automatic transfer 
of data offers a solution for the observation that patients seem to save up their measurements before 
registering them. Many patients saved up their measurements over several days or even weeks to 
register them all at once. More than one-third of our participants displayed a mean delay of 5 or more 
days between measurement and registration of data. This is alarming as frequent monitoring and 
taking immediate action in case of early signs of graft failure is vital to prevent or diminish damage to 
the kidney transplant. An explanation for saving up measurements before registering them might be 
that the measured creatinine values remained stable. However, patients seemed to postpone 
registration regardless of the stability of their kidney function. Indeed, postponement of registration 
appeared to be the main reason why patients had not followed up the advice to contact the hospital 
when creatinine levels had alarmingly increased by over 15%. Patients’ perception of these significant 
increases could have been influenced by the fact that the innovative device that was used during this 
study tended to be less accurate than hospital laboratory measurements[35]. As a consequence, 
patients might have been inclined to attribute sudden increases in level of creatinine to a technical 




Strengths and limitations 
To the best of our knowledge, this is the first study to assess adherence to a protocol of self-monitoring 
creatinine and to investigate the accuracy and reliability of patient generated creatinine data. Enabling 
patients to self-monitor kidney function at home would have important advantages, especially for 
patients living in remote areas. There are, however, some limitations that must be considered when 
interpreting our findings. First, the study was conducted at a single institute. As each hospital has its’ 
own way of delivering care, results might be different when conducted in other institutions. Our 
findings do, however, resemble what has previously been found in other disease populations. Second, 
participation in this study was voluntary and we selected patients with access to the internet. 
Therefore, it is possible that our patients had an above-average motivation to self-monitor. It is 
therefore likely that the current findings provide a conservative estimate of the true incidence of non-
adherence and inaccuracy. In line with this, patients reported very strong intentions to engage in self-
monitoring both at the start and after four months into the trial[38]. Their intention was found to be 
especially associated with their overall affective reaction towards using the system[38]. A considerable 
number of eligible patients had to be contacted to inform whether they were interested in study 
participation instead of giving informed consent immediately. However, the limited variance found in 
level of intention to engage in self-monitoring suggests that patients who had to be contacted were 
not more hesitant to engage in self-monitoring than patients who provided immediate informed 
consent.  
Last, the way (non-)adherence was determined is arbitrary to some extent. As the importance of (very) 
frequent monitoring differs per subpopulation and parameter of interest, no gold standard for what 
can be considered adherent is available. High blood pressure, for example, needs to be present over a 
longer period of time before becoming detrimental, while an increasing level of creatinine can be 
indicative of a rejection episode leading to irreversible damage or even loss of the transplanted kidney 
if not quickly noticed. 
 
Implications  
This study shows that level of adherence to a protocol of self-monitoring creatinine in the first year 
after kidney transplantation was generally good, although adherence declined over time. In addition, 
our results suggest that measuring every day in the first period after transplantation might be too 
burdensome. Further, 90% of data was shown to be accurately reported. In line with previous findings, 
however, several patients reported more favourable data than they actually measured. This suggests 
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that some patients might be inclined to select more favourable values for registration, which could 
leave early signs of graft failure unnoticed. Further, the majority of patients did not register their 
measured values on the day of measurement, but saved up measurements over several days to 
register them all at once. This so-called delayed registration was the main reason for patients not 
having followed up the advice to contact the hospital in case of a significantly increased level of 
creatinine.  
This study is part of a larger project in which the safety and usability of self-monitoring kidney function 
after transplantation supported by a SMSS is investigated. The current results showing that patients 
seem inclined to select more favourable creatinine values for registration and to postpone registration 
suggest a challenge to the safety of self-monitoring. This should be well-considered when designing 
self-monitoring care systems, for example by ensuring that self-measured data are transferred 
automatically to a SMSS. Using devices that can transfer data automatically and providing active 
feedback to patients (e.g. by sending text messages or emails) instead of having patients to log on to 
a website will eliminate the issues of data-selection and delayed registration, and as such contribute 
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In the last decade significant improvements in kidney transplant outcome have been achieved thanks 
to the availability of more effective immunosuppressive medications, and improved organ 
preservation, surgical techniques and antimicrobial prophylaxis [1]. 
However, patients continue to be at risk for acute rejection of their kidney graft, mainly in the first year 
after transplantation. The most important parameter for rejection is deterioration of renal function, 
measured by the concentration of serum level creatinine. As early detection of a rejection episode is 
mandatory to minimize permanent damage to the kidney graft[2-7], kidney transplant patients in the 
Netherlands visit the outpatient clinic about 20 times during the first year post-transplantation. Based 
on the experiences in other conditions where frequent monitoring is required, we expected that self-
monitoring kidney function after transplantation has the potential to increase patient satisfaction[8-
14], detect complications after transplantation early [15, 16] and reduce healthcare consumption[17-
19] at the same time. With that, self-monitoring aligns seamlessly with the concept of value-based 
healthcare, a strategy that is increasingly being used to challenge the rising care expenditure and 
improve the quality of healthcare[20].  
The general objective of this thesis was to investigate whether self-monitoring kidney function after 
transplantation supported by a self-management support system (SMSS) is well accepted and can 
replace part of regular care safely without loss of quality of care. Different studies have been 
performed to answer this question. The results of these studies will be discussed below, arranged by 
the main themes that have been described in the papers that are included in this thesis. 
 
The acceptance of self-monitoring kidney function supported by an SMSS 
 
Patient’s readiness to self-monitor 
The feasibility of self-monitoring is highly dependent on the readiness of kidney transplant patients to 
monitor at home. The willingness to participate in the study and the satisfaction of patients who 
engaged in self-monitoring are important indications for this readiness. The response rate in both the 
pilot study (94%, as described in chapter 2) and RCT (77%, as described in chapter 5) shows that kidney 
transplant patients seem very motivated to self-monitor kidney function. The difference between 
these two studies is not fully explained, but may be partly due to the inclusion of recipients of deceased 
donor kidneys in the RCT but not in the pilot study. As these patients could not be recruited 
beforehand, they were approached shortly after transplantation, when they may still have been too 
overwhelmed with the event of the transplantation to decide on study participation. Further, these 
  
 
patients were on average older and in worse condition, which may have made self-monitoring kidney 
function supported by an online system less attractive to them.  
High levels of satisfaction with self-monitoring kidney function after transplantation were expressed 
in both the pilot study (described in chapter 2) and RCT (described in chapter 5). The use of both the 
creatinine and blood pressure meter was considered pleasant and useful, despite level of trust in the 
accuracy of the creatinine device being relatively low. In the interviews with patients on their 
experience with self-monitoring kidney function after transplantation, patients were shown to be very 
positive taking into account the nearly unanimous (95%) recommendation of self-monitoring to other 
kidney transplant patients. Further, 75% of the interviewees said they would have liked to continue 
self-monitoring beyond the first year post-transplantation. The high levels of satisfaction with self-
monitoring that we found in both studies aligns with what has been described before [9, 11, 13, 21, 
22].  
 
Factors related to patients’ satisfaction with self-monitoring  
The high response rates and levels of satisfaction that were found in both the pilot study and RCT 
suggest that many kidney transplant patients are eager to perform self-monitoring tasks. Still, eleven 
patients (18% of the intervention group) decided to quit self-monitoring. In all 7 cases with a known 
reason for quitting, the reason was study-related. Four patients indicated they had too little trust in 
the accuracy of the used creatinine device to continue using it. The importance of perceived reliability 
was also shown in the pilot study, where a positive relationship was found between level of satisfaction 
and level of trust in the accuracy of the creatinine device. This corresponds with existing literature, 
showing that patients’ confidence in the accuracy and perceived reliability of devices is an important 
prerequisite to the acceptance of these devices[23, 24]. One patient did not want to continue self-
monitoring as he experienced difficulties when trying to log on to the SMSS for the first time. Although 
extra support was offered, he seemed to have concluded that online registration of measurements 
would be too difficult. Difficulty being the main reason for not wanting to continue may refer to two 
other findings. It may underline the importance of self-efficacy that was found in the pilot study, where 
patients were more satisfied if they had a higher level of self-efficacy regarding their own self-
monitoring skills. The correlation between level of self-efficacy and level of satisfaction has been 
described before[25, 26] suggesting that thoroughly instructing and supporting patients is important 
for successful and satisfactory self-monitoring. Difficulty in this case may also refer to the effort 
someone is willing to invest, which corresponds to our finding that the expected additional burden of 
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Further, 2 patients indicated they experienced too little benefit of self-monitoring creatinine post-
transplantation, perhaps due to the limited number of outpatients that were actually replaced by 
telephone appointments. The remaining 4 patients did not provide a reason for quitting but did not 
perform or register any measurements and were therefore considered voluntary dropouts. If self-
monitoring creatinine would become an integrative part of transplant aftercare, with the alternation 
of outpatient and telephone consults embedded in everyday practice, this would probably increase 
the perceived benefit of self-monitoring on the one hand and the perceived importance of patients to 
perform and register their measurements on the other. Considering this, the level of integration or 
implementation of procedures into care appears to be an important factor for patient satisfaction. This 
corresponds to one of our pilot study results, showing that a higher level of perceived autonomy 
support from physicians was related to a higher level of patient satisfaction. This finding also suggests 
that patients consider self-monitoring to be part of a care system in which their physicians keep playing 
an important role. It has indeed been shown before that patients consider self-monitoring a less 
attractive option if this automatically implies a substantial loss of human interaction with the clinical 
staff[23].  
The importance of experienced self-efficacy, involvement of physicians and autonomy support 
corresponds to Self-Determination Theory[27], where competence, relatedness and autonomy are 
considered basic human needs. Taking this into account, the experience and result of self-monitoring 
kidney function can be optimized if patients feel competent to perform the required actions, 
experience a connection with their healthcare professionals and feel supported by them to play an 
important role in their own care.  
 
Patients’ acceptance of a self-monitoring support system 
During the RCT (described in chapter 5), patients used a self-management support system (SMSS), that 
included the creatinine and blood pressure devices, eLearning, personal health record to register self-
measured values and a feedback system that advised patients on their next action (continue regular 
schedule, measure again or contact the hospital). To study factors related to acceptance of the SMSS, 
we used a self-developed questionnaire that was based on the Technology Acceptance Model 
(TAM,[28]) and one of its’ extensions, the Unified Theory of Acceptance and Use of Technology, 
(UTAUT, [29]). Both the TAM and UTAUT are well-known theories that explain people’s acceptance of 
technology. In these theories, several factors are described to explain behavioural intention, the 
degree to which an individual intends to use a new system. Behavioural intention has been widely used 
to evaluate user acceptance of technology [28-32]. In TAM and UTAUT, effort expectancy is usually 
  
 
considered as the main predictor of behavioural intention, whereas a less important factor is people’s 
affective response towards the system. In our study, however, the behavioural intention to start or to 
continue using the SMSS was very strongly related to patients affect towards the SMSS[29], with affect 
being represented by items that asked patients whether they considered using the ADMIRE system to 
be pleasant and whether it gave them peace of mind. Our diverging finding may be explained by the 
fact that the expected additional burden of self-monitoring after kidney transplantation was the main 
reason for patients to decline participation in the first place. This is different to what happens when 
an entire organization implements a new technology that replaces the old one, a situation where the 
TAM and UTAUT have traditionally been used to study user acceptance. When people are ‘free’ to 
choose whether to use a system or not, their affect towards the pertaining system may become much 
more important. Comments made by patients in the interviews at the end of participation confirm the 
role of affect in behavioural intention, especially the feelings of being safe. The majority of interviewed 
patients (75%) indicated that, if possible, they would have liked to continue using the SMSS beyond 
the first year post-transplantation as it gave them a feeling of safety. We do, however, need to take 
into account that patients were asked to evaluate the SMSS as a whole, including the measurement 
devices, eLearning, online personal health record and feedback system, while patients might have held 
different attitudes and feelings towards the various components of the SMSS. This could have 
influenced our findings. For example, logging of eLearning usage showed that intervention patients 
made very little use of the eLearning modules. More than 50% of the intervention patients had never 
used the eLearning modules or spent less than one minute looking at it. As patients knew they would 
also receive a live instruction, they may have considered using the eLearning as too much effort, 
especially given the timing: recipients of a living donor kidney were requested to look at the eLearning 
modules in the week(s) prior to their transplantation when they may have been more occupied with 
their upcoming surgery than with preparing for self-monitoring. This may suggest that effort 
expectancy instead of affect was the main factor contributing to the intention (not) to use the 
eLearning. For future studies, it would therefore be interesting to study whether the role of affect, 
effort expectancy and other factors of TAM and UTAUT is different for the various components of an 
SMSS. 
The ADMIRE project was a cooperation between the Leiden University Medical Centre, the Technical 
University of Delft and TNO. Supported by the expertise of the TU Delft and TNO, different studies have 
been performed to investigate patients preferences for the interface design to optimize the 
acceptance of future SMSSs[33]. The results of these studies suggest that a patients’ preference is 
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and the content of feedback (i.e. green, orange or red traffic light with corresponding advice). More 
experienced patients seem to prefer a factual interface, showing only measurement history, medical 
information and the current advice, over a guided style, that provides more support for interpretation 
and an avatar showing empathy to address emotional needs. This preference became especially 
apparent in case of a green traffic light, indicating that a patients’ condition was stable. Apart from 
these general findings, much diversity in preferences was observed. This argues for an interface design 
that can be tailored to the preferences of an individual patient. However, as these studies also showed 
that patients often do not use the option to adapt the interface, a default setting based on level of 
experience and potentially even content of feedback is recommended[33].  
 
The effect of self-monitoring on experienced empowerment and self-efficacy 
Self-monitoring has previously been shown to result in an increased sense of the ability to care for 
oneself, often termed patient empowerment and self-efficacy [9, 13, 34]. The World Health 
Organization defines empowerment as ‘a process through which people gain greater control over 
decisions and actions affecting their health’[35]. Self-efficacy is defined as ‘one's belief in one's ability 
to succeed in specific situations or accomplish a task’ [36]. During the RCT (described in chapter 5), the 
Partners in Health questionnaire was used to measure level of self-management behavior, including 
items that reflect both empowerment and self-efficacy. We expected self-management behaviour to 
increase more in the self-monitoring population, but both the intervention and control group had high 
levels of self-management behaviour at baseline already which further increased over time. Although 
this finding is not in line with our hypothesis, it does make sense that the level of self-management 
behaviour increased in both groups. Patients in the control group did not have access to the creatinine 
measurements, but they did engage in self-monitoring blood pressure, which is part of standard care 
after kidney transplantation.  
 
Doctors’ acceptance of the SMSS 
For a successful implementation of a new SMSS, it is also highly important that the concerning system 
is accepted by the other users: the doctors.  During the RCT, 70% of the doctors (n=15) treating kidney 
transplant patients had logged on to the SMSS in less than half of their total number of appointments. 
Three doctors had never visited the SMSS although having had multiple (telephonic) consults. Results 
from the interviews with pilot participants that were held in an early phase of the project (described 
in chapter 2) also indicated that doctors generally paid little attention to the self-measured creatinine 
data. These findings do, however, need to be placed within the right perspective. The pilot study took 
  
 
place in 2010 and early 2011, the RCT started early 2012. Considering the speed of technological 
developments and digitalization of our society, the finding   that several doctors were somewhat 
hesitant towards using the SMSS system will probably no longer be representative anno 2018, as 
doctors are now more used to delivering part of their care in a digital way. Besides the lack of 
experience with eHealth at that time, some other potential causes for the limited SMSS use can be 
distinguished. First, some of our doctors were critical about the accuracy of the creatinine device that 
was used. It has been concluded before that doctors need to feel confident in order to be able to share 
some of the control with patients[37] and that diagnostic confidence is key to incorporating remote 
monitoring into the transplant clinic[38]. In addition, as many patients brought a handwritten note 
with their recent measurement results to the consultation, most doctors might have considered 
discussing the paper print as being less time-consuming than logging on to the SMSS. Although access 
to the SMSS was integrated into the hospital information system, actually obtaining the data required 
an additional step. Both routine and time have been shown to be important factors in the adoption of 
new ways of delivering care[37, 39, 40]. Third, during the kick-off meeting for this study, many doctors 
stated that ‘there is more to outpatient care of kidney transplant patients than checking creatinine and 
blood pressure’. Doctors generally feel highly responsible for ensuring that high-quality care is 
achieved[37, 40, 41] and using patient acquired creatinine and blood pressure only may have clashed 
with their perception of professional responsibility.  
Fourth, the (potential) benefits of self-monitoring kidney function at home are less obvious for doctors 
than for patients. In a recent paper describing the development of a conceptual model for the design 
and evaluation of eHealth interventions in chronic disease, it was stated that it is important to 
emphasize the role that eHealth can play to support healthcare providers[42]. In the current study, 
some doctors requested for prolonged use of the creatinine device in case a transplant patients’ 
condition was unstable or requested the use of the creatinine device for non-transplant kidney 
patients for whom increased kidney function monitoring was required. In these cases, self-monitoring 
made it easier for doctors to keep closer track of their patients’ condition without having to increase 
the number of laboratory analyses and outpatient visits. Especially indicative for the importance of 
perceived usefulness is the finding that one of the doctors who was more critical of self-monitoring 
and had never logged on to the SMSS asked for the use of the creatinine device for a non-transplant 
patient. This may illustrate that healthcare professionals’ perception that self-monitoring is really 
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The safety of self-monitoring  
 
The accuracy of the creatinine device  
One of the most important prerequisites for safe self-monitoring is the use of reliable measurement 
devices. When evaluating the performance of a measurement device, it is important to take the 
purpose of the measurement into consideration [43]. For measuring kidney function, one can 
distinguish diagnostic and monitoring purposes. A diagnostic purpose of measurement refers to the 
necessity to give an accurate indication of the current kidney function directly, for example before 
administering iodinated contrast media. In people with a decreased kidney function, iodinated 
contrast media can lead to contrast-induced nephropathy, one of the major causes of hospital-
acquired acute kidney injury[44]. The accuracy of a single measurement is less important for a 
monitoring purpose, as one is interested in how kidney function develops over time. As the suitability 
of the StatSensor® for kidney transplant follow up had never been studied, we investigated whether 
the StatSensor® can be used both for detecting current renal function with a single creatinine 
measurement and for kidney function monitoring purposes. In chapter 4, we first evaluated the 
suitability of the StatSensor® to detect current renal function with a single measurement. Therefore, 
the traceability and exchangeability of StatSensor® results was compared to an isotope-dilution mass 
spectrometry (IDMS) traceable laboratory method, which is the gold standard for creatinine 
assays[45]. Our results showed that the StatSensor® creatinine device does not fulfil desirable nor 
minimum analytical performance criteria, which suggests that the StatSensor® is not suitable for 
detecting current renal function of kidney transplant patients with a single creatinine measurement. 
These findings are in agreement with previous studies that showed insufficient analytical validity of 
the StatSensor® in other populations [46, 47] compared to an IDMS traceable laboratory method. 
Improving the analytical performance of the StatSensor® would improve the potential for using the 
StatSensor® for diagnostic purposes.  
As detection of rejection episodes after kidney transplantation mainly reflects a monitoring purpose, 
it is important to investigate whether a device is able to detect trends in sequential measurements. 
The reliability of a single test results is less critical for monitoring over time. For recently transplanted 
patients, clinicians are especially interested in sudden increases in serum creatinine of >10% as this 
requires further analysis or intensified follow-up. We investigated whether a >10% change in serum 
creatinine (as measured by the central IDMS-traceable laboratory method) can also be detected when 
using StatSensor® for trend monitoring. A reasonable correlation (R = 0.77) between changes detected 
by the central laboratory and the StatSensor® was found. The StatSensor® correctly identified an 
  
 
increase of 10% (true positive) in 70% of all cases and a decrease of 10% (true negative) in 67% of all 
cases. These results were obtained in a laboratory setting. For self-monitoring to be a safe alternative 
to regular transplant follow-up, it is important to know whether the creatinine device is also sufficiently 
able to detect deteriorations in kidney function when used by patients. For the detection of clinically 
relevant increases in creatinine (>10%), we even found a higher level of agreement when self-
monitoring was conducted in a real-life setting by patients themselves: in 78% of all relevant cases a 
similar trend for home-based and laboratory-based creatinine levels was observed (described in 
chapter 5). The higher level of similarity between home-based and laboratory-based creatinine trends 
first suggests that patients are able to correctly perform the creatinine measurements at home. 
Second, it suggests that the accuracy of the creatinine device and test strips has improved over time. 
The test strips that were used during the laboratory study came from a batch that was manufactured 
at least 2 years before the batches of strips that were used during the RCT. With the test strips being 
constantly improved, this could possibly explain the increase of 10% in similarity between home and 
laboratory measurements and it may indicate that the ability of the StatSensor® to detect changes in 
kidney function is improving.  
However, to make the StatSensor® a more reliable tool for self-monitoring, the further improvement 
of its analytical performance remains very important as this will automatically improve its’ clinical 
performance (both for diagnostic and monitoring purposes). Awaiting the improvement of the 
analytical performance of the StatSensor®, two manoeuvres could offer a provisional solution. First, it 
is desirable that the number of false negatives is decreased, as it leads to delayed detection of 
rejection, which is dangerous and should not or hardly occur. If applied to the StatSensor®, one could 
choose a cut-off percentage that is lower for StatSensor® results than for laboratory measurements. 
For example, by lowering the StatSensor® cut-off percentage to ≥5%, the number of correctly identified 
relevant increases in level of creatinine (≥10% as determined by the central laboratory method) would 
have increased from 70% to 82%. A drawback of this approach is that it would result in an increased 
number of false positives and, consequently, additional diagnostic interventions. Second, the clinical 
performance regarding monitoring will improve when the number of measurements is increased. With 
increasing the frequency of StatSensor® measurements, a more reliable trend will be obtained. As 
patients perform the measurements themselves, we could advise patients to increase their 
measurement frequency. With lowering the cut-off and a guideline to measure in a higher frequency, 
the chances of detecting rejection are increased and theoretically, the number of outpatient visits can 
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There are, however, two reasons why the percentage of similar trends found in the RCT could actually 
even be an underestimation of the real similarity between home-based and laboratory-based 
creatinine measurements. First, level of agreement was based on a comparison between laboratory-
based creatinine trends and self-measured values that were registered in the SMSS, not on values that 
were stored in the creatinine device. As in about 10% of registrations the registered value did not 
correspond to the actually measured one, it is expected that level of correspondence between 
laboratory-based and home-based creatinine trends will be higher if values from the devices’ memory 
are used. Second, level of agreement between self-measured and laboratory-based creatinine trends 
could have been higher if the protocol was followed more strictly. When determining the protocol, we 
assumed that every other face to face visit would be replaced by a telephonic consult resulting in a 
lower frequency of laboratory analyses. We used a 1:7 ratio for determining the required 
measurement frequency, meaning that ideally patients performed seven creatinine measurements to 
replace one outpatient visit with laboratory assessment. As less outpatient visits were replaced by a 
telephonic consult than expected (causing the frequency of laboratory analysis to be higher than 
expected), the number of self-monitored values in between two laboratory assessments was lower. It 
is possible that the correspondence between home- and laboratory-based creatinine trends would 
have been even better if more home measurements in between two laboratory assessments would 
have been available, because a higher number of measurements results in a more reliable trend.  
 
Non-inferiority to regular care 
To investigate whether self-monitoring kidney function supported by a SMSS can indeed lead to a 
reduction in number of outpatient visits in the first year post-transplantation without compromising 
on quality of care, a randomized controlled trial was performed (described in chapter 5). Self-
monitoring led to a significant decrease in number of outpatient visits and total number of 
reimbursable minutes spent per patient. This achievement was made without compromising on quality 
of care, indicated by the absence of differences between intervention and control patients regarding 
kidney function, blood pressure, quality of life and general satisfaction at one-year follow-up. Five self-
monitoring patients experienced a rejection episode during their participation in the RCT. In three of 
these cases, the emerging rejection was detected earlier (i.e. in between two consults) due to the 
creatinine measurements performed at home, while none appeared to be missed. 
The actual difference in number of face-to-face visits between the intervention and control group was, 
however, smaller than expected. Following our protocol exactly (i.e. replacing half of the face to face 
visits by a telephonic one from week eight after transplantation onwards), the expected difference in 
  
 
number of visits between intervention and control patients would have been six. The actual difference 
between intervention and control group was, however, 2.3 visits. If more patients had responded to 
the SMSS feedback to contact the hospital (see chapter 5), the difference in number of visits would 
have been even smaller as these patients would probably have had to come to the hospital for further 
investigation. Other studies have also reported that reductions in regular care using eHealth were 
lower than expected [38, 48]. The hesitance of healthcare professionals to use eHealth equipment is 
suggested as an important factor contributing to the results falling short of expectation [38], which 
corresponds to the seemingly limited acceptance of the SMSS by the healthcare professionals during 
the RCT.  
 
Patient’s adherence to a self-monitoring protocol  
Adherence to a measurement protocol is important for all patients who engage in self-monitoring, but 
especially for kidney transplant patients. As most patients who develop graft rejection are 
asymptomatic and present with an increased serum creatinine only, frequent measuring is essential to 
make the difference between treatment in time and damage to or even loss of the kidney transplant. 
Based on data that was derived from the RCT, we concluded in chapter 6 that level of adherence to 
self-monitoring creatinine was generally good. Well above 90% of all patients performed the requested 
number of measurements during month 2-4 after transplantation. Adherence was somewhat lower 
during the first month (75%) when a high measurement frequency was requested, and at the longer 
term during months 5-12 after transplantation (85%). Two studies reporting on level of adherence to 
monitoring vital signs after lung transplantation found similar percentages of adherence being above 
80% for the entire study period[49, 50]. For self-monitoring blood pressure, patients with uncontrolled 
hypertension were shown to be adherent for about 73% of the entire study period[51, 52]. In both 
studies, level of adherence was highest in the first few weeks and declined gradually over time. The 
level of adherence that has been found in the current study therefore corresponds to percentages that 
have previously been reported. In contrast, we did not find the highest levels of adherence in the first 
period. This may have been due to a strenuous measurement protocol: patients had to measure every 
day in the first month. In these first weeks when patients have to recover and have to get used to life 
post-transplantation, performing measurements in such a high frequency might be too burdensome. 
Further, in this first period face-to-face visits were not yet replaced by telephonic consults and patients 
therefore visited the hospital at least weekly to monitor early signs of graft failure. Due to this high 
frequency of visits, patients may have felt a reduced need to perform measurements at home, as they 
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during the whole study period. Although the number of face-to-face visits was significantly lower for 
our intervention group, the reduction in number of visits was less than anticipated. Patients therefore 
continued to visit the outpatient clinic relatively often, potentially resulting in a lower perceived need 
to perform (all requested) measurements. 
 
The reliability of patient-reported data 
For self-measured values to be clinically useful, they need to be reported accurately. In chapter 6, we 
showed that approximately 90% of both creatinine and blood pressure measurements was registered 
correctly in the SMSS. This percentage corresponds to what has previously been described for patient-
reported blood pressure[51, 53] and anticoagulation[54], but is much higher than has been observed 
for patient-reported levels of blood glucose[55-57]. In case of non-correspondence between measured 
and actually registered values, the values that were registered in the SMSS were significantly lower 
than those actually measured. This suggests that patients select, alter or add values in such a way that 
their creatinine profile looks more positive. This corresponds to what has been found in a population 
of patients self-monitoring International Normalized Ratio (INR), where the measurements that fell 
within the desired range were significantly higher when using patient-reported data compared to data 
stored in the device[35]. For patients with diabetes or hypertension, it was found that inaccurate 
reporting increased with increasing levels of blood glucose[56] or blood pressure[53]. Why patients 
report values that look better than the values they actually measured or add non-existent 
measurements has not yet been fully clarified. For diabetes, it has been suggested that patients report 
false glucose levels due to a feeling of guilt for not having achieved glycaemic goals[57] or add 
phantoms values in an attempt to fill up logbooks and satisfy their healthcare providers[55]. Both 
situations seem to represent an attempt to be a ‘good’ patient. However, altering and selecting data 
that is not representative of the actual clinical situation or adding phantom values in any case may be 
dangerous. This can lead to suboptimal treatment and, eventually, to worsened patient outcomes[53, 
55]. Kendrick and colleagues have indeed shown that women with pregnancy-derived diabetes 
received suboptimal treatment due to a large difference between their reported glucose values and 
what they had actually measured[57]. It also seems to work the other way around: diabetic patients 
who were more reliable in their reporting had a significantly better glycaemic control[55]. This is 
probably due to a clinicians’ ability to adjust therapy more precisely if measurements are reported 
accurately. To rule out the possibility of incorrect reporting, other authors have already recommended 




Timely registration of measurements 
To make optimal use of the feedback system that was incorporated into the SMSS, measurement 
results had to be registered as soon as possible after the measurement was performed. Many patients, 
however, saved up their measurements over several days or even weeks to register them all at once 
(chapter 6). This probably occurred because logging on to the SMSS took time and registering multiple 
measurements at once was therefore considered more efficient. However, when measurements are 
registered retrospectively, the advice given by the SMSS is no longer up to date. One can imagine 
patients saving up measurements in case of a stable creatinine trend, but patients seemed to have 
postponed registration regardless of the stability of their kidney function. This is alarming as frequent 
monitoring and taking immediate action in case of early signs of graft failure is vital to prevent or 
diminish damage to the kidney transplant. Postponed registration appeared to be the main reason why 
patients had not followed up the advices that were generated by the SMSS. For example, the advice 
to contact the hospital (which only appeared when creatinine had increased by >15%) was given 24 
and followed 14 times (58%). In the remaining 10 cases (concerning 10 individual patients) 
measurements were registered with several days delay. If only cases with registration on the day of 
measurement were taken into account, adherence to contacting the hospital was 100%. Postponed 
registration of measurements will no longer be an issue in case a device is used that can automatically 
transfer data, combined with a system that can send the automatic feedback to a patients’ mobile 
phone directly.  
 
Clinical implications and directions for future research 
The results as described in this thesis show that self-monitoring kidney function after transplantation 
seems attractive to kidney transplant patients and can lead to a significant decrease in number of 
outpatient visits without compromising on quality of care. Further, self-monitoring offers a convenient 
solution to increase monitoring frequency, which could probably lead to earlier detection and 
treatment of complications and, consequently, improved clinical outcomes. However, the results as 
described in this thesis also indicate there is some room for improvement. For example, although the 
readiness of kidney transplant patients to self-monitor was high considering the high response rate in 
both the pilot study and randomized controlled trial, a few patients quit their participation voluntarily. 
The main reason for quitting was because of problems related to the creatinine device. Further, some 
patients indicated they experienced too little benefit of self-monitoring creatinine post-
transplantation. The fact that the reduction in number of outpatient visits was smaller than expected 
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readiness of kidney transplant patients to self-monitor was high considering the high response rate in 
both the pilot study and randomized controlled trial, a few patients quit their participation voluntarily. 
The main reason for quitting was because of problems related to the creatinine device. Further, some 
patients indicated they experienced too little benefit of self-monitoring creatinine post-
transplantation. The fact that the reduction in number of outpatient visits was smaller than expected 




monitoring is well accepted among patients and has the potential to improve health care after kidney 
transplantation. To further increase the potential of self-monitoring kidney function after 
transplantation to replace part of regular outpatient care, we suggest that the following three points 
need careful consideration.  
 
The accuracy of measurement devices 
The use of a creatinine device that is less accurate than what both healthcare professionals and 
patients are used to may have played an important role in the limited reduction of outpatient visits. 
As a transplanted kidney is a valuable asset, it is understandable that both healthcare professionals 
and patients are careful when considering new methods of monitoring kidney function. Patients could 
turn to the SMSS for interpretation of their creatinine value, but many patients saved up their 
measurements over several days before registering them online. This suggests that patients 
interpreted their measurements themselves before registering them in the SMSS. However, the 
fluctuations in level of self-measured creatinine (even in relatively stable situation) made it difficult for 
patients to put a single value in the correct perspective, which may have hampered their trust in the 
creatinine device.  
Although we had shown that the self-monitored creatinine values can be used for trend-analysis, using 
the creatinine device may have clashed with what healthcare professionals perceive to be their 
professional responsibility. It has been concluded before that for doctors to feel (more) confident 
about sharing control with their patients, the biomedical aspects of care need to be well addressed 
[37]. This is an important prerequisite to create doctors’ support for new interventions. If we had used 
a creatinine device with a more continuous level of accuracy, doctors would probably have felt more 
at ease with replacing outpatient visits with a telephonic consult. Dried blood spot analysis may offer 
an alternative to patients self-monitoring creatinine in case reduction of outpatient visits is the main 
objective, as dried blood spots have been shown to give reliable creatinine results[59, 60]. However, 
with dried blood spot analyses there is a delay between blood drawing and test results of at least two 
days, as the dried blood spots first have to be sent to a laboratory before they can be analysed and 
linked back to the patient. This is not a problem when a regular outpatient visit is being replaced and 
the patients’ condition is stable, but hampers direct treatment if this is necessary. Moreover, dried 
blood spot analysis becomes cumbersome in case an increased monitoring frequency is required. And 
finally, using dried blood spot analyses does not seem to increase patient involvement and autonomy 
regarding their own treatment. Patients perform the blood collection themselves, but are usually 
dependent upon the laboratory and their doctor for analysis and interpretation. In conclusion, 
  
 
improving the accuracy of the point of care creatinine device as used in the RCT is desirable for at least 
two reasons. First, the device can analyse a drop of blood within seconds, accelerating the detection 
of a deteriorating kidney function and the start of treatment. Second, it enables patients to become 
full-fledged partners in their own care, as they perform the full cycle of blood drawing, interpretation 
of test result (whether or not supported by a feedback system) and acting (i.e. contacting their doctor) 
in case the results give cause for concern.  
 
A multidisciplinary approach in developing and implementing eHealth 
A second point that should be taken into account is that the developmental process of the ADMIRE 
system may not have been optimal. Many eHealth interventions for chronic conditions have been 
shown to struggle with engaging both patients and healthcare professionals, with low uptake and high 
dropout rates[42]. It has been stated that many of the approaches that are being used to develop 
eHealth technologies are not productive enough to create technologies that are meaningful, 
manageable and sustainable[61]. According to the World Health Organization, a mismatch between 
context and technology is the main reason why up to three quarters of the implementation of new 
medical devices fails[62]. This mismatch could be due to the fact that practice can’t keep up with the 
ongoing technological developments. It takes years to fully implement a new procedure, and by then 
the ‘new’ procedure will probably be outdated already. However, there are also other factors that can 
contribute to the mismatch between context and technology. The Normalization Process Theory (NPT) 
[63] states that for a successful implementation of new health technologies, it is important that there 
is a (shared and individual) understanding of the benefits of a new technology and a general 
expectation that the concerning technology makes people’s life or work easier[64]. So, the 
implementation of new services is expected to run more smoothly if all parties involved see the added 
value of a new technology. In the ADMIRE project, we especially focused on the experiences of patients 
with self-monitoring. In cooperation with the technical university of Delft, different studies have been 
performed in parallel to the RCT to learn more about patients’ acceptance of our SMSS and their 
preferences for, for example, feedback style[33, 65]. The results of these studies gave us the tools to 
explain some of our study findings and to give recommendations for implementation to enable future 
use of SMSSs in kidney transplant patients. However, the opinion of the other group of end users, the 
healthcare professionals, has probably not been sufficiently taken into account. For example, the first 
time we found out that the medical staff considered it unrealistic to start replacing face to face visits 
with telephonic consults directly from discharge after transplantation was during the kick-off meeting 
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been consulted. More extensive qualitative research during the development of the SMSS and ADMIRE 
logistic protocol may have guaranteed that concerns could be addressed earlier, for example by also 
listening carefully to physicians that were more critical of self-monitoring.  
 
Study design 
Third, a traditional randomized controlled trial (RCT) design may not have been the best choice in the 
current situation. According to Van der Meijden and colleagues[66], the evaluation of eHealth is often 
aimed at measuring the effects of the eHealth intervention while the value of evaluations to improve 
a technology during development and implementation is neglected. Unlike in evaluating drugs, users’ 
opinions of or reactions to computer systems decide whether or not a system will have an effect[67]. 
It is needed to understand what differences eHealth technologies can make in healthcare, why eHealth 
technologies make these differences, and why eHealth technologies may not have the expected 
impact[68]. To answer these questions, it is important to take the conditions for implementation into 
account right from the start, by performing formative evaluations to test design assumptions and 
prototypes throughout the entire process [69]. We used process variables (i.e. number of logons to 
the SMSS, number of outpatient visits) as a proxy for acceptance, but we did not gather more in-depth 
information about why the current eHealth technology worked very well for patients but did not 
succeed in gaining an optimal effect. For example, if we had taken a more practical approach and 
performed formative evaluations during the RCT, we would have observed that less outpatient 
appointments were replaced than anticipated. By discussing these findings openly with both 
healthcare professionals and patients we could have tried to figure out the reasons for not scheduling 
telephonic instead of outpatient appointments and, if possible, have made changes to the protocol 
accordingly to optimize the possible effectiveness. The advantage of such a flexible approach is that 
one can deliver a protocol that has shown to be ‘the best practice’ (within the boundaries of available 
time and money) instead of having to stick to the more rigid procedures that are concomitant to an 
RCT.   
 
General conclusion 
Self-monitoring kidney function after transplantation is highly appreciated by patients and can improve 
the detection of complications while leading to a reduction in healthcare consumption at the same 
time. To increase the potential of self-monitoring kidney function to replace part of standard 
outpatient care, it is recommended to use accurate measurement devices and design the protocol with 
the help of a multidisciplinary and representative project group. For future eHealth-related studies, it 
  
 
is recommended to choose a study design that includes formative evaluations. To get the most out of 
a study, it is important to notice shortcomings that reveal itself during a study and be able to act 
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After kidney transplantation, patients have to visit the outpatient clinic frequently to monitor their 
kidney function. The high frequency of these appointments is burdensome to both the recovering 
patient and to healthcare resources. Experiences that have been gathered in other conditions requiring 
chronic care show that self-monitoring important clinical parameters at home has the potential to 
increase patient satisfaction and accelerate the detection of complications while reducing healthcare 
consumption at the same time. The general objective of this thesis was to investigate whether self-
monitoring kidney function after transplantation supported by an online self-management support 
system (SMSS) can replace part of regular care safely and without loss of quality of care.  
 
In chapter 2, the results of a prospective pilot study that was performed to investigate kidney 
transplant patients’ experiences and satisfaction with self-monitoring kidney function after 
transplantation are described. Thirty patients self-monitored their level of creatinine and blood 
pressure and registered the measurement results in an online SMSS, where both patients and doctors 
had access to. The results showed that patients were highly motivated to self-monitor kidney function 
and reported high levels of general satisfaction. The receipt of an automatic warning when creatinine 
level was increased was considered the most important benefit of the SMSS. The use of both the 
creatinine and blood pressure meters was considered pleasant and useful, despite levels of trust in the 
accuracy of the creatinine device being relatively low. Trust in the accuracy of the creatinine device 
appeared to be related to level of variation in subsequent measurement results, with more variation 
accompanying lower levels of trust. Some patients expressed disappointment about their physicians 
paying little attention to the recorded measurement values. Average adherence to the monitoring 
protocol was good, but large individual differences between patients were found that increased over 
time. Based on these findings we concluded that at-home monitoring of creatinine and blood pressure 
after transplantation offers a promising strategy. However, important prerequisites for a successful 
implementation of self-monitoring in transplant care seem to be confidence in the accuracy of the 
devices that are used and patients experiencing support from their physicians. 
 
For the design and implementation of SMSS, it is important to understand the factors that influence 
patients’ acceptance of such systems. The results of a study in which we aimed to identify these key 
factors is described in chapter 3. Level of acceptance of the SMSS that was used throughout the 
randomized controlled trial (RCT, see chapter 5), expressed as behavioural intention to start or 
continue using the system, was investigated using a self-developed questionnaire based on two 
models that have been used before to explain people’s acceptance of technology. Fifty kidney 
  
 
transplant patients completed the questionnaire before and after having used the SMSS for 4 months. 
Patients were found to be on average positive towards using the SMSS, both in advance of use and 
after having used the SMSS for 4 months. Behavioural intention could mostly be explained by patients’ 
affect towards the SMSS (26% explained variance), with affect referring to whether patients liked to 
use the system. This is different than what is usually found, with the degree of ease associated with 
using the system (effort expectancy) traditionally being one of the most important factor explaining 
behavioural intention. However, as patients were ‘free’ to choose whether they used the SMSS or not, 
it makes sense that their appreciation of using the system was a crucial factor. This finding suggests 
that the emotional experience of using a SMSS should be taken into account when designing and 
implementing a system to be used in healthcare.  
 
In chapter 4 we describe the results of a study investigating the analytical performance of the 
creatinine device that was used throughout our studies, the StatSensor® Xpress-i™, for both detecting 
current renal function with a single measurement and monitoring renal (dys)function with subsequent 
measurements in kidney transplant patients. Concerning single measurements, the total allowable 
error criterion of 6.9% was not met. Further, the average overall coefficient of variation (CV) for the 
StatSensor® was 10.4% using capillary whole blood results while this was < 1.5% for the central 
laboratory serum creatinine method. Based on these findings, we concluded that the StatSensor® at 
that time was not suitable for detecting kidney (dys)function of kidney transplant patients in case of 
single capillary blood measurements. During kidney transplant follow-up, however, creatinine values 
are usually interpreted by comparing subsequent measurements, reflecting a monitoring purpose in 
which the uncertainty of a single creatinine test results is less critical. Our results showed a reasonable 
correlation (R=.77) between the percentages change that were detected by the central laboratory and 
the StatSensor® device. A sudden increase in creatinine of >10% is of special interest, as this suggests 
further analysis or intensified follow-up is needed. The StatSensor® correctly identified a difference of 
> 10% (true positive) in 70% and a difference of ≤ 10% (true negative) in 67% of all cases (total 
agreement 68%). We concluded that although StatSensors’® ability to detect changes in kidney 
function needs improvement, it does have potential for monitoring creatinine in case StatSensor® 
measurements are performed in a higher frequency than laboratory creatinine analyses. This will result 
in a more reliable trend, as the confidence interval decreases proportionally to the square root of the 
number of performed measurements, given a normal distribution. As such, the chances of detecting 
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The objective of the study that is described in chapter 5, was to investigate whether self-monitoring 
kidney function supported by an online Self-Management Support System (SMSS), where both patient 
and doctor had access to, can lead to a reduction in number of outpatient visits in the first year post-
transplantation without compromising on quality of care. 119 patients were randomized to the 
intervention group, with patients self-monitoring creatinine and blood pressure and face to face and 
telephonic consults being alternated, or the control group, who received standard post-
transplantational care. Number of outpatient contacts and clinical outcomes (eGFR, blood pressure, 
satisfaction and quality of life) were compared between the two groups. For the intervention group 
specifically, we looked at the extent to which creatinine trends measured at home were comparable 
to laboratory-based creatinine trends. Further, twenty intervention patients were interviewed on their 
self-monitoring experiences. The results showed that self-monitoring can lead to a significant decrease 
in number of outpatient visits (16.02 and 18.35 face to face visits for the intervention and control 
group, respectively, p .007) without compromising on quality of care, as was indicated by the absence 
of differences between intervention and control patients for eGFR, blood pressure, quality of life and 
general satisfaction at one year follow-up. Remarkably, the medical staff poorly adhered to the 
protocol of replacing physical visits with telephonic consults, leading to an underestimation of the true 
effect of self-monitoring on number of outpatient visits.  
 
In 78% of relevant creatinine increases (>10%), a similar trend for home-based and laboratory-based 
measurements was observed, which is 10% higher than what was found in the study reported in 
chapter 3. Interview data showed that satisfaction was high: 95% of the interviewed patients would 
recommend self-monitoring to others and 75% would have liked to continue self-monitoring beyond 
one year. These results led to the conclusion that self-monitoring creatinine after transplantation is 
highly appreciated by patients and enables the number of outpatient visits to be reduced without 
having to compromise on quality of care. Improving the implementation of self-monitoring into post-
transplantational care is expected to lead to even greater reductions in number of outpatient visits. 
 
Chapter 6 describes a study in which we investigated the level of adherence to the self-monitoring 
protocol used during the RCT, the reliability of patient-reported test results and whether patients took 
appropriate actions based on their measurements. Level of adherence to the self-monitoring protocol 
was generally good, with well above 90% of all patients performing the requested number of 
measurements during month 2-4 after transplantation. Adherence was lower during the first month 
and during months 5-12 after transplantation. Approximately 90% of both creatinine and blood 
  
 
pressure measurements were correctly registered in the SMSS. In cases of non-correspondence 
between measured and registered values, the values that were registered in the SMSS appeared to be 
significantly lower than those actually measured. This suggests that patients select, alter or add values 
in such a way that their creatinine profile looks more positive. The percentage of patients following 
the advice that was shown automatically when a new creatinine value was registered in the SMSS 
ranged from 53-85%, depending on the specific feedback. The advice to contact the hospital, which 
was given in case level of creatinine had increased by >15%, was followed in only 58%. This is alarming 
as taking immediate action in case of early signs of graft failure is vital to prevent or diminish damage 
to the kidney transplant. Many patients had saved up their measurements over several days or weeks 
to register them all at once. With registering measurements retrospectively, the advice given by the 
SMSS was no longer up to date, which was probably the main reason why patients did not follow it.  
Patients’ tendency to postpone registration and to select lower creatinine values for registration and 
the suboptimal adherence to the automatic advice might challenge the safety of self-monitoring. This 
should be well considered when designing self-monitoring care systems, for example by ensuring that 
self-measured data is transferred automatically to an SMSS. 
 
CONCLUSION 
The studies that were performed and are described in this thesis show that self-monitoring kidney 
function after transplantation is an attractive option to kidney transplant patients and can lead to a 
significant decrease in number of outpatient visits without compromising on quality of care. Further, 
self-monitoring could offer a relatively cheap way to increase monitoring frequency, which could lead 
to earlier detection and treatment of complications and, consequently, improved clinical outcomes. 
But the results of these studies also show there is room for improvement. To unravel the full potential 
of self-monitoring kidney function after transplantation, it is recommended to use accurate 
measurement devices that both patients and healthcare professionals have confidence in, design a 
protocol with the involvement of a multidisciplinary group that is truly representative of all 
stakeholders (including patients and physicians that are more critical of self-monitoring) and choose a 
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Niertransplantatiepatiënten moeten regelmatig terug komen op de polikliniek om hun nierfunctie te 
laten controleren.  De hoge frequentie van deze bezoeken vormt een belasting voor zowel patiënten 
als voor de organisatie en bekostiging van zorg. Onderzoek in andere populaties met een chronische 
zorgbehoefte heeft aangetoond dat het thuis monitoren van belangrijke klinische parameters kan 
leiden tot een hogere mate van tevredenheid onder patiënten en het sneller opmerken van 
complicaties enerzijds en een verminderd zorggebruik anderzijds. De centrale onderzoeksvraag binnen 
dit proefschrift was of een deel van de zorg na niertransplantatie naar de patiënt kan worden 
overgedragen, die hierbij ondersteund wordt door een online self-management support system 
(SMSS), zonder dat dit ten koste gaat van de kwaliteit van zorg. Hiertoe zijn verschillende studies 
uitgevoerd, waarvan de bevindingen hieronder worden samengevat.  
 
In hoofdstuk 2 worden de resultaten beschreven van een pilotstudie naar de ervaringen van patiënten 
met het zelf-monitoren van nierfunctie na transplantatie. Dertig living donor 
niertransplantatiepatiënten monitorden thuis hun kreatinineniveau en bloeddruk en registreerden de 
resultaten in een online SMSS, waar ook hun arts toegang tot had. De hoge respons rate (>90%) 
suggereert dat deze patiënten zeer gemotiveerd zijn om thuis hun nierfunctie en bloeddruk te meten. 
Patiënten waren erg tevreden over de opzet van het onderzoek en ervoeren het gebruik van de 
zelfmeetapparatuur als prettig en nuttig. Sommige patiënten twijfelden echter aan de accuratesse van 
de kreatininemeter. Dit bleek gerelateerd te zijn aan de mate van variatie in opeenvolgende metingen, 
waarbij meer variatie gerelateerd was aan minder vertrouwen in de accuratesse van de meter. De 
automatische melding die patiënten ontvingen wanneer het kreatinineniveau was gestegen werd als 
het belangrijkste voordeel van het SMSS ervaren. Sommige patiënten waren teleurgesteld vanwege 
de weinige aandacht die hun behandelend arts aan de online geregistreerde kreatininemetingen 
schonk. Deze bevindingen leidden tot de conclusie dat het zelf meten van kreatinine en bloeddruk na 
een niertransplantatie een veelbelovende optie is. Belangrijke voorwaarden voor een succesvolle 
implementatie van zelf-monitoring in de transplantatiezorg zijn onder andere vertrouwen in de 
accuratesse van de gebruikte apparatuur en betrokkenheid van zorgverleners.  
 
Voor het ontwerpen en implementeren van een SMSS is het belangrijk om te begrijpen welke factoren 
de mate van acceptatie van zulke systemen beïnvloeden. Hoofdstuk 3 beschrijft een studie naar de 
acceptatie van de SMSS zoals gebruikt in de gerandomiseerde studie (zie hoofdstuk 5).  Op basis van 
twee modellen die eerder zijn gebruikt om de acceptatie van nieuwe technologie te verklaren werd 
een vragenlijst ontwikkeld. De acceptatie van de SMSS werd bepaald door behavioural intention, de 
  
 
intentie om de SMSS te blijven gebruiken, te meten. Vijftig niertransplantatiepatiënten vulden de 
vragenlijst in voor aanvang van het gebruik van de SMSS en nadat ze deze gedurende vier maanden 
hadden gebruikt. Patiënten stonden over het algemeen positief tegenover de SMSS, zowel voor- als 
nadat ze ervaring hadden met het gebruik ervan. De intentie om de SMSS te (blijven) gebruiken kon 
met name worden verklaard door het gevoel dat patiënten bij de SMSS hadden (26% verklaarde 
variantie), bijvoorbeeld in hoeverre ze het prettig vonden om het systeem te gebruiken. Dit is anders 
dan wat op basis van de literatuur werd verwacht, waar het (verwachte) gemak waarmee de SMSS 
gebruikt kan worden (effort expectancy) meestal de belangrijkste factor is die behavioural intention 
verklaart. Omdat er sprake was van een vrije keuze om aan de studie mee te doen, is het echter 
begrijpelijk dat de mate waarin patiënten het prettig vonden om de SMSS te gebruiken een belangrijke 
rol speelde. Deze bevinding suggereert dat tijdens het ontwerpen en implementeren van een 
soortgelijk systeem in de zorg rekening moet worden gehouden met het gevoel dat patiënten bij 
(gebruik van) het betreffende systeem ervaren.  
 
In hoofdstuk 4 worden de resultaten beschreven van een studie naar de analytische prestaties van de 
kreatininemeter die gedurende de hier beschreven studies werd gebruikt, de StatSensor® Xpress-i™. 
Hierbij hebben we gekeken naar de accuratesse van de StatSensor® toegepast voor het meten van een 
enkele kreatininewaarde en voor trendmonitoring. Wat betreft de meting van een enkele waarde, 
werd het gebruikelijke criterium van 6,9% total allowable error niet gehaald. De gemiddelde coefficient 
of variation (CV) van de StatSensor® was 10,4% ten opzichte van een CV van <1,5% in het klinisch 
laboratorium van het LUMC. Op basis van deze bevindingen is geconcludeerd dat de StatSensor® op 
dat moment niet geschikt was om bij niertransplantatiepatiënten op basis van een enkele meting 
nier(dys)functie te bepalen. Na een niertransplantatie wordt echter vooral de ontwikkeling van het 
kreatinineniveau over een bepaalde periode gemonitord, waarbij de accuratesse van een enkele 
waarde minder van belang is. Het tweede deel van ons onderzoek wees uit dat veranderingen in 
kreatinineniveau over tijd zoals gedetecteerd door het klinisch laboratorium en de StatSensor® redelijk 
goed met elkaar correleerden (R=.77). In de klinische praktijk wordt met name gekeken naar 
plotselinge stijgingen van >10%, omdat hier een oorzaak aan ten grondslag kan liggen die nadere 
analyse vergt. De StatSensor® identificeerde een verschil van >10% (true positive) in 70% en een 
verschil van ≤10% (true negative) in 67% van de gevallen correct, met een gemiddelde 
overeenstemming van 68%. Hoewel het vermogen van de StatSensor® om veranderingen in nierfunctie 
goed op te pikken moet worden verbeterd, werd geconcludeerd dat de StatSensor® potentie heeft om 
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uitgevoerd dan de reguliere meetfrequentie in het klinisch laboratorium. Meer metingen resulteert in 
een betrouwbaardere trend, omdat het betrouwbaarheidsinterval kleiner wordt wanneer de wortel 
van het aantal uitgevoerde metingen stijgt (uitgaande van een normaalverdeling). Met meer metingen 
neemt de kans op het detecteren van een rejectie toe en kan, theoretisch, het aantal poliklinische 
afspraken veilig worden teruggebracht.  
 
Het doel van de studie die in hoofdstuk 5 wordt beschreven was om te onderzoeken of het zelf-
monitoren van nierfunctie ondersteund door een online Self-Management Support System (SMSS) kan 
leiden tot een reductie van het aantal poliklinische bezoeken in het eerste jaar na niertransplantatie, 
zonder ten koste te gaan van de kwaliteit van zorg. In totaal werden 119 patiënten verdeeld over de 
interventiegroep, waarin patiënten zelf hun kreatinine en bloeddruk monitorden en poliklinische en 
telefonische contacten werden afgewisseld, en de controlegroep, waarin patiënten de reguliere post-
transplantatiezorg ontvingen. Het aantal poliklinische afspraken en de klinische uitkomsten (eGFR, 
bloeddruk, tevredenheid en kwaliteit van leven) van beide groepen werden met elkaar vergeleken. 
Voor de interventiegroep werd verder gekeken in hoeverre de kreatininetrends die thuis waren 
gemeten overeenkwamen met de trends zoals gemeten in het klinisch laboratorium. Verder werden 
20 patiënten geïnterviewd over hun ervaring met het zelf-monitoren van nierfunctie na 
niertransplantatie.  
De resultaten tonen aan dat zelf-monitoren tot een significante daling van het aantal poliklinische 
consulten kan leiden (16 en 18,5 respectievelijk voor de interventie- en controlegroep, p .007) zonder 
dat dit ten koste gaat van de kwaliteit van zorg, wat blijkt uit de afwezigheid van enig verschil tussen 
de interventie- en controlegroep voor eGFR, bloeddruk, kwaliteit van leven en tevredenheid met 
ontvangen zorg op 1 jaar follow-up. Een opvallende bevinding was dat het medisch personeel zich niet 
goed aan het protocol hield wat betreft het vervangen van poliklinische afspraken door een telefonisch 
consult. Dit heeft vermoedelijk geleid tot een onderschatting van het daadwerkelijke effect dat zelf-
monitoren op het verminderen van het aantal poliklinische bezoeken kan hebben.    
In 78% van de relevante stijgingen in kreatinineniveau (>10%) werd een vergelijkbare trend gezien 
tussen thuis gemeten en in het laboratorium bepaalde kreatininemetingen. Dit is 10% hoger dan wat 
werd gevonden in de studie die in hoofdstuk 3 staat beschreven. Uit de interviews blijkt dat patiënten 
erg tevreden waren: 95% raadt het zelf-monitoren van nierfunctie na transplantatie aan 
medepatiënten aan en 75% had het prettig gevonden om de thuismetingen ook na het eerste jaar na 
transplantatie voort te kunnen zetten.  
  
 
Deze bevindingen leidden tot de conclusie dat het zelf-monitoren van nierfunctie na transplantatie 
zeer gewaardeerd wordt door patiënten en kan leiden tot een significante daling van het aantal 
poliklinische afspraken, zonder op kwaliteit van zorg in te boeten. Verwacht wordt dat een betere 
implementatie van zelf-monitoring in de post-transplantatie zorg tot een grotere daling van het aantal 
poliklinische afspraken kan leiden.   
 
Hoofdstuk 6 beschrijft een studie waarin werd onderzocht in hoeverre patiënten zich aan het 
meetprotocol houden, hoe betrouwbaar de online geregistreerde meetwaarden zijn en of patiënten 
de juiste actie ondernemen wanneer hun metingen daarom vragen. Patiënten hielden zich het beste 
aan het protocol gedurende maand 2-4 en het minst tijdens de eerste weken van deelname: 90% 
respectievelijk 70% van de patiënten had minimaal driekwart van de gevraagde metingen verricht. 
Rond de 90% van alle kreatinine- en bloeddrukmetingen was correct in de SMSS geregistreerd. Voor 
de 10% kreatininemetingen waarbij gemeten en geregistreerde waarden niet overeenkwamen bleken 
de geregistreerde waarden significant lager dan de daadwerkelijk gemeten waarden. Dit suggereert 
dat patiënten waarden selecteren, wijzigen of zelfs toevoegen die tot een gunstiger kreatinineprofiel 
leiden.  
Het automatisch gegeneerde advies werd in 53-85% opgevolgd, afhankelijk van de exacte feedback. 
Het advies om contact op te nemen met het ziekenhuis, dat alleen werd gegeven indien het 
kreatinineniveau met >15% was gestegen, werd in slechts 58% van de gevallen opgevolgd. Dit is 
verontrustend, omdat het bij het signaleren van een verminderde nierfunctie belangrijk is om snel te 
handelen, zodat permanente schade aan het niertransplantaat kan worden beperkt of zelfs 
voorkomen. Veel patiënten spaarden hun metingen een aantal dagen op voordat ze de resultaten 
invoerden in de SMSS. De feedback was op het moment van registreren dan niet meer relevant en 
werd vermoedelijk daarom niet opgevolgd.  
Het uitstellen van de registratie van nieuwe metingen, het selecteren van lagere kreatininewaarden 
voor registratie en het suboptimaal opvolgen van het meetprotocol vormen een potentiele bedreiging 
voor de veiligheid van zelf-monitoren. Hier moet rekening mee worden gehouden bij de ontwikkeling 
van zorgprocessen waar zelf-monitoring een rol speelt, bijvoorbeeld door apparatuur te gebruiken die 
gemeten waarden automatisch naar een SMSS kan versturen.   
 
CONCLUSIE 
De studies die worden beschreven in dit proefschrift tonen aan dat het zelf-monitoren van nierfunctie 
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significant minder poliklinische afspraken, zonder dat dit nadelige consequenties heeft voor de 
kwaliteit van zorg. Daarnaast biedt zelf-monitoren een relatief goedkope manier om de 
meetfrequentie te verhogen. Door vaker te meten kunnen complicaties eerder worden opgemerkt en 
behandeld, wat een positief effect heeft op de klinische uitkomsten na transplantatie. De beschreven 
studies tonen echter ook aan dat er nog veel ruimte is voor verbetering. Om het potentieel van zelf-
monitoren na niertransplantatie volledig in kaart te brengen, is het aan te raden om gebruik te maken 
van apparatuur waar zowel patiënten als zorgverleners vertrouwen in hebben, de studie vorm te geven 
in samenwerking met een multidisciplinaire groep waarin alle stakeholders vertegenwoordigd zijn 
(inclusief patiënten en zorgverleners met en kritische(re) houding ten opzichte van zelf-monitoren) en 
een studiedesign te kiezen waar ook ruimte is voor formatieve evaluaties in plaats van voor uitsluitend 
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